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As all cancers, breast cancer starts with uncontrolled cell division as a result of 
(often multiple) mutations, due to damaged DNA, which are not picked up by 
the DNA repair system. Cells that originate from uncontrolled cell division can 
develop into a tumour, which is either benign or malignant. With respect to breast 
cancer, uncontrolled cell growth starts in the milk ducts, lobules (milk producing 
glands) or the connective tissue in between the ducts and lobules. If the tumour 
remains in its original place it is called an in situ carcinoma, which is usually a 
ductal carcinoma in situ (DCIS) in case of breast tumours. Lobular carcinoma 
in situ (LCIS) is uncommon, without symptoms and generally not visible on a 
mammogram.1
A tumour becomes invasive when it breaks through the basement membrane, after 
which it can invade nearby tissues and enter the bloodstream.1 Once in the blood 
vessels, malignant cells can spread (metastasize) to various sites. This is only 
possible when certain criteria are met, e.g. the growth of new blood vessels from 
the pre-existing vasculature (angiogenesis). There is no consensus on whether 
or not an invasive breast cancer is always preceded by an in situ carcinoma.
The stage of breast cancer is often determined using the TNM-classification 
system, which defines the size of the tumour (T), possible regional lymph 
node involvement (N) and possible distant metastases (M). Invasive disease is 
categorized in stages T1 – T4, which represent different tumour sizes and possible 
tumour extension to chest wall and/or skin (T4).2 Stage T1 is subdivided in T1a, T1b 
and T1c, which differ in size (Table 1). In case of regional lymph node involvement, 
i.e. regional lymph node metastases, the disease is classified as ‘node positive’. 
Other, non-regional, lymph node metastases and metastases which spread through 
the bloodstream are coded as ‘distant metastases’ (M1). Distant metastases often 
occur in the lungs, pleura, bones, liver, brain, lymph nodes, peritoneum, skin or 
adrenals.3




Ductal carcinoma in situ
T1 Invasive tumor; greatest dimension ≤ 2 cm
T1a Invasive tumor; greatest dimension ≤ 0.5 cm
T1b Invasive tumor; greatest dimension > 0.5 cm and ≤ 1 cm
T1c Invasive tumor; greatest dimension > 1 cm and ≤ 2 cm
T2 Invasive tumor; greatest dimension > 2 cm and ≤ 5 cm
T3 Invasive tumor; greatest dimension > 5 cm
T4
Invasive tumor; any size with direct extension to chest 
wall and/or skin
N0 No regional lymph node metastases
N1
Movable ipsilateral level I, II axillary lymph node(s) 
metastases
N2
Metastases ipsilateral level I, II axillary lymph node(s) 
that are clinically fixed or in clinically detected ipsilateral 
internal mammary nodes in the absence of axillary 
lymph node metastases
N3
Metastases ipsilateral infraclavicular (level III axillary) 
lymph node(s) with or without level I, II axillary lymph 
node or internal mammary lymph node involvement
M0 No distant metastases
M1 Distant metastases
Adapted from: Edge S BD, Comptom CC,Frits AG, Greene FL, Trotti A. AJCC Cancer 
Staging Manual. 7 ed: Springer-Verlag New York; 2010. XV, 648 p.
Risk factors
Although many breast cancers are caused by random errors in DNA replication, 
there are known factors that could increase breast cancer risk. Besides gender and 
age, risk factors that are associated with a high relative risk are dense breasts, a 
previous biopsy and a family history of breast cancer. The latter could indicate 
inherited cases of breast cancer, often associated with mutations in BRCA1 and 




Other known mutations, which moderately elevate breast cancer risk, include 
CHECK2, ATM and NF1.4
Several reproductive factors are also associated with elevated risk of breast cancer, 
for example advanced age at first birth, nulliparity, and low age at menarche 
increase breast cancer risk.5, 6 Lifestyle factors that affect the risk of breast cancer 
include a lack of physical activity, smoking, being overweight or excessive alcohol 
consumption.7 Reproductive factors can also lead to a lower than average risk of 
breast cancer. Parity, ever breastfeeding and young age at menopause have been 
shown to be associated with a moderately decreased breast cancer risk.5, 6
BREAST CANCER TREATMENT
Almost all women with breast cancer are treated. Most tumours, DCIS and invasive 
cancers, are primarily treated through breast-conserving surgery (lumpectomy) 
or mastectomy, with or without radiation. The majority of women with (invasive) 
breast cancer is additionally treated with adjuvant treatment, including hormone 
therapy, chemotherapy, radiotherapy and targeted therapy (or combinations 
of these therapies). Adjuvant treatment considerably improved over the last 
decades. Adjuvant systemic therapy, including chemotherapy, hormonal therapy 
and immunotherapy, can be administered to minimize the recurrence risk and 
the risk of metastasizing or to control metastatic breast cancer. A patient can 
also be treated with neo-adjuvant treatment to decrease the tumour size before 
surgery.8
BREAST CANCER SCREENING
Population-based cancer screening is performed in an asymptomatic, healthy 
population. Screening enhances diagnosis of breast cancer in an early (localized) 
stage, improving tumour stage distribution compared to clinically diagnosed 
cancers. Breast cancers diagnosed at an early stage have a higher chance of being 
treated successfully, which may lead to prolonged survival. The stage shift caused 
by screening results in less advanced treatment among women with screen-
detected cancers compared to non-screened women. Although screening can result 
in improved survival and may avert breast cancer deaths, it can also have adverse 
effects and cause harm. As the population invited to screening is considered to be 
healthy and screening is thus only beneficial for a rather small number of women, 
disadvantages associated with screening should be limited. The balance between 
benefits and harms of screening has often been a topic of debate.9-11
Because screening brings the date of diagnosis forward, the period between 
diagnosis and death (lead time) is generally longer with screening, even if breast 
cancer death is not postponed or prevented (Figure 1). Prolonged breast cancer 
survival due to screening may thus be misleading and breast cancer mortality 
(reduction) is therefore a better measure to assess the effect of screening.
Population based breast cancer screening programmes make use of mammography 
screening. A mammogram is a x-ray image of the breast with moderately high test 
sensitivity and high specificity.12
Benefits of mammography screening
Ten randomised trials of mammography screening were conducted in the 1970s 
and 1980s.13-17 Meta-analyses of these trials, showed a reduction in breast cancer 
mortality of around 20%.18, 19
Because of the extensive debate about the balance between the benefit and harms 
of mammography screening, an independent panel of experts on mammography 
screening was formed in the UK.11 After conducting a large review including a 
meta-analysis, with 13 years of follow-up, the panel estimated that the breast cancer 
mortality reduction due to mammography screening was 20% for women invited 
to screening.
In addition to the trials, numerous observational studies have been conducted to 
estimate the effect of screening on breast cancer mortality. Using the evidence from 
observational studies, the International Agency for Research on Cancer recently 




screening to be 40% in women aged 50 to 69 years who attended screening.20 The 
reduction in breast cancer mortality was 23% for women in the same age range who 
were invited to screening. The observational evidence for a reduction in breast
Figure 1. In a situation with screening, breast cancers can be detected earlier during the 
screen detectable phase. The time that the diagnosis is brought forward is referred to as 
the ‘lead time’. Screening is beneficial if life years are gained and the time of death is thus 
postponed (A). However, it is important to note that survival is always prolonged with 
screening, as the diagnosis is brought forward in time, even if no life years are gained and 
the time of death is not postponed (B). BC: breast cancer
cancer mortality from mammography screening for women aged 70 to 74 years 
was also considered to be sufficient.20
Next to breast cancer mortality reduction in a screened versus non-screened 
population, beneficial outcome measures of mammography screening are the 
number of life years gained, less advanced breast cancer stage and less advanced 
treatment.
Harms of mammography screening
One of the most important potential adverse outcomes of screening is 
overdiagnosis of breast cancer. Overdiagnosis is defined as screen-detection 
of tumours that would never have presented clinically during an individual’s 
lifetime in the absence of screening. Overdiagnosis can occur because some cases 
of screen-detected DCIS or indolent invasive breast cancer may never present 
clinically during a woman’s lifetime, due to slow growth, a complete lack of growth 
or regression of the lesion21, 22. In this case, an individual will die of another cause 
than breast cancer. However, overdiagnosis is also possible with respect to lesions 
with average or high growth rates if women die of other causes. Overdiagnosis 
results in more individuals being diagnosed in the presence of screening and may 
lead to overtreatment in the screening setting. Complications or side effects as a 
consequence of overtreatment are undesired, since treatment of overdiagnosed 
cancers will not improve survival.
Other harms associated with screening are false-positive findings and false 
reassurance. It has been suggested that false-positive mammograms increase 
short-term, but not long-term anxiety.23 False reassurance might occur when, in 
case of a false-negative screen result, an individual is less perceptive to symptoms 
of breast cancer because of the reassuring negative screen.
Evaluation of a screening programme
The performance of a breast cancer screening programme is measured using 




interval cancer rate, the referral rate and the false-positive rate. In addition, the 
stage distributions of screen- and clinically detected cancers are also monitored.
For screening to be effective, the interval cancer rate should be rather low and the 
detection rate relatively high. Interval cancers are usually defined as breast cancers 
diagnosed after a negative screening examination (i.e. not resulting in a referral), 
within the first two years after screening.
Performance indicators are used to calculate programme sensitivity and specificity. 
Programme sensitivity is defined as the proportion of true-positives among all 
breast cancers (true-positives and false-negatives), diagnosed within two years 
after the screening examination.24 To calculate the programme sensitivity, interval 
cancers are often used to approximate the number of false-negative findings. 
However, the number of interval cancers includes not only cancers missed at 
screening, but also fast growing cancers that were not detectable during the 
screening examination. The programme sensitivity is therefore lower than the 
test sensitivity of mammography. The programme specificity is calculated as the 
proportion of true-negative findings among all negative screening examinations 
(true negative and false-positive findings), within the first two years after screening. 
Another measure is the positive predictive value: the chance of having breast 
cancer after a positive screening examination. Also important for the effectiveness 
of a screening programme are a high attendance rate and, as mentioned earlier, a 
more favourable stage distribution for screen-detected cancers.
Breast cancer screening in the Netherlands
Biennial breast cancer screening was gradually implemented in the Netherlands 
between 1989 and 1997. Initially only women aged 50-69 years were invited, until 
1998, when the upper age limit of screening was extended to 74 years between 1998 
and 2001. In the period 2004-2010, screen-film mammography was replaced by 
digital mammography, reaching full transition in June 2010. Before 2004, 2-view 
mammography (cranial-caudal and mediolateral-oblique) was performed at first 
screens whereas at subsequent screens only 1-view examinations (mediolateral-
oblique) were performed. The number of 2-view mammograms at subsequent 
screens increased steadily and after 2010, 2-view mammography was performed 
at all subsequent screening rounds. The reading policy in the Netherlands is double 
reading with, in case of disagreement, consensus or arbitration.25
The attendance rate over the last years has been around 80% in the Netherlands.24 
Analyses of Dutch screening data have shown that the percentages of advanced 
stage breast cancer (stages III and IV) among women who were screened 
and women who were not screened or irregularly screened were 10% and 23% 
respectively.26
In the Netherlands, breast-conserving therapy is more common among screen-
detected cancers than among cancers detected outside of screening, namely 71% 
versus 38%.24 In addition, the percentage of adjuvant therapy after surgery is 
significantly lower for screen-detected cancers than for breast cancers in women 
who were not screened (50% versus 68%).24
BREAST CANCER INCIDENCE AND MORTALITY IN THE NETH-
ERLANDS
The breast cancer incidence in the Netherlands is one of the highest in Europe.27 
Breast cancer incidence in women aged 50-54 years increased substantially 
around the implementation of mammography screening in the Netherlands 
(1989-1994), compared to the years before implementation (Figure 2). This steep 
rise in incidence, caused by the detection of prevalent cases of breast cancer 
during the first screening rounds, attenuated around 1994. There is a peak in 
the incidence trend of women aged 70-74 in 1999, during the extension of the 
screening programme to age 70-74 years. Around the same time, the incidence 
in older women, aged 75-79, decreases significantly because part of the breast 
cancers in this age group are detected earlier due to screening in the age group 




Figure 2. Breast cancer incidence in the Netherlands for different age groups between 
1975 and 2018.
The squares represent observations based on regional data as national data was lacking 
during this period.
Breast cancer mortality has decreased significantly over the last 25 years in the 
Netherlands. This decline is present in all five-year age groups between 40 and 79 
years (Figure 3).24, 28 The reduction in breast cancer mortality over the years was 
probably caused by the implementation of the breast cancer screening programme 
around 1990 and the introduction of adjuvant chemo- and hormonal therapy.29, 
30 Adjuvant treatment improved substantially over the last 25 years, which 
additionally contributed to breast cancer mortality reduction.31 In the highest age 
group, 75-79 years, there is a steep decline in breast cancer mortality shortly after 
the extension of the screening programme to 70-74 years between 1998 and 2001 
(Figure 3).24
Survival
As concluded above, breast cancer mortality decreased over the last decades, 
despite the rise in breast cancer incidence. Survival after diagnosis thus increased 
over this period. In the Netherlands, 5-year survival after diagnosis of invasive 
breast cancer changed from 78% with a diagnosis between 1991-1995 to 88% with 
a diagnosis between 2011-2015.32
Improved survival is, as well as breast cancer mortality reduction, probably the 
result of both early detection due to screening and improvements in (adjuvant) 
therapy. As discussed earlier, prolonged survival does not always result in delayed 
or averted breast cancer death.
Figure 3. Breast cancer mortality in the Netherlands for different age groups between 
1985 and 2015.
POSSIBLE NEW DEVELOPMENTS IN BREAST CANCER 
SCREENING
Screening before age 50 years
Breast cancer incidence among women aged 40-49 years has been increasing over 
the last decades.33, 34 The impact of screening on breast cancer mortality may be 




age, including a lower breast cancer incidence, lower sensitivity of mammography 
due to greater breast density and, possibly, more aggressive tumour growth. Meta-
analyses of randomised controlled trials in which women aged 40 to 49 at entry 
were included, report a breast cancer mortality reduction of 8-15%.19, 35 However, 
methodologically these analyses may be flawed as the benefit of screening observed 
in women aged 40 to 49 at randomization, may be partially attributable to early 
detection of breast cancer by screening these women at age 50 and older36. 
Findings of the United Kingdom (UK) age trial suggested a breast cancer mortality 
reduction of 12% from annual mammography starting at 39-41 years, with 17 years 
of follow-up.37 The reduction was however only statistically significant after 10 
years of follow-up (25% reduction) and not at 17 years of follow-up.
The largest cohort study that compared breast cancer mortality in Swedish women 
aged 40 to 49 years, between women invited and not invited to screening, showed 
a breast cancer mortality reduction of 26% for women invited to screening and 
29% for women attending screening.38 The effect of lowering the starting age of 
breast cancer screening is therefore interesting to explore.
Risk-based screening
In most countries, organized screening programmes invite all women in a specific 
age group (often 50-69 or 50-74 years), regardless of their risk of breast cancer. 
However, breast cancer risk varies for different ages as a result of changes in risk 
factors with increasing age. A woman’s individual risk of breast cancer, dependent 
on her age and the presence or absence of risk factors (e.g. breast density, family 
history of breast cancer), may affect the balance between benefits and harms 
associated with screening. Better individual harm-benefit ratios may also lead to 
an improved balance on the population level. An alternative to offering a uniform 
screening strategy is a risk-based approach, in which the target age range, the 
screening interval and possibly the screening method can be adjusted to different 
risk groups. There are several European studies in which risk factors for breast 
cancers are being identified.39-42
New screening technnologies
There are multiple studies on alternatives for mammography, for the whole 
screening population or a specific – often high-risk - subgroup. Frequently studied 
technologies are magnetic resonance imaging (MRI), digital breast tomosynthesis 
and ultrasound.
Because MRI has a relatively high sensitivity compared to other imaging modalities 
for breast cancer detection, it is used to screen women with a high risk of breast 
cancer, due to familial or genetic predispositions.43-45 The use of MRI to screen 
women with dense breasts is currently investigated.46 Compared to mammography, 
MRI has prolonged acquisition time and higher false-positive rates47 and costs.
Digital breast tomosynthesis is of particular interest as it has been suggested as a 
replacement for digital mammography, for the whole eligible screening population, 
in the long term. By generating a 3D-like image of the breast, tomosynthesis 
has the potential to overcome the issue of overlapping breast tissue on a 2D 
mammogram, which may result in improved diagnostic accuracy compared 
to digital mammography.48, 49 Tomosynthesis screening leads however to an 
increase in reading time, compared to digital mammography and higher costs.50, 51 
Estimates for the false-positive rate with tomosynthesis vary considerably between 
studies from substantial decreases to significant increases compared to digital 
mammography.52-55
MICROSIMULATION MODELLING OF BREAST CANCER 
SCREENING
Microsimulation models are used in an increasing number of studies to evaluate 
the effect of disease interventions, including cancer screening. By extrapolating 
the results of randomised controlled trials, models are able to estimate the impact 
of screening under many different circumstances, including those that are not 
feasible to test in trials due to ethical, time- or cost-related issues.56, 57 Conditions 
that can easily be tested or varied using modelling are lifelong follow-up and the 




can simulate multiple screening scenarios, whereas in trials usually only one 
or a few strategies are tested. Optimum screening policies are therefore often 
determined using models.58 Furthermore, models have the ability to adjust the 
estimated effect of screening to changes in screening policy (e.g. transition to 
digital mammography), while maintaining other conditions.59 Also, models can 
make predictions for the future and are able to quantify unobservable factors 
associated with screening including overdiagnosis59 and the relative contribution 
of screening and treatment to cancer mortality reduction.29, 30
MISCAN
The MISCAN (MIcrosimulation SCreening ANalysis) model for breast cancer 
screening was developed in the 1980’s and has frequently been used for the 
(economic) evaluation of mammography screening and for recommendations for 
screening policy.59-61 MISCAN has been well reported and validated in the past 
and has been frequently recalibrated and updated.61 Important components of 
the model are: the population demographics, the natural history of breast cancer, 
the screening component and the treatment component. The model simulates a 
population consisting of individual life histories, based on life-tables of Dutch 
women. Subsequently, the natural history of breast cancer (without screening) 
is simulated resulting in the onset of breast cancer in a subset of women in the 
population at a certain point in time, which may eventually lead to breast cancer 
death. Model outcomes are then estimated for a situation without screening. 
Hereafter, mammography screening and improvements in prognosis of survival 
after screen-detection are modelled. In the presence of screening, tumours can 
become screen-detected during the preclinical detectable phase, before clinical 
symptoms are present. Screening can therefore lead to earlier detection and 
treatment of breast cancer and may, thereby, improve survival and may prevent 
breast cancer death. In the model, screen-detected and clinically detected tumours 
are primarily treated with surgery and may be treated with adjuvant therapy, based 
on Dutch treatment probabilities.
In MISCAN, breast cancer is modelled through tumour progression and starts 
with the development of preclinical ductal carcinoma in situ (DCIS), which may 
progress through the invasive successive stages T1a, T1b, T1c and T2+ (modelled 
as a semi-Markov process). DCIS progression into T1a varies from immediate 
transition to slow progression. A small fraction of DCIS is assumed to regress. At 
each stage, a tumour can become screen-detected in the presence of screening, 
clinically diagnosed if symptoms are present or progress to the next stage (Figure 
4).
The monitored performance indicators from the evaluation of the national 
screening programme are used as input for MISCAN, either as direct input or as 
data used for model calibration.
Cost-effectiveness analysis
In a cost-effectiveness analysis the benefits of screening are compared to the 
costs of screening. Benefits of breast cancer screening are often defined as life 
years gained, which result from averted breast cancer deaths. A cost-effectiveness 
threshold, often referred to as a willingness-to-pay-threshold, is used to determine 
whether or not an intervention is cost-effective.
In European countries, organized breast cancer screening has been demonstrated 
to be cost-effective.25, 62 Most European breast cancer screening programmes are 
targeted to women aged 50-69 years, with a screening interval of 2 years.63 This 
age range has been extended to 40 years, 74 years, or both in some European 
countries. However, even if there is general consistency among European countries 
with respect to their screening policies, the cost-effectiveness of screening may 
differ between countries because it depends on country-specific characteristics 
such as the breast cancer incidence; tumour stage distribution and breast cancer 
mortality before the start of screening; the target age range and screening interval; 
the structure and organization of the health care system; the coverage of the 
population by invitation64; the costs of screening and the costs of diagnostics 
and treatment. Another important factor that affects the cost-effectiveness is the 
attendance rate of the programme. Attendance rates differ substantially between 




It is also important to assess the cost-effectiveness of on-going screening 
programmes, as the ratio of effects and costs may change over time. Assessing 
the cost-effectiveness of current screening programmes is particularly relevant 
when changes in screening policies are considered - for example extension of the 
age range - or when a new screening technology is available.
Figure 4. Possible transitions in the MISCAN model.
RESEARCH QUESTIONS AND OUTLINE OF THESIS
The aim of this thesis is to quantify the effects of breast cancer screening. This 
thesis consists of two parts. The first part evaluates the performance indicators over 
the period with digital mammography screening in the Netherlands and compares 
these to the performance indicators of former screen-film mammography. The 
effect of both screen-film and digital mammography screening on breast cancer 
mortality rates in the Netherlands is also assessed in this part. In the second part 
of this thesis, the benefits, harms and cost-effectiveness of different alterations to 
the current screening strategy are described.
Part One: Evaluation of current breast cancer screening in the 
Netherlands
Research question 1: How do the performance indicators of current breast 
cancer screening in the Netherlands change over time and what is the effect 
of screening on breast cancer mortality rates?
In chapter 2, the detection rates, interval cancer rates and other important 
performance indicators after the transition to digital mammography are evaluated 
and compared to indicators with screen-film mammography. In chapter 3, the 
reduction in breast cancer mortality trends in different age groups over the last 20 
years, after the introduction of the Dutch screening programme, is quantified.
Part Two: Quantifying the cost-effectiveness, harms and benefits 
of different screening strategies and screening modalities in the 
Netherlands using microsimulation modelling
Research question 2: To what extent do alterations to current screening 
change the harm-benefit ratios and cost-effectiveness estimates of current 
screening?
Chapter 4 presents the cost-effectiveness of different screening strategies starting 




In Chapter 5, we identify optimal screening strategies for women with a low and 
high relative risk of breast cancer, under the condition that the cost-effectiveness 
of screening in the Netherlands is not negatively affected. In Chapter 6, the 
incremental cost-effectiveness of screening with digital breast tomosynthesis in 
the Netherlands, compared to digital mammography screening, is assessed by 
conducting a probabilistic sensitivity analysis.
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ABSTRACT
Background: Between 2003 and 2010 digital mammography (DM) gradually 
replaced screen-film mammography (SFM) in the Dutch breast cancer screening 
programme (BCSP). Previous studies showed increases in detection rate (DR) 
after the transition to DM. However, national interval cancer rates (ICR) have 
not yet been reported.
Methods: We assessed programme sensitivity and specificity during the transition 
period to DM, analysing nationwide data on screen-detected and interval cancers. 
Data of 7.3 million screens in women aged 49-74, between 2004-2011, were linked to 
the Netherlands Cancer Registry to obtain data on interval cancers. Age-adjusted 
DRs, ICRs and recall rates (RR) per 1000 screens and programme sensitivity and 
specificity were calculated by year, age and screening modality.
Results: 41,662 screen-detected and 16,160 interval cancers were analysed. The 
DR significantly increased from 5.13 (95% confidence interval (CI):5.00-5.30) in 
2004 to 6.34 (95%CI:6.15-6.47) in 2011, for both in situ (2004:0.73;2011:1.24) and 
invasive cancers (2004:4.42;2011:5.07), whereas the ICR remained stable (2004: 
2.16 (95%CI2.06-2.25);2011: 2.13 (95%CI:2.04-2.22)). The RR changed significantly 
from 14.0 to 21.4. Programme sensitivity significantly increased, mainly between 
ages 49-59, from 70.0% (95%CI:68.9-71.2) to 74.4% (95%CI:73.5-75.4) whereas 
specificity slightly declined (2004:99.1% (95%CI:99.09-99.13);2011:98.5% 
(95%CI:98.45-98.50)). The overall DR was significantly higher for DM than for 
SFM (6.24;5.36) as was programme sensitivity (73.6%;70.1%), the ICR was similar 
(2.19;2.20) and specificity was significantly lower for DM (98.5%;98.9%).
Conclusions: During the transition from SFM to DM, there was a significant rise 
in DR and a stable ICR, leading to increased programme sensitivity. Although the 
recall rate increased, programme specificity remained high compared to other 
countries. These findings indicate that the performance of DM in a nationwide 
screening programme is not inferior to, and may be even better, than that of 
SFM.
INTRODUCTION
Sensitivity and specificity are considered to be important quality assurance 
indicators for the performance of screening. The sensitivity of a breast cancer 
screening programme (BCSP) is calculated using the detection rate (DR) of screen-
detected cancers and the interval cancer rate (ICR). The number of published 
studies that report interval cancers on a national level is low1-4. Data on nationwide 
interval cancers are difficult to obtain, as an accurate linkage between national 
screening data and the national cancer registry is required. In addition, because 
the number of interval cancers can only be determined at the end of an interval 
between screening rounds, there is an inherent delay in the availability of the data 
(usually two years), compared to data on cancers detected at screening.
In the past decade, many Western BCSPs made the transition from screen-film 
mammography (SFM) to digital mammography screening (DM)5-9. DM has been 
shown to influence the performance of BCSPs, leading to higher detection rates 
than SFM, through increased recall rates6, 10-13. In most studies, the increase in 
cancer detection was largely driven by a significant rise in the detection of DCIS. 
It has been argued that increased DCIS detection leads to a substantial rise in 
overdiagnosis of breast cancer without contributing to breast cancer mortality 
reduction. However, a recently published study showed an association between 
increased screen-detection of DCIS and fewer subsequent invasive interval cancer 
cases14. DM may thus also have the potential to lower ICRs.
In the Netherlands, the transition from SFM to DM was realised between 2003 and 
201015, 16. In the same period, the percentage of 2-view mammography at subsequent 
screens increased from 50% to over 90%17, 18. Several Dutch studies showed 
statistically significant improvements in cancer detection for DM compared to 
SFM13, 19-22, whereas others found no significant differences16, 23. However, so far, only 
regional interval cancer rates during the transition to DM in the Netherlands have 
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The objective of this study was to evaluate the national performance of the BCSP 
in the Netherlands during the transition period to DM by assessing programme 
sensitivity and specificity, using screen-detected and interval cancers between 
2004 and 2011.
METHODS
Dutch Breast Cancer Screening Programme
The Dutch BCSP is carried out by 5 regional Cancer Screening Organisations (65 
screening units), which invite all eligible women based on the population registry, 
aged 50-74 years, biennially to take part in screening. The attendance rate is around 
80%. From 2003 onwards, a pilot phase started in which DM was introduced next 
to SFM, increasing the proportion of DM from 1% to 7% of all screens in 2007. 
This period was followed by a roll-out phase in which DM expanded from 10% in 
2008, to 42% in 2009 and 100% in June 2010.
We collected data on all screens between 2004 and 2011. At initial screens 2-view 
mammography, with double reading, was performed. In 2004, about half of the 
subsequent screens had a second view and this proportion increased to 93% in 
2010. The reading policy was double reading with consensus or arbitration. Women 
were only recalled if both independent readers concluded that the screening 
mammogram was positive or if a third reader came to this conclusion, in case of 
disagreement.
Data
All screen-detected and interval cancers between 2004 and 2011 were analysed. 
To classify cancers as screen-detected or interval cancers, records of all screening 
examinations were linked to the Netherlands Cancer Registry (NCR). Linkages 
were made using an algorithm to identify identical subjects with high probability. 
The NCR classified the positive matches (94% of all breast cancers) preliminarily 
into screen-detected and interval cancers. Unclassified cancers were checked 
manually by the Cancer Screening Organisations, using information from the 
patient’s medical file. A small fraction of all women screened (0.01%) did not give 
permission to link their records.
Information on whether DM or SFM was performed was derived from the separate 
screening units, following the rollout schedule for digitization.
Definitions
Screening examinations were defined as mammograms following an invitation 
to screening. These examinations were subdivided in initial screens, regular 
subsequent screens within 2.5 years after previous screening and irregular 
subsequent screens 2.5 years or later after previous screening (4% of all screens 
between 2004-2011). The latter were not used in this study: as the precise length 
of the irregular interval could not be determined from the aggregated dataset, 
including irregular subsequent screens would lead to distortion of (i.e. higher) 
detection- and interval cancer rates. Positive screens were considered to be screens 
with a suspicious mammographic lesion leading to recall and negative screens 
those without suspicious mammographic lesions, without any recommendation. 
Thus, screen-detected breast cancers were all diagnosed as a direct consequence 
of recall for further assessment, within one year after a positive screen.
All breast cancers diagnosed within two years after a negative screen were 
considered to be interval cancers. This concerned cancers arising from:
- Lesions that were screen-detectable at time of screening but were missed 
or not recalled
- Lesions that were present at screening but had minimal signs and were not 
recalled
- Lesions that were not present at screening and emerged within the screening 
interval
Interval cancers could also occur after a false-positive screen: if the cancer detected 
in the interval did not resemble the earlier detected lesion or was localized in the 
other breast, it was considered to be an interval cancer and coded accordingly. 
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Interval cancers were thus calculated using all screens and not only women with a 
negative screen. Both ductal carcinomas in situ (DCIS) and invasive cancers were 
included in the number of screen-detected and interval cancers.
We defined programme sensitivity as the number of screen-detected cancers 
expressed as a proportion of the total number of breast cancers diagnosed in 
women who were screened, within two years after screening (screen-detected 
cancers + interval cancers). Programme specificity was defined as the number 
of negative screens in women without breast cancer as a proportion of the total 
number of screens in women without a breast cancer diagnosis (true negatives 
+ false-positives), within two years after screening. The false-positive rate was 
calculated as the number of recalls that did not lead to a breast cancer diagnosis 
per 1000 screens. As for some recalls the final diagnosis is not known, the numbers 
of true- and false-positives do not completely add up to the number of recalled 
women.
Age-adjusted recall (RR), false-positive (FPR), detection (DR) and interval cancer 
rates (ICR) per 1000 screens were calculated, using the total number of invitations 
during 2004-2011 as reference population. The positive predictive value (PPV) 
was calculated as the percentage screen-detected cancers (true positives) of all 
women recalled (true and false-positives). Performance indicators were based on 
all screening examinations (initial + regular subsequent), calculated by calendar 
year and age and presented with 95% confidence intervals (CI).
Analysis
Screening examinations performed at age 75 (N=9,507) and interval cancers 
diagnosed within two years after screening at age 75 (N=16) were excluded 
because of small numbers. Results are presented for the age group 49-74 and were 
calculated for the period 2004-2011, for all screening examinations and for DM 
and SFM screens separately.
Whether differences in outcomes were statistically significant was determined 
using the 95% confidence intervals. For proportions these intervals were calculated 
using the standard formula (P ± 1.96*s.e.). The 95% confidence intervals for the rates 
were calculated using a log linear model (exp(b+ log(N)); Poisson distribution) and 




Between 2004 and 2011, 7343327 screens (initial + regular subsequent) were 
performed within the Dutch BCSP (Table 1). There were 41662 breast cancers 
detected by screening; the DR was 5.7 per 1000 screens, of which 0.94 were DCIS. 
The recall rate (RR) was 17.8 per 1000 screens and the FPR 12.1 (PPV:33.5%). The 
16,160 interval cancers identified led to an ICR of 2.2 per 1000, of which 0.1 were 
DCIS (data not shown). The programme sensitivity was 71.4% and the programme 
specificity 98.8%.
Trends over time
The DR significantly increased by more than 20% over the study period, from 5.1 
per 1000 to 6.3 and the ICR remained stable (Figure 1a; Supplementary material 
1a). The DRs of both DCIS (+0.5) and invasive breast cancers (+0.7) increased 
(Supplementary material 1a). The detection rate increased for all age groups 
over the entire study period (Fig. 2a; Supplementary material 2a). Detection also 
increased with age from 55 years onward; in the youngest ages (in particular 49 
years) the detection rate was relatively high due to prevalent screening.
The overall ICR remained stable over the study period (2004: 2.2 per 1000 screens; 
2011: 2.1; Fig. 1a; Supplementary material 1a). The interval cancer rate showed a 
slightly decreasing tendency for the younger age groups over the study period and 
a slight increase in the trend for the older ages (Fig. 2b; Supplementary material 
2b). The fluctuation in the overall interval cancer rate was mainly determined 
by the rate for invasive breast cancers (Fig. 3). There were slight decreases in the 
age-adjusted overall interval cancer rate in 2007, 2009 and 2011 relative to the 
previous year (not statistically significant), accompanied by a decline in invasive 
2
42 43
Detection and interval cancer rates Chapter 2
interval cancers alone in 2007 and in both invasive and in situ interval cancers in 
2009 and 2011 (Fig. 3; Supplementary material 3).
The programme sensitivity increased from 70.0% in 2004 to 74.4% in 2011 (Figure 
4a; Supplementary material 1a) and increased statistically significant from 2010 
(compared to 2004). The overall programme sensitivity was mainly determined















No. false-positives 88862 38621 50241
No. recalls 130524 55021 75503
Recall rate 17.8 (17.7-17.9) 21.0 (20.8-21.2) 16.0 (15.9-16.1)
False positive rate 12.1 (12.0-12.2) 14.8 (14.7-15.28) 10.6 (10.5-10.7)
Detection rate 
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2.2 (2.2-2.2) 2.2 (2.1-2.3) 2.2 (2.2-2.3)
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33.5 (33.2-33.7) 31.5 (31.1-31.9)
34.9 (34.5-
35.2)
Rates are presented per 1000 screens
by SFM between 2004-2008 and increased steeply with the expansion of DM 
between 2008-2011 (Figure 4a; Supplementary material 1b, 1c). The programme 
sensitivity strongly varied by age in 2004, which attenuated with the expansion of 
DM due to a significant increase in programme sensitivity for women aged 49-59 
(Supplementary material 4). Trends in programme sensitivity of all breast cancers 
and invasive cancers only were similar between 2004-2008 (Figure 5). In 2009-
2010, there was an increase in the sensitivity of all cancers but not of invasive 
cancers only, which reflects an increased detection of DCIS. In 2011, there was 
a similar rise in both groups, thus reflecting an increased detection of invasive 
cancers.
The RR increased significantly over time from 14.0 to 21.4 (Supplementary material 
1a). The programme specificity significantly declined slightly from 99.1% to 98.5% 
(Figure 4b; Supplementary material 1a). The difference in programme specificity 
between DM and SFM was most prominent in the beginning of the study period 
and decreased over time.
DM versus SFM
Overall results
Of all screens, 2620442 were DM (36%) and 4722885 SFM (64%; Table 1). The 
RR for DM was 1.3 times higher than the RR for SFM. The DR was significantly 
higher for DM than for SFM (6.2 vs. 5.4), leading to higher programme sensitivity 
(73.6% vs. 70.1%). Both the DR of DCIS and invasive cancers was significantly 
higher for DM (1.1 and 5.1 respectively) than for SFM (0.83 and 4.5) (Table 1). The 
PPV and programme specificity were significantly lower for DM (31.5% and 98.5% 
respectively) than for SFM (34.9% and 98.9%). The ICRs were equal (2.2).
Trends over time
The DR of DM was higher than that of SFM in all years, and significantly higher in 
2004, 2007 and 2009 (Figure 1b; Supplementary material 1b, 1c). The ICRs were 
similar over the years (except for 2004).
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Figure 1. Age-adjusted detection and interval cancer rates per 1000 women screened for 
all screens (a) and DM or SFMa (b)
aIn 2011 all screens were DM screens. Abbreviations: detection rate (DR); interval cancer 
rate (ICR); digital mammography (DM); screen-film mammography (SFM)
Figure 2. Age-specific detection (a) and interval cancer rates (b) per 1000 women screened
2
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Figure 3. Age adjusted-interval cancer rate (per 1000 women screened) for all, invasive 
and in situ carcinomas
Figure 4. Aged-adjusted programme sensitivity (a) and programme specificity (b) for all 
screens, DMa and SFM (49–74).
aThe percentage DM screens between 2004 and 2007 was considerably small; in 2011, all 
screens were DM screens. N.B. scale Y-axis differs between graph a and b. Abbreviations: 
digital mammography (DM); screen-film mammography (SFM).
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DISCUSSION
This nationwide study shows that the detection rate and programme sensitivity 
in the Dutch BCSP significantly increased during the transition from SFM 
to DM. This rise was most prominent for women under age 60. Despite the 
substantial improvement in detection, there was no decrease in the overall ICR. 
The programme specificity declined slightly as a result of the increased recall 
rate. Slight decreases were observable in the trend in interval cancers for younger 
women. The detection of both DCIS and invasive cancers and programme 
sensitivity were significantly higher for DM than for SFM, whereas the ICR was 
similar and the programme specificity was slightly lower for DM.
The increase in cancer detection can be partially explained by the transition to DM. 
Other studies also reported higher DRs for DM6, 10, 12, 13. DM has been demonstrated 
to lead to a substantially higher DCIS detection compared to SFM in the 
Netherlands13, 20, 22. There have been concerns that the increase in screen-detection 
of DCIS leads to overdiagnosis rather than to a significant additional reduction 
in breast cancer mortality24. Therefore, some might argue that the rise in breast 
cancer detection in this study largely reflects overdiagnosis. However, the results 
of a recent study suggest that for every 1.5-3 screen-detected DCIS cases, one 
subsequent invasive interval cancer is averted; at levels of DCIS up to 1.5 per 1000 
women screened (0.94 in our study)14. In addition, our findings show a significant 
increase in the detection of invasive breast cancers, which are less likely to be 
overdiagnosed than DCIS. Nevertheless, we recognize that a substantial rise in 
cancer detection may lead to a somewhat higher absolute number of overdiagnosed 
cases. Next to the transition to DM however, other factors also contributed to 
the increase in breast cancer detection. This increase already started in the mid-
1990s, far before the introduction of DM18. First, the higher DR may also have 
resulted from an increase in the underlying breast cancer incidence over the years. 
It has been shown that the underlying breast cancer incidence in the Netherlands 
increased before the introduction of screening between 1975-1990 in women later 
invited to screening and in women not yet invited to screening (40-49) before and 
after the introduction of screening (1975-2004)25, which has also been reported for 
other countries26, 27. It is reasonable to expect that the rise in background incidence 
continued after implementation of screening, due to increases in risk factors for 
breast cancer, including older age at first pregnancy and menarche and breast 
feeding at a later stage in life28-30. For example, in the Netherlands, the average age 
at birth of first child has increased from 26 years in 1970 to 29 years in 200431.
Second, the significant increase in the percentage of 2-view mammography at 
subsequent screens during our study period (50% in 2005; >90% in 201118) is likely 
to have contributed to higher breast cancer detection17, 32, 33. Finally, the DR may 
have increased due to changes in screening protocol. Following the outcomes of a 
study by Otten et al.34, the national recall strategy was altered and the RR in the 
Netherlands increased from 0.9% in 2000 to 1.8% in 200718.
We think that the stable interval cancer rate with the increasing trend in detection 
could also in fact reflect a reduction in the ICR, given the increase in background 
breast cancer incidence. The rise in detection may have prevented the interval 
cancer rate to increase as a result of increased breast cancer incidence.
Our estimate for the overall ICR (2.2 per 1000 screens) is in line with earlier 
reported rates from the BCSP in Germany (2.3)35 and Norway (1.8)2. We found 
that DM performed significantly better than SFM in terms of DR and programme 
sensitivity, at the expense of significantly higher RRs and FPRs and slightly lower 
programme specificity. These findings are also consistent with results of earlier 
studies6, 10, 12, 13, 19. We found RRs (expressed as the percentage of screens recalled 
for further assessment) of 1.6% for SFM and 2.1% for DM throughout the study 
period. Recently reported RRs for DM in other European BCSPs range from 2.9% 
to 6.1%5-7, 9, 36, 37. Therefore, RRs in the Netherlands are still rather low compared 
to other countries6, 12, 36, 38.
We did not find a difference in ICR between DM and SFM. Similar ICRs for DM 
and SFM were also reported for other BCSPs37, 39. It might be too early to observe 
the full effect of the transition to DM on the ICR. We observed a small, non-
significant, decrease in the overall ICR in 2011 but we need future data, after a 
few years of full DM screening, to determine whether or not this will turn into a 
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further statistically significant decline. Although we did not observe a significant 
difference in the overall ICR, looking at specific age groups we found that the ICR 
at initial screening in women aged 49-51 years was significantly lower for DM than 
for SFM (2.3 vs. 2.6 per 1000 screens; Additional file 1 S5). This finding corresponds 
to the results of the DMIST trial, which showed a higher diagnostic accuracy for 
DM than for SFM in pre- and perimenopausal women with dense breasts under 
the age of 5010.
The major strength of this study was the availability of national data on a large 
number of interval cancers. Thus, this study is the first nationwide analysis 
of sensitivity and specificity in the Dutch BCSP during the transition to DM. 
Furthermore, DM expanded during the second half of the study period and the 
effect of the transition from SFM to DM could therefore be studied well.
This study also had some limitations. Single screening examinations were not 
labelled as DM or SFM at time of screening and information about the proportion 
DM and SFM, during the years in which both modalities were used, had to be 
obtained from the screening units. The screens for which it was uncertain whether 
they were performed using screen-film or digital mammography were added to the 
screen-film group. This could lead to underestimation of detection rates for DM 
and to increased apparent detections rates for SFM. The difference in detection 
of DM relative to SFM could thus be (somewhat) greater than we report and our 
estimates may therefore be conservative. In addition, 2% of all breast cancers in 
the NCR database could not be classified as screen-detected or interval cancer.
Conclusions
In conclusion, the detection rate in the Dutch breast cancer screening programme 
substantially increased between 2004 and 2011, whereas the interval cancer rate 
was stable over time. The recall rate increased over the study period, resulting in a 
decrease in programme specificity over time, even though the current specificity of 
the Dutch programme is still relatively high (in international context). DM resulted 
in higher detection rates than SFM, with similar interval cancer rates. The overall 
interval cancer rate, slightly, but non significantly declined in younger age groups 
and a significant rise in programme sensitivity in women under age 60 years was 
observed, which may be partly attributable to the transition to DM. Particularly 
young women may therefore have benefited from the change to DM but further 
exploration is needed to confirm these findings.
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SUPPLEMENTARY MATERIAL
1a. Performance indicators (age-adjusted rates per 1000 screens) 




































































































































































1b. Performance indicators (age-adjusted rates per 1000 screens) 





















































































































































2011a - - - - - - -
aIn 2011, all screens were digital. Abbreviations: screen-film mammography (SFM).
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1c. Performance indicators (age-adjusted rates per 1000 screens) 






































































































































































Abbreviations: digital mammography (DM).
2a. Age-specific detection rate per 1000 screens by calendar year
2004 2005 2006 2007 2008 2009 2010 2011
49 4.98 4.91 5.27 5.50 5.92 5.95 7.16 7.04
50-54 4.18 3.84 4.11 4.17 4.35 4.51 5.26 5.01
55-59 4.47 4.23 4.38 4.65 4.67 4.79 4.99 5.23
60-64 5.43 5.41 5.76 6.05 6.01 6.25 6.49 6.83
65-69 6.16 6.31 6.79 7.11 7.20 7.38 7.19 7.78
70-74 6.69 7.14 7.25 8.15 7.82 7.68 7.91 7.87
C.I. low
49 4.38 4.32 4.66 4.87 5.27 5.30 6.47 6.35
50-54 3.92 3.59 3.85 3.90 4.08 4.23 4.97 4.73
55-59 4.19 3.96 4.11 4.37 4.38 4.50 4.69 4.93
60-64 5.08 5.06 5.40 5.70 5.67 5.91 6.15 6.48
65-69 5.75 5.90 6.36 6.68 6.76 6.94 6.77 7.35
70-74 6.22 6.67 6.76 7.64 7.32 7.18 7.41 7.38
C.I. high
49 5.67 5.58 5.96 6.21 6.64 6.68 7.93 7.80
50-54 4.76 4.11 4.39 4.45 4.63 4.80 5.57 5.31
55-59 5.09 4.51 4.66 4.95 4.97 5.10 5.30 5.55
60-64 6.18 5.78 6.14 6.43 6.37 6.61 6.84 7.19
65-69 7.01 6.75 7.25 7.57 7.66 7.85 7.63 8.24
70-74 7.61 7.66 7.78 8.70 8.36 8.21 8.44 8.39
Abbreviations: confidence interval (C.I.)
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2b. Age-specific interval cancer rate per 1000 screens by calendar 
year
2004 2005 2006 2007 2008 2009 2010 2011
49 2.77 2.60 2.47 2.38 2.80 2.64 2.54 2.42
50-54 2.21 2.21 2.63 2.38 2.25 2.31 2.33 1.96
55-59 2.31 2.41 2.12 2.14 2.19 2.01 2.19 2.03
60-64 2.20 1.93 2.14 2.09 2.41 2.25 2.30 2.15
65-69 1.83 1.92 2.09 2.10 2.09 2.12 2.39 2.20
70-74 1.82 1.91 1.95 1.90 2.22 2.02 2.27 2.38
C.I. low
49 2.33 2.18 2.06 1.98 2.37 2.22 2.14 2.04
50-54 2.02 2.02 2.42 2.18 2.06 2.11 2.14 1.79
55-59 2.12 2.21 1.94 1.95 1.99 1.83 2.00 1.84
60-64 1.98 1.73 1.92 1.89 2.20 2.05 2.10 1.96
65-69 1.61 1.70 1.86 1.87 1.86 1.89 2.15 1.98
70-74 1.59 1.67 1.71 1.66 1.96 1.78 2.02 2.12
C.I. high
49 3.30 3.10 2.96 2.87 3.32 3.14 3.02 2.89
50-54 2.63 2.42 2.85 2.59 2.46 2.52 2.54 2.15
55-59 2.75 2.62 2.32 2.35 2.40 2.22 2.40 2.23
60-64 2.61 2.16 2.38 2.31 2.65 2.47 2.52 2.35
65-69 2.18 2.17 2.36 2.36 2.34 2.38 2.65 2.45
70-74 2.17 2.18 2.23 2.17 2.52 2.31 2.57 2.67
Abbreviations: confidence interval (C.I.)
3. Age standardised interval cancer rates for all cancers, invasive 
cancers and in situ cancers (95% confidence interval)
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4. Age-specific programme sensitivity of all screens (based on first 
two years after a screen)
2004 2005 2006 2007 2008 2009 2010 2011
49 64.2% 65.4% 68.1% 69.8% 67.8% 69.3% 73.8% 74.4%
50-54 65.4% 63.4% 61.0% 63.6% 65.9% 66.1% 69.3% 71.8%
55-59 65.9% 63.7% 67.3% 68.5% 68.1% 70.4% 69.4% 72.1%
60-64 71.2% 73.7% 72.9% 74.4% 71.3% 73.6% 73.8% 76.1%
65-69 77.1% 76.7% 76.4% 77.2% 77.5% 77.7% 75.1% 78.0%
70-74 78.6% 78.9% 78.8% 81.1% 77.9% 79.1% 77.7% 76.8%
C.I. low
49 59.3% 60.5% 63.4% 65.1% 63.4% 64.9% 69.9% 70.5%
50-54 62.9% 60.8% 58.5% 61.1% 63.4% 63.7% 67.1% 69.6%
55-59 63.5% 61.3% 64.9% 66.1% 65.7% 68.0% 67.1% 69.9%
60-64 68.6% 71.2% 70.5% 72.1% 69.1% 71.4% 71.8% 74.2%
65-69 74.5% 74.2% 74.0% 74.9% 75.2% 75.4% 72.8% 75.9%
70-74 76.0% 76.4% 76.3% 78.8% 75.4% 76.7% 75.3% 74.4%
C.I. high
49 69.2% 70.3% 72.8% 74.4% 72.3% 73.7% 77.7% 78.2%
50-54 67.9% 66.0% 63.5% 66.1% 68.3% 68.5% 71.5% 74.0%
55-59 68.3% 66.2% 69.8% 70.9% 70.5% 72.8% 71.8% 74.3%
60-64 73.8% 76.2% 75.4% 76.6% 73.5% 75.7% 75.8% 78.0%
65-69 79.6% 79.2% 78.9% 79.5% 79.8% 79.9% 77.3% 80.0%
70-74 81.2% 81.4% 81.3% 83.4% 80.3% 81.6% 80.0% 79.1%
Abbreviations: confidence interval (C.I.)
5. Age-adjusted results for all, DM and SFM between 2004 and 2011 
for women aged 49-51
All (95% C.I.) DM (95% C.I.) SFM (95% C.I.)




No. interval cancers 1936 648 1288
No. false-positives 23682 10762 12920
Recall rate 33.6 (33.2-34.0) 47.7 (46.9-48.6) 31.9 (31.4-32.4)
False positive rate 27.7 (27.3-28.1) 40.4 (39.9-40.9) 26.3 (25.9-26.8)
Detection rate (all) 5.9 (5.7-6.1) 7.3 (6.97-7.61) 5.7 (5.5-5.9)
Detection rate DCIS 1.1 (1.03-1.2) 1.9 (1.81-2.00) 1.2 (1.1-1.3)
Detection rate 
invasive
4.8 (4.7-5.0) 5.4 (5.2-5.6) 4.5 (4.3-4.7)
Interval cancer rate 2.5 (2.4-2.7) 2.3 (2.2-2.4) 2.6 (2.5-2.8)
Programme 
sensitivity (%)
69.7 (68.6-70.8) 76.3 (74.6-77.9) 68.5 (67.1-70.0)
Programme 
specificity (%)
97.2 (97.2-97.2) 95.9 (95.8-96.0) 97.4 (97.3-97.4)
Positive predictive 
value (%)
16.5 (16.2-16.8) 15.1 (14.9-15.4) 17.5 (17.2-17.8)
Rates are presented per 1000 screens
2
Chapter 3
The effect of population-based 
mammography screening in Dutch 
municipalities on breast cancer 
mortality: 20 years of follow-up
Valérie D.V. Sankatsing, Nicolien T. van Ravesteyn, Eveline A.M. Heijnsdijk, 
Caspar W.N. Looman, Paula A. van Luijt, Jacques Fracheboud, Gerard J. 
den Heeten, Mireille J.M. Broeders, Harry J. de Koning
International Journal of Cancer 2017;141(4):671-677.
66 67
Chapter 3 Screening and breast cancer mortality
ABSTRACT
Background: Long-term follow-up data on the effects of screening are scarce and 
debate exists on the relative contribution of screening versus treatment to breast 
cancer mortality reduction. Our aim was therefore to assess the long-term effect 
of screening by age and time of implementation.
Methods: We obtained data on 69,630 breast cancer deaths between 1980 and 2010 
by municipality (N=431) and age of death (40-79) in the Netherlands. Breast cancer 
mortality trends were analysed by defining the municipality-specific calendar year 
of introduction of screening as year 0. Additionally, log-linear Poisson regression 
was used to estimate the turning point in the trend after year 0, per municipality, 
and the annual percentage change (APC) before and after this point.
Results: Twenty years after introduction of screening breast cancer mortality was 
reduced by 30% in women aged 55-74 and by 34% in women aged 75-79, compared 
to year 0. A similar and significant decrease was present in municipalities that 
started early (1987-1992) and late (1995-1997) with screening, despite the difference 
in availability of effective adjuvant treatment. In the age groups 55-74 and 75-79 the 
turning point in the trend in breast cancer mortality was estimated in year 2 and 
6 after the introduction of screening respectively, after which mortality decreased 
significantly by 1.9% and 2.6% annually.
Conclusions: These findings show that the implementation of mammography 
screening in Dutch municipalities is associated with a significant decline in breast 
cancer mortality in women aged 55-79, irrespective of time of implementation.
INTRODUCTION
Mammography screening has been shown to reduce breast cancer mortality in 
various randomised controlled trials1-4. Following the outcomes of these trials, 
population-based screening programmes have been implemented in many 
European countries5. In the Netherlands, mammography screening for women 
aged 50 to 69 was gradually implemented between 1987 and 1997 and extended to 
age 74 between 1998 and 2001.
Numerous observational studies have assessed the impact of population-based 
screening on breast cancer mortality6-10. The International Agency for Research on 
Cancer (IARC) has recently released a report on breast cancer screening in which 
the value of these studies was assessed11. Based on observational studies that were 
considered to be “informative for evaluating the effectiveness of mammographic 
screening programmes”, the experts concluded that there is sufficient evidence for 
the effectiveness of mammography screening in reducing breast cancer mortality in 
women aged 50 to 69 and 70 to 74. The studies supported an average 23% reduction 
in breast cancer mortality in 50 to 69 year old women invited to screening and a 
reduction of approximately 40% in women who attended screening11.
Trends in breast cancer mortality rates are often analysed to estimate the 
effectiveness of screening programmes. In order to assess the effect properly, long 
follow-up after full screening coverage is crucial. However, trend studies with 
adequate follow-up are scarce12. The aim of this study was to assess the effect of 
population-based screening on breast cancer mortality rates in the Netherlands 
between 1980 and 2010 using a long follow-up of 20 years after the start of 
nationwide screening (corresponding to 13 years after full screening coverage was 
achieved) and approximately 10 years after the extension of screening from age 69 
to age 74. By analysing breast cancer mortality between 1980 and 2010, this study 
will add 10 years of follow-up to previous work6. In addition, the long(er) follow-up 
after the extension of screening allowed us to assess the full impact of screening 
between age 50 and 74. Furthermore, breast cancer mortality was analysed at the 
municipality level and we could, therefore, account explicitly for the municipality-
specific introduction year of screening.
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Apart from screening, adjuvant therapy also contributes to a reduction in breast 
cancer mortality13-16. Adjuvant therapy was introduced in the Netherlands in the 
early 1980’s for women aged 50 years and older17 and has improved over time14. The 
proportion of breast cancer patients receiving adjuvant therapy in the Netherlands 
has increased substantially since the early 1980’s17-20. It has been argued that 
more effective therapy will lead to a smaller screening effect21. We therefore also 
compared trends in breast cancer mortality rates in municipalities that started 
early with screening to trends in late starting municipalities, in which more 
effective treatment was available.
METHODS
Dutch breast cancer screening programme
The breast cancer screening programme for women aged 50-69 in the Netherlands 
was initiated in 1987-89 in municipalities adjacent to two pilot municipalities 
(Utrecht and Nijmegen). From 1990 onwards, the screening programme was 
gradually implemented throughout the country, reaching full coverage in 1997. 
The programme was extended to age 74 between 1998 and 2001. Due to the 
gradual implementation, there were differences in calendar year of introduction 
of screening between municipalities. In 2003, a pilot study was conducted in which 
digital mammography was introduced. The proportion of digital mammography 
screens steadily increased from 1% in 2003 to 100% in June 2010.
Women aged 50-74 years are invited to screening once every two years in the 
Netherlands. Mammograms are read independently by two readers. Initially, 2-view 
mammography was only performed at first screening with 1-view mammography at 
subsequent screens. However, 2-view mammography was increasingly performed 
at subsequent screens over the years, from around 50% of all screens in 2004 to 
over 90% in 201022, 23. The attendance rate in the Dutch screening programme has 
been around 80% since the introduction of screening, with only small differences 
between age groups22. The recall rate was 9.9 per 1000 women screened during 
the introduction of screening, between 1990-1997, and increased to 21.4 per 1000 
in 201122.
Between 1980 and 2010, the number of municipalities decreased from 812 to 431, 
due to mergers of municipalities. Our dataset included all municipalities, and thus 
consisted of municipalities that remained unchanged between 1980 and 2010, 
municipalities that were merged, but had the same calendar year of introduction of 
screening and a small number of municipalities that were merged and had different 
calendar years of introduction of screening. In the latter group the linking of breast 
cancer deaths occurring after the merger of municipalities to the correct calendar 
year of introduction of screening is not straightforward and is described in the 
Methods of the Supplementary material.
Data
Breast cancer deaths between 1980 and 2010 and population data by calendar 
year, age at death (ages 40-79) and municipality were obtained from Statistics 
Netherlands24. All deaths in the Netherlands are recorded by Statistics Netherlands 
by cause of death and last known address. The cause of death is assessed by use 
of the death certificate with the indication of death determined by the attending 
physician.
Based on evidence from the literature, many have argued to expect a delay of 
3-5 years after first invitation to screening (age 50) in the full effect of screening 
on breast cancer mortality25. We therefore used the following age groups: 55-74 
(referred to as ‘women invited to screening’); 40-54 (‘younger women’); 75-79 
(‘older women’).
Statistical analyses
To correct for the gradual implementation of screening, we transformed calendar 
years (1980-2010) to years relative to the municipality-specific year of introduction 
of screening, defined as year 0. Preceding and subsequent years, before and after 
the introduction of screening, were indicated as year -1, -2, -3 etc. and 1, 2, 3 etc. 
respectively. Results are thus presented by year since introduction of screening 
instead of calendar year. Because of the gradual implementation, the maximum 
follow-up period of a municipality after the introduction of screening ranges from 
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13 (introduction of screening in 1997) to 23 (introduction of screening in 1987) 
years.
Breast cancer mortality trends were analysed using log-linear Poisson regression. 
We calculated breast cancer mortality rates per 100 000 woman-years, using 
the number of breast cancer deaths as the numerator and the mid-year female 
population size as the denominator. Age-standardisation26 was done to allow for 
(visual) comparability of mortality rates. In addition, we calculated breast cancer 
mortality rates relative to the rate at time of introduction of screening in women 
invited to screening (55-74), for each year before and after the introduction of 
screening, by using the breast cancer mortality rate in year 0 as a reference value 
(value 1 in the graph). The relative breast cancer mortality rate in a given year thus 
reflects the proportion of breast cancer mortality compared to the breast cancer 
mortality rate in year 0, in which screening was introduced. Corresponding 95% 
confidence intervals (CIs) were also calculated.
We performed an additional analysis by using log-linear Poisson regression (on the 
number of breast cancer deaths and woman-years) to assess the best estimate for 
a knot (referred to as ‘turning point’) in the trend in breast cancer mortality after 
the introduction of screening (year 0), using the municipality-specific calendar 
year of introduction of screening. This turning point reflects the most probable 
year in which the mortality trend changes after the introduction of screening. 
Slopes before and after the turning point were estimated to calculate the annual 
percentage change (APC) and the corresponding 95% CI. The methods and results 
of this analysis are extensively described in the Methods of the Supplementary 
material. All analyses were performed using R 3.0.2.
Early, intermediate and late starters
We divided municipalities into three groups of comparable size: early starters 
(introduction of screening between 1987 and 1992), intermediate starters 
(introduction between 1993 and 1994) and late starters (introduction between 
1995 and 1997). Adjuvant therapy was administered to 15% of patients in the 
Netherlands between 1975 and 1984 versus 49% of patients between 1995 and 
200419. We therefore assumed that late starters have higher treatment coverage and 
more effective treatment available in the years before and after the introduction 
of screening than early and intermediate starters. We compared breast cancer 
mortality trends in early, intermediate and late starting municipalities for the age 
group invited to screening (55-74) and we used log-linear Poisson regression to 
estimate the turning point and the slopes before and after this point (For results 
turning points see Supplementary material).
RESULTS
Our dataset consisted of 431 municipalities in 2010 and 69 630 breast cancer deaths 
between 1980 and 2010 (Table 1). The distribution of breast cancer deaths among 
age groups and early, intermediate and late starters is also shown in Table 1.
Table 1. Distribution of breast cancer deaths among age groups and starter groups, before 
and after the municipality-specific introduction of screening










All ages (40-79) 69 630 26 557 43 073
40-54 17 911 6 541 11 370
55-74 40 559 15 932 24 627
75-79 11 160 4 084 7 076
All starters (1987-1997)b 39 563 15 932 23 631c
1987-1992 (early) 17 430 6 077 11 353
1993-1994 (intermediate) 13 380 5 668 7 712
1995-1997 (late) 8 753 4 187 4 566
aIncluding the year of introduction (year 0). bRestricted to age 55-74 years. cLower number 
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The age-standardised breast cancer mortality rates by age group relative to the year 
in which screening was introduced at the municipality level (year 0) are displayed 
in Figure 1. In women invited to screening (55-74), there is a slight increase in 
breast cancer mortality before the introduction of screening at the municipality 
level followed by a strong decrease afterwards. A similar decline is visible for 
women aged 75-79, a few years later (women aged 70-74 were on average invited 
to screening 5 years later than women aged 50-69). In women aged 40-54, the 
mortality rate starts to decline moderately a few years before the introduction of 
screening (Figure 1). The underlying rates per year relative to the introduction 
of screening are listed in the Supplementary material (Supplementary material 
1a, 1b).
The relative breast cancer mortality rate for women aged 55-74 shows a reduction 
in breast cancer mortality 20 years after the introduction of screening of 30% 
(Figure 2). In the age group 75-79, there was a significant 34% reduction in year 
20, compared to year 0 (Figure 1).
The turning point in the breast cancer mortality trend was estimated in year 2 
after the introduction of screening in women aged 55-74 years and in year 6 after 
introduction in women aged 75-79 years, with corresponding significant annual 
decreases of 1.9% and 2.6% respectively from these points onwards (Supplementary 
material 2).
Early, intermediate and late starters
The age-standardised mortality rates, for women invited to screening (age-group 
55-74), are similar for early, intermediate and late starters before and after the 
introduction of screening. All three groups show a strong and similar decline in 
breast cancer mortality related to the introduction of screening at the municipality 
level, despite the (expected) difference in therapy regimens (Figure 3).
The trend in breast cancer mortality was estimated to change from a stable 
to a significantly declining rate in year 2 (early starters; 1987-1992) and year 4 
(intermediate and late starters; 1993-1994 and 1995-1997) after the introduction of 
screening. After the turning point the mortality rates in the three groups declined 
significantly between 2.2% and 2.9% per year (Supplementary material 2).
Figure 1. Age-standardised breast cancer mortality rates for age groups 40-54, 55-74 and 
75-79 by year relative to introduction of screening
DISCUSSION
Our results show a strong change in breast cancer mortality trends in women aged 
55-74 and 75-79, related to the municipality-specific introduction of screening in 
the age groups 50-69 and 70-74. The results support that mammography screening 
from age 50 to 74 contributes to a reduction in breast cancer mortality. The decline 
in breast cancer mortality in women aged 55-74 was estimated to be 30% after 
20 years of follow-up since the introduction of screening. For these women we 
estimated a significant annual decline of 1.9% over 11-21 years of follow-up, from 
year 2 after the introduction of screening onwards. Breast cancer mortality in older 
women (75-79) was reduced by 34% after 20 years of follow-up and was estimated 
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to decrease significantly by 2.6% annually over 7-17 years of follow-up, from year 
6 after the introduction of screening onwards.
Figure 2. Relative breast cancer mortality rates for age group 55-74 by year relative to 
introduction of screening
Dashed lines represent 95% CI.
The observed start of the decline in breast cancer mortality (and the estimated 
turning point in year 2) might seem early and in conflict with the expectation 
that the full effect of screening cannot be observed before 3-5 years after the first 
invitation to screening (we only accounted for a time delay in age, not for a delay 
in calendar time). However, the estimate of the delay in the effect of screening 
is largely based on results of the randomized controlled trials of breast cancer 
screening, which started in the early 1980’s. As the number of breast cancer deaths 
in our study is substantially higher than in any of the trials, which had around 750-
2000 breast cancer deaths1, 27, 28, it is plausible that the effect of screening already 
occurs before 3 years after its introduction. Also, at the time of introduction of 
screening, there may have been women with metastasized breast cancer who 
were not yet diagnosed and who would have died within two years in the absence 
of screening. Screen-detection may have averted death in some of these cases, 
which could have led to a rapid effect on breast cancer mortality rates in terms 
of mortality reduction. More importantly, a change in the trend in breast cancer 
mortality, from a stable to a downwards trend, after the introduction of screening 
is likely to occur before the point in time at which the full effect of screening can 
be observed.
Figure 3. Age-standardised breast cancer mortality rates for early (1987-1992), intermediate 
(1993-1994) and late (1995-1997) starters, for age group 55-74
A major strength of our study is the long period of follow-up of more than 10 years, 
both after full coverage of the screening programme was achieved in 1997 and from 
the extension of screening from age 69 to age 74 in 1998. Another strength is that 
we had nationwide coverage, as we obtained mortality data of all 431 municipalities 
in the Netherlands in 2010, and 69 630 breast cancer deaths.
Trend analyses of population mortality rates over time are often considered to have 
drawbacks with respect to the quantification of the effect of screening12. Our study 
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was carefully designed to account for some of these drawbacks. We accounted for 
differences in calendar year of introduction of screening between municipalities by 
analysing our data by year relative to introduction of screening at the municipality 
level rather than by calendar year. An observed effect of screening may be diluted 
by breast cancer deaths in women diagnosed with breast cancer before screening 
was introduced (prevalent tumours). This may, however, not be a major issue in our 
analysis as we assessed breast cancer mortality in the age group 55-74 (rather than 
50-74) and we calculated the annual percentage change in breast cancer mortality 
rates after the estimated turning point (rather than directly after the introduction 
of screening). These aspects of study design have been argued to limit the bias 
resulting from inclusion of death from prevalent tumours12. Nevertheless, there 
will be some dilution of the screening effect in the first years after the introduction 
of screening. However, it is plausible that the turning point in the trend occurs 
before the full effect of screening can be observed, even if there is dilution in the 
early years after the introduction of screening.
Our study had some limitations. As women who participated in screening, at 
the time it was introduced, in a certain municipality may have moved to another 
municipality afterwards, the correlation between the municipality-specific 
introduction year of screening and female inhabitants will become smaller 
over time. In addition, a study based on individual data would have been more 
accurate and reliable. However this was not possible due to privacy legislation. 
Furthermore, in the Netherlands participation is relatively high (on average 80% 
in each screening round)22, but, because we had no individual data on screening 
participation, the screening effect is diluted by non-participation. Finally, the 
comparisons between the trends in the age group invited to screening (55-74) and 
younger women (40-54) should be considered with caution as the administration of 
adjuvant treatment before and after the introduction of screening differed between 
these age groups in the Netherlands17.
After introduction of screening, we observed a 30% reduction in breast cancer 
mortality in women invited to screening which is consistent with reduction 
estimates in the age group invited to population-based screening from other 
studies29, 30 and in agreement with the 25% reduction shown by the randomized 
trials of mammography screening25. Our results are in line with trend studies, 
with adequate follow-up after complete coverage of screening, which demonstrate 
a strong association between the introduction of mammography screening and 
breast cancer mortality reduction8, 29. Furthermore, we estimated an annual decline 
in breast cancer mortality of 1.9% from year 2 after the introduction of screening 
onwards in women aged 55-74, which corresponds to the previously reported 
1.7% annual decline, after the introduction of screening in the Netherlands6. Our 
estimate is also within the range of reductions of 1 – 9% per year, reported by 
earlier European trend studies12, 31.
The effect of the extension of the upper age limit of screening to age 74 between 
1998 and 2001 on breast cancer mortality in women aged 75 and older was not (yet) 
reflected in the results of earlier research6, because of limited follow-up after this 
extension. Women aged 70-74 were, on average, invited 5 years later to screening 
than women aged 50-69. Having long-term follow-up data now, our results support 
a downturn in breast cancer mortality for women aged 75-79, showing a steep 
decline in this age group. The size of the change in the breast cancer mortality 
trend, after the introduction of screening, observed in this study was larger in the 
oldest age group (75-79) than in younger women aged 55-74 (APC of 2.6 vs APC of 
1.9), which is in line with earlier findings10, 32. The decline in breast cancer mortality 
in this group reflects a long-term accumulation of screening between ages 50 and 
69 and screening between ages 70 and 74. Also, the benefit of screening, in terms 
of breast cancer mortality reduction, has been shown to increase with the number 
of screens attended33, 34. In addition, as older women tend to have slower tumour 
growth rates and less dense breasts35-37, test sensitivity of mammography is higher 
at older age38-40.
In women aged 40-54, breast cancer mortality rates started to decline moderately 
a few years before the introduction of screening. The most probable cause for this 
downturn is the increasing use of adjuvant therapy, which younger women received 
significantly earlier than women in the age group 55-74 in the Netherlands22. Before 
the introduction of adjuvant therapy in the 1980’s for postmenopausal women 
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(above the age of 55 years), premenopausal node-positive women (under age 55 
years) already had received adjuvant chemotherapy for ten years17,18. Moreover, 
the proportion of node-positive patients under age 55 years that received adjuvant 
chemotherapy increased substantially before and around the introduction of 
screening in the Netherlands17. Opportunistic screening (for high-risk women) 
outside the screening programme may also lower breast cancer mortality41. As 
we expected beforehand, we did not find a turning point related to screening for 
the age group 40-54 (Appendix) as only a small part of this group is invited to 
screening (i.e. 50-54) and even in this subgroup the full effect of screening may 
not be observable yet.
The effect of adjuvant treatment on breast cancer mortality is clearly also 
intertwined in the trend in women aged 55-74. A recent modelling study predicted 
that adjuvant treatment caused a 13.9% reduction in breast cancer mortality in 
the total Dutch population in 2008, compared to a setting without adjuvant 
treatment16. Simulation of biennial screening from 50-74 resulted in an additional 
15.7% reduction in breast cancer mortality. Similar contributions of adjuvant 
treatment and screening to the observed breast cancer mortality reduction were 
also predicted by an earlier modelling study from the United States42.
It is difficult to disentangle the effect of screening and treatment after the 
introduction of screening. Adjuvant endocrine therapy (Tamoxifen) was 
introduced in the 1980s in the Netherlands, before the introduction of screening, 
for postmenopausal patients with node-positive and estrogen receptor (ER) 
positive breast cancer17. Over the years, adjuvant treatment has improved and its 
usage has increased significantly14, 17-20. For example, from 1998 onwards, node-
negative patients also received adjuvant systemic therapy, which is likely to have 
contributed to the decline in breast cancer mortality afterwards. Our results show 
that breast cancer mortality did not decrease before the introduction of screening 
in women invited to screening and older women, despite these improvements in 
therapy, which is in line with previous work8, 32. We did not observe differences 
in breast cancer mortality rates between municipalities in which screening was 
introduced rather early and municipalities in which screening was introduced 
rather late, with the latter having more effective adjuvant treatment available in 
the years before and after the introduction of screening. More importantly, a strong 
significant decline in breast cancer mortality shortly after the introduction of 
screening was present in both early, intermediate and late starters, suggesting 
a crucial role for screening in this downturn, irrespective of the quality and the 
extent of treatment. The annual decline after the turning point is stronger in late 
starters (2.9%) than in early starters (2.2%), which may indicate a synergistic effect 
between early detection and improved adjuvant treatment.
In conclusion, our results show a significant decrease in breast cancer mortality 
shortly after the introduction of screening at the municipality level in women 
invited to screening and in older women, similar in early starting municipalities 
and late starting municipalities (with more effective adjuvant treatment available), 
indicating that this decrease is strongly associated with the implementation of the 
national screening programme. 3
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SUPPLEMENTARY MATERIAL
1a. Age-standardised breast cancer mortality rates per 100 000 
woman-years for the age group 40-54, 55-74 and 75-79 years per 
year relative to the introduction of screening
Year 40-54 55-74 75-79
-15 53.0 108.6 145.3
-14 46.0 107.1 131.2
-13 41.9 94.7 145.7
-12 47.5 102.5 160.8
-11 43.9 98.5 161.0
-10 47.0 102.0 146.7
-9 47.2 103.4 171.5
-8 43.8 104.9 161.5
-7 46.2 107.5 158.9
-6 44.9 99.7 143.0
-5 46.9 104.1 160.8
-4 45.8 107.5 171.8
-3 47.2 106.1 160.7
-2 47.0 100.5 158.0
-1 46.4 105.8 163.0
0 45.7 107.4 163.6
1 43.1 104.3 168.3
2 42.3 100.4 166.9
3 43.4 99.1 157.5
4 38.8 96.8 169.6
5 42.7 96.0 166.0
6 41.2 95.6 165.9
7 38.4 90.1 169.2
8 39.9 89.3 164.9
9 38.3 84.5 152.5
10 37.2 77.9 144.8
11 36.9 82.0 137.5
12 33.9 78.5 123.7
13 32.2 76.5 132.1
14 34.6 79.6 124.7
15 32.9 71.6 117.5
16 33.2 75.9 106.2
17 29.8 79.8 114.6
18 34.2 75.3 113.6
19 29.2 72.7 116.5
20 32.5 74.6 107.7
1b. Age-standardised breast cancer mortality rates per 100 000 
woman-years for early, intermediate and late starters (age 55-74 







-12 93.1 106.6 102.4
-11 97.6 95.5 104.2
-10 100.3 99.0 109.6
-9 96.2 107.7 110.5
-8 109.5 103.0 98.4
-7 109.8 105.5 106.2
-6 94.1 105.5 101.8
-5 110.8 104.4 90.4
-4 105.0 111.7 105.7
-3 107.7 108.1 100.1
-2 106.3 86.9 110.0
-1 109.5 99.4 107.9
0 110.5 105.1 104.6
1 107.3 102.2 101.4
2 98.3 104.4 98.3
3 99.4 95.1 104.1
4 101.2 90.4 99.4
5 94.2 100.3 92.9
6 99.3 93.2 92.6
7 92.0 85.5 93.9
8 94.2 87.9 82.9
9 87.5 82.6 82.2
10 82.7 72.2 78.0
11 82.7 82.6 80.0
12 80.9 79.8 71.9
13 78.2 75.3 74.8
14 87.7 73.4 73.2
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ADDITIONAL ANALYSIS
Methods
We used log-linear Poisson regression (on the number of breast cancer deaths and 
woman-years) to assess the best estimate for a knot (referred to as ‘turning point’) 
in the trend in breast cancer mortality after the introduction of screening (year 
0), using the municipality-specific calendar year of introduction of screening. Two 
connecting linear splines were estimated for all possible positive integer values for 
the turning point (year 0, 1, 2, etc.) for each municipality separately, resulting in 
scaled deviances for all possible values for the turning point. The deviances were 
summed for all municipalities and the year with the smallest summed deviance 
was considered the best fit for the turning point. Thus, the turning point reflects 
the most probable year in which the mortality trend changes after the introduction 
of screening. Slopes before and after the turning point were estimated to calculate 
the annual percentage change (APC) and the corresponding 95% CI.
Models
To correct for the gradual implementation of screening, we transformed calendar 
years to years relative to the municipality-specific year of introduction of screening 
(range -t to t, with the municipality-specific year of introduction of screening 
defined as t = 0).
In order to determine the turning point (the best estimate for the lag time 
between introduction of screening and the turning point in the trend), the linear 
splines before and after the turning point and the corresponding deviances were 
estimated for all possible integer values of the turning point, using a log-linear 
Poisson regression model. The turning points (k) were restricted to occur after 
the introduction of screening and assumed to be integers, thereby ranging from 0 
(introduction screening, t = 0) to n (the number of municipality-specific follow-
up years since the introduction of screening until 2010, which depends on the 
calendar year of introduction of screening). The deviances of all municipalities 
were aggregated per possible turning point, resulting in a summed deviance for 
each turning point. The year with the smallest summed deviance was considered 
the best fit for the turning point (k*).
For municipalities that remained unchanged during our study period and for 
municipalities without differences in calendar year of introduction of screening 
that were merged we used the following model (a ‘Municipality-specific Model’) 
to determine the turning point in the trend:
where:
yik number of deaths in age class i and year k relative to start screening
yîk fitted value for the number of deaths in age class i and year k relative to start 
screening
αi log of the mortality rate in age class i in start year of screening 
β1 slope parameter before the turning point 
β2 slope parameter after the turning point 
PYit number of person-years in age class i and year j
log (PYit) offset parameter: log of the number of person-years in age class i and year j
J1;J2 linear spline relative to year since start screening per municipality
t time in years since start screening per municipality 
k location of possible turning point relative to t (year since start screening)
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Using the correct calendar year of introduction of screening is complicated if 
municipalities with a different calendar year of introduction year of screening 
merge. Because we only had information on address at time of death it is not 
possible to link a breast cancer death that occurs after the merger of municipalities 
to the municipality that the woman who died from breast cancer lived in at the 
time screening was introduced and, thus, to the corresponding calendar year of 
introduction of screening. Therefore, the model described above was not applicable 
to municipalities with different calendar years of introduction of screening that 
were merged at some point between 1980 and 2010, as after the merger only the 
combined data can be observed. For these municipalities we therefore used a 
more complex model (‘Municipality-specific Mixture Model’), which takes into 






φijm estimated numbers in the original municipality m (age class i and year j). This 
refers to both before and after the municipal merger
J11;J21;J12;J22 linear splines relative to year since start screening per municipality
PYijm number of person-years in the original municipality m in age class i and year j
log (PYijm) offset parameter: log of the number of person-years in the original 
municipality m in age class i and year j
yijm fitted value for the number of deaths in original municipality m in age class i 
and year j
µi fraction of the population that belongs to the (former) municipality m in ageclass i
λ last year before the merger
This model uses the assumption that, after the merger of municipalities, woman-
years at risk after the merger are divided proportionally between the former 
municipalities based on the age specific woman-years at risk in the last year 
before the merger (µi). After the merger only the combined data of the merged 
municipalities can be observed and the combined data are therefore the sum of the 
expected numbers from the original municipalities. Slope parameters are assumed 
to be equal in the former municipalities before the merger but differences in breast 
cancer mortality level (relative to the year of introduction of screening) were 
modelled using a single parameter for each municipality, assuming that hazard 
ratios are equal for all age classes (β4).
After the turning point was determined, slopes before and after this point were 
estimated using an aggregated Poisson regression model: 
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where:
yik number of deaths in age class i and year k relative to start screening
yîk fitted value for the number of deaths in age class i and year k relative to start 
screening
αi log of the mortality rate in age class i in start year of screening 
β1 slope parameter before the turning point 
β2 slope parameter after the turning point 
PYit number of person-years in age class i and year j
log (PYit) offset parameter: log of the number of person-years in age class i and year j
J1;J2 linear spline relative to year since start screening per municipality
t time in years since start screening per municipality 
k* location of turning point (best fit) relative to t (year since start screening)
It was not feasible to take into account differences in municipality-specific year of 
introduction of screening of merged municipalities in this analysis. We therefore 
considered the year of introduction of screening of the largest former municipality 
as the year of introduction of screening for the whole municipal merger and thus 
neglected the introduction years of the other smaller former municipalities. We 
could therefore aggregate the number of breast cancer deaths and person-years 
at risk for all municipalities by age class (µ) and years relative to the introduction 
of screening (-t to +t). Thus, in this model, mortality levels (relative to the year 
of introduction of screening) and slopes before and after the turning point are 
assumed to be equal in municipalities with different calendar years of introduction 
of screening that merge. The model uses age class as intercept and a linear spline 
before and after the turning point (relative to the year since introduction of 
screening (-t to +t) and generates the overall estimate of the slope before and 
after the turning point. 
The more complicated regression model (Mixture Model) failed to fit for a 
few small municipalities that emerged from a complicated merger and these 
municipalities were therefore removed from the dataset. 
Results
For women invited to screening (55-74), the turning point in the breast cancer 
mortality trend was estimated in year 2 after the introduction of screening (Table 
2). The trend changed from a non-significant trend (APC -0.19, 95% CI: -0.43 – 
0.05) before year 2 to a statistically significant annual decline of 1.93% (95% CI: 2.14 
– 1.72) after year 2. The turning point was estimated in year 6 after the introduction 
of screening for women aged 75-79 (women aged 70-74 were invited to screening 5 
years later on average than women aged 50-69). There was no significant trend in 
breast cancer mortality before year 6 (APC 0.23%, 95% CI: -0.12 – 0.58); hereafter 
an annual decrease of 2.56% (95% CI: 3.09 – 2.04) was estimated. For women 
aged 40-54, the turning point in the trend after the introduction of screening was 
estimated in year 10, with a statistically significant 1.08% (95% CI: 1.30 – 0.87) 
annual decline before year 10 and a stronger annual decrease of 1.97% (95% CI: 
2.55 – 1.39) after year 10.
The turning point in the trend was estimated in year 2 after the introduction of 
screening for early starters (1987-1992) and in year 4 for intermediate (1993-1994) 
and late starters (1995-1997). Before the turning point there was no significant 
trend in breast cancer mortality estimated in these groups (APC 0.18, 95% CI: 
-0.27 – 0.62; -0.15, 95% CI: -0.56 – 0.26; 0.01, 95% CI: -0.44 – 0.45 respectively). 
After the turning point breast cancer mortality rates declined significantly with 
2.15% (95% CI: 2.46 – 1.85), 2.55% (95% CI: 2.98 – 2.12) and 2.93% (95% CI: 3.55 – 
2.30) per year, respectively (Table 2).
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2. Estimated turning point after municipality-specific introduction 
of screening and annual percentage change (APC) before and after 
the turning point for different age groups and for early, intermedi-















-0.19 (-0.43 to 
0.05)




0.23 (-0.12 to 
0.58)






-1.08 (-1.30 to 
-0.87)








0.18 (-0.27 to 
0.62)






-0.15 (-0.56 to 
0.26)






0.01 (-0.44 to 
0.45)
-2.93 (-3.55 to 
-2.30)
<0.001
a In year after introduction of screening. b p value for difference in slope before and after 
estimated turning point. c Women aged 70-74 were invited to screening 5 years later on 
average than women aged 50-69.
Discussion
We estimated an annual decline in breast cancer mortality of 1.9% from year 2 after 
the introduction of screening onwards in women aged 55-74, which corresponds 
with the previously reported 1.7% annual decline, after the introduction of 
screening.6 Our estimate is also within the range of reductions of 1 – 9% per year, 
reported by earlier European trend studies12, 30.
The turning point for women aged 75-79 was estimated in year 6 after the 
introduction of screening (for women aged 50-69), which is later than for women 
invited to screening (year 2) and which can be explained by the fact that women 
aged 70-74 years were not invited to screening until the extension of the upper-age 
limit of the programme between 1998 and 2001. However, a turning point in year 
6 is still quite early keeping in mind that in a significant part of the municipalities 
screening was already introduced in the early 90s and the upper age limit was 
not extended until 1998. This rather early downturn in breast cancer mortality in 
women aged 75 and older may partly be attributable to screening participation of 
these women between ages 50 and 69.
We did not expect to find a turning point related to screening for the age group 
40-54 as only a small part of this group is invited to screening (i.e. 50-54) and even 
in this subgroup the full effect of screening may not be observable yet. Indeed, the 
turning point in the trend in breast cancer mortality for this age group in year 10 
is unlikely to be related to the introduction of screening. Of course, screening is 
likely to have contributed to some extent to the decline in breast cancer mortality 
after the introduction of screening in this age group, however it is plausible that 
this contribution does not translate into a turning point that is strongly associated 
with the introduction of screening. Nevertheless, we chose to assess the turning 
point in the trend after the introduction of screening for the age group 40-54 to 
make sure that no turning point similar to the one for the age group 55-74 (in 
year 2 after the introduction of screening) was found. If this would be the case, it 
would be plausible that a factor other than screening had a significant role in the 
turning of the trend.
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ABSTRACT
Background: In the Netherlands, routine mammography screening starts at age 
50. This starting age may have to be reconsidered because of the increasing breast 
cancer incidence among women aged 40 to 49 and the recent implementation of 
digital mammography.
Methods: We assessed the cost-effectiveness of digital mammography screening 
that starts between age 40 and 49, using a microsimulation model. Women were 
screened before age 50, in addition to the current programme (biennial 50-74). 
Screening strategies varied in starting age (between 40 and 50) and frequency 
(annual or biennial). The numbers of breast cancers diagnosed, life-years gained 
(LYG) and breast cancer deaths averted were predicted and incremental cost-
effectiveness ratios (ICERs) were calculated to compare screening scenarios.
Results: Biennial screening from age 50 to 74 (current strategy) was estimated to 
gain 157 life years per 1,000 women with lifelong follow-up, compared to a situation 
without screening, and cost €3,376/LYG (3.5% discounted). Additional screening 
increased the number of LYG, compared to no screening, ranging from 168 to 
242. The costs to generate one additional LYG (i.e. ICER), comparing a screening 
strategy to the less intensive alternative, were estimated at €5,329 (biennial 48-74 
vs. current strategy), €7,628 (biennial 45-74 vs. biennial 48-74), €10,826 (biennial 
40-74 vs. biennial 45-74) and €18,759 (annual 40-49 + biennial 50-74 vs. biennial 
40-74). Other strategies (49 + biennial 50-74 and annual 45-49 + biennial 50-74) 
resulted in less favourable ICERs.
Conclusions: These findings show that extending the Dutch screening programme 
by screening between age 40 and 49 is cost-effective, particularly for biennial 
strategies.
INTRODUCTION
Breast cancer is the most commonly diagnosed form of cancer among women 
aged 30 and older in the Netherlands 1. Mammography screening allows for early 
detection and early treatment of breast cancer, with the aim of averting breast 
cancer death. In the Netherlands, women aged 50 to 74 are invited biennially 
to screening. Various randomised controlled trials demonstrated a statistically 
significant breast cancer mortality reduction due to mammography screening in 
this age group 2-4. Furthermore, Otto et al. 5, 6 showed that the Dutch population-
based screening programme is effective in reducing breast cancer mortality. The 
evidence for the benefit of mammography screening for younger women is less 
conclusive7-9, however an effect for this age group is supported by several studies. 
Although the UK Age Trial showed a non-significant 17% reduction in breast 
cancer mortality9, a statistically significant breast cancer mortality reduction of 
15 to 18% associated with screening for women aged 39 to 49 or 40 to 49 at entry 
was demonstrated by several meta-analyses of randomised controlled trials10-13. 
In addition, a recent Swedish observational study that compared breast cancer 
mortality rates between women aged 40 to 49 who were invited to screening 
and women who were not invited to screening demonstrated a 26% statistically 
significant breast cancer mortality reduction14. Younger women may benefit 
less from mammography screening because of factors associated with younger 
age, including a lower breast cancer incidence 1 and a lower test sensitivity of 
mammography due to higher breast density and, possibly, faster growing tumours 
15, 16. However, results from the DMIST trial show that digital mammography 
improves test sensitivity for younger women with dense breasts compared to film 
mammography17.
Due to the controversy over screening before age 50 there is no consensus on 
whether or not to offer screening to women aged 40 to 49. The American Cancer 
Society recommends screening starting at age 40 18, whereas the U.S. Preventive 
Services Task Force stated that “the decision to start regular, biennial screening 
mammography before the age of 50 years should be an individual one and take 
patient context into account, including the patient’s values regarding specific 
benefits and harms” 19. There is also no wide agreement in Europe, although the 
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majority of European national screening programmes do not invite women under 
age 50 years. Routine mammography screening is currently extended to age 47 in 
the UK, as a result of the outcomes of the UK Age Trial20.
Biennial mammography screening for women aged 50 to 74 in the Netherlands 
has been shown to reduce breast cancer mortality at reasonable cost21. Two 
important reasons to consider a lower starting age of routine screening in the 
Netherlands are the increasing incidence of breast cancer among women aged 40 
to 49 (2.4% annually between 1995 and 2004) 22 and the recent implementation 
of digital mammography. It is unclear, however, whether extending screening to 
women younger than 50 years is cost-effective. This study therefore assesses the 
cost-effectiveness of digital mammography screening between ages 40 and 49 in 
addition to current screening in the Netherlands.  
METHODS
Model overview
The effects of screening were assessed using the MISCAN microsimulation model21, 
23. MISCAN simulates individual life histories of women and the natural history of 
breast cancer in a subset of these women. First, breast cancer incidence and breast 
cancer mortality are estimated in a situation without screening. Subsequently, 
mammography screening and treatment related improvements in survival are 
simulated, in order to determine the impact of screening and treatment on the 
life histories. Breast cancer starts with the onset of a preclinical ductal carcinoma 
in situ (DCIS) and continues with its progression through the invasive successive 
stages T1A, T1B, T1C and T2+. At each stage, a tumour may become screen-
detected (if screening is present), clinically detected (if symptoms are present) 
or may progress to the next preclinical stage (Figure 1)24. Screening leads to the 
detection of smaller tumours, which may improve survival after diagnosis. Women 
with a screen- or clinically detected cancer may receive adjuvant treatment, which 
also improves survival.
Figure 1. Transitions in the MISCAN model
Adopted from de Gelder et al., 200924. The arrows represent the possible transitions.
Model parameters and assumptions
The MISCAN model was updated earlier by de Gelder et al., using Dutch screening 
and treatment data from 1975 to 2008 and international data23. We updated this 
model with regard to test sensitivity of mammography and background breast 
cancer incidence (described below). Other parameters were adopted from the 
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earlier model, including the mean duration of preclinical screen-detectable cancer, 
transition probabilities between tumour stages and survival rates after clinical 
diagnosis and screen-detection (Supplementary material 1).
 All parameters were specified by age (including ages 40-49) and tumour stage and 
survival rates were also specified by lymph node status. Dutch data from screening 
organisations and comprehensive cancer centres were used to estimate the mean 
duration of preclinical screen-detectable cancer and the transition probabilities 
between tumour stages1, 25. Survival rates after screen-detection were estimated 
using data from the Swedish randomised controlled trials3, 4, 26, 27. Probabilities of 
receiving adjuvant treatment (endocrine therapy, chemotherapy or a combination 
of the two) and survival rates after receiving adjuvant treatment were incorporated 
using data from Dutch regional comprehensive cancer centers1, 25 (data by age, stage 
and calendar year) and data from the EBCTCG meta-analysis28 respectively.
Test sensitivity of mammography was estimated earlier using Dutch screening 
data on rates of screen-detected and interval cancers between 1990 and 2007 
and between 1990 and 2005 respectively 23. As digital mammography completely 
replaced film mammography in 2010 in the Netherlands and women in our analysis 
are screened from 2014 onwards, we refitted the model for age- and stage specific 
test sensitivity of digital mammography. The model was recalibrated using Dutch 
digital screening data including age-specific detection- and interval cancer rates 29, 
stage distribution and stage-specific detection rates 30 and breast cancer incidence 
between 2007 and 20111. We also incorporated future trends in breast cancer 
incidence. The trend in background breast cancer incidence (in the absence of 
screening) between 1975 and 2008 was modelled previously with MISCAN by 
assuming an annual rise in breast cancer incidence of 1.4%23. Because extrapolating 
this annual rise to the period of time of our analysis would lead to an unlikely high 
incidence, we assumed that the rise diminished from 2008 to a constant incidence 
from the year 2028 onwards (Supplementary material 1).
The effect of screening might be smaller for women aged 40 to 49 due to, amongst 
others, higher breast density15, 16. Test sensitivity of mammography and positive 
predictive value (PPV) of a screening mammogram are therefore likely to be lower 
for younger women. Recent Dutch data on screening characteristics of women aged 
40 to 49 are unavailable. Based on different trials, we estimated test sensitivity for 
women aged 40 to 49 to be up to 25% lower than test sensitivity for women aged 55 
and older 31. In order to account for a gradual change, test sensitivity was linearly 
interpolated between age 50 and 55. Stage-specific test sensitivities are shown in 
the Supplementary material 1. The PPV of a digital screening mammogram was 
estimated to be 30% for women aged 50 and older, based on findings of a recent 
Dutch study 30. The PPV for women aged 40 to 49 was assumed to be 12% (40% of 
the PPV for women aged 50 and older) 17, 32, 33.
In the Netherlands, mammography is often repeated in the hospital after recall for 
further assessment because of a suspicious screening mammogram34. Therefore, 
we assumed that all women recalled for further assessment would undergo an 
additional (diagnostic) mammogram.
Screening strategies
A cohort of 10 million Dutch women was simulated and women were followed from 
age 40 to death (from 2014 to 2074). Screening strategies varied in starting age 
(between 40 and 50) and frequency (annual or biennial). Women were screened 
biennially between age 50 and 74 in all strategies, in accordance with the current 
programme. Additional effects of strategies could therefore directly be linked to 
screening before age 50. Women aged 40 to 49 have been shown to have higher 
interval cancer rates than older women, due to greater mammographic breast 
density and higher tumour growth rates16, 35. Therefore, we considered both biennial 
and annual screening for women aged 40 to 49. The following strategies were 
simulated: 1) biennial screening from age 50 to 74 (current strategy), 2) one screen 
at age 49 and biennial screening from age 50 to 74, 3) biennial screening from age 
48 to 74, 4) biennial screening from age 45 to 74, 5) annual screening from age 45 
to 49 and biennial screening from age 50 to 74, 6) biennial screening from age 
40 to 74, 7) annual screening from age 40 to 49 and biennial screening from age 
50 to 74. In addition, to compare the cost-effectiveness of lowering the starting 
age of screening to the cost-effectiveness of increasing the stopping age, biennial 
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screening from age 50 to 76 was simulated. An 80% attendance to screening was 
assumed 29.
For each strategy, the number of invitations, mammograms, screen- and clinically 
detected tumours (stage- and age specific), total life-years and breast cancer deaths 
were predicted. Results are presented per 1,000 women, aged 40 in 2014, with 
lifelong follow-up. The number of false positive findings was calculated using the 
number of screen-detected cancers and a PPV of 30% (women aged 50 and older) 
or a PPV of 12% (women aged 40 to 49).
Costs and effects
We adopted a health care payer perspective36 and calculated direct medical costs 
including costs of screening, diagnostics and treatment. An overview of all costs 
is shown in Table 129, 37-39.
Both the effects of screening and adjuvant treatment are simulated with MISCAN. 
In order to predict the effect of screening, breast cancer mortality is estimated in 
a scenario with adjuvant treatment and screening and compared to breast cancer 
mortality in a scenario with adjuvant therapy but without screening. The effect of 
screening was estimated by predicting life-years gained (LYG). Costs and effects 
were calculated from the lowest starting age of screening (40 years) until death. 
Both effects and costs were discounted at 3.5% per year to take time preference 
into account 40. In order to meet Dutch standards, we also used a discount rate of 
1.5% for effects and 4% for costs (Supplementary material 2).
Screening strategies were ranked according to their effectiveness (number of LYG). 
The cost-effectiveness ratio was calculated for the current screening strategy 
(biennial 50-74), the least effective scenario, as the difference in costs between 
current screening and no screening divided by the number of LYG by current 
screening. Subsequently, in order to compare screening scenarios, incremental 
cost-effectiveness ratios (ICERs) were calculated for strategies that screen 
additionally between ages 40 and 49 as the difference in costs divided by the 
difference in LYG between a strategy and the previous, less effective, strategy in 
the ranking. The ICER of a strategy therefore reflects the costs required to generate 
one additional LYG, compared to the previous strategy. Strategies were defined 
as dominated if an alternative, more effective strategy existed that required lower 
costs to generate an additional LYG. Non-dominated strategies were considered 
to be efficient. We compared ICERs to a cost-effectiveness threshold of £20,000 - 
£30,000 (approximately €24,000 - €36,000) per quality-adjusted life-year (QALY) 
gained 40. Strategies that did not exceed this threshold were considered to be cost-
effective.
Sensitivity analyses
Univariate sensitivity analyses were performed in order to assess to what extent 
parameter values and assumptions affected the costs per LYG and the ranking 
of efficient screening strategies. First, we varied the test sensitivity of digital 
mammography for women aged 40 to 49 (50% and 100% of the test sensitivity for 
women aged 55 and older). Second, we varied the PPV of digital mammography for 
women aged 40 to 49 (9% and 15%). Third, we simulated a constant background 
breast cancer incidence (equal to incidence in 2008) as well as an annual increase 
in incidence of 1%. Fourth, in our analysis, all women who are screened and recalled 
for further assessment were assumed to undergo an additional mammogram (in 
addition to the screening mammogram) in the hospital. This may however not 
always be true in practice and we therefore also tested the assumption that instead 
of all women, only 50% of the women would undergo an additional mammogram 
in the hospital.
Finally, in order to assess the effect of screening strategies on quality of life we 
estimated quality-adjusted life-years (QALYs), using utility estimates with a value 
between 0 (worst imaginable health state) and 1 (healthy state). We included 
reductions in utility associated with screening participation and a positive screen 
of 0.006 for 1 week and 0.105 for 5 weeks respectively41. To take into account 
reductions in utility from breast cancer treatment, we used adjusted health 
utilities reported by Stout et al.42, with minor adjustments in the application of 
these utilities as our model cannot discriminate between regional and distant 
breast cancer stages (Supplementary material 1). Women who do not die of breast 
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cancer were assumed to experience a loss in quality of life of 0.1 for 2 years from 
diagnosis if diagnosed with in situ or localised breast cancer and a loss of 0.25 for 
2 years from diagnosis if diagnosed with regional or distant breast cancer. For 
women who die of breast cancer, a reduction of 0.4 was calculated from diagnosis 
until breast cancer death.




Digital screening mammogram 58
Diagnosis
Magnetic Resonance Imaging (MRI)b 367.59
Consultation after recallc 69.05
Ultrasound 77.08















aCosts are in Euros.
bMRI is assumed to be performed to measure the effect of neo-adjuvant therapy for all 
T2+ cancers.
cThe number of consultations after recall in the presence of screening is calculated by 
using the number of screen-detected cancers and a positive predictive value (PPV) of 
30%30 (ages 50-74) or 12% (ages 40-49). The number of consultations after recall in the 
absence of screening is calculated by using the number of clinically detected cancers and 
a PPV of 58.3%39.
dAll biopsies are assumed to be image-guided and therefore coincide with an ultrasound. 
The number of biopsies is calculated by using the number of breast cancers diagnosed and 
a PPV of 66.7%29. Costs of biopsy are calculated as the mean costs of FNA and biopsy.
eAll women recalled for further assessment are assumed to undergo an additional 
mammogram.
fMean treatment costs per tumour stage.
hEstimate from de Koning et al. 199238; indexed to current price levels.
RESULTS
Model validation
As women in our analysis are screened and followed in the future (2014-2074), we 
were not able to compare model predictions to observed data. However, our model 
predicted trends in breast cancer incidence and mortality from 1989 to 2011 quite 
well (Supplementary material 3, 4).
Effects of screening
Without screening, 135 cases of breast cancer and 45 breast cancer deaths were 
predicted to occur among 1,000 women, aged 40 years, followed over their 
lifetimes (undiscounted) (Table 2).
Screening these women biennially from age 50 to 74 (current strategy) averted 
12 breast cancer deaths and gained 157 life-years (13 LYG per breast cancer 
death averted), compared to no screening. In total, 138 breast cancer cases were 
diagnosed, of which 53 were screen-detected and 3 were overdiagnosed (138 - 135). 
Screening led to 124 false positive findings.
Strategies that screened additionally before age 50 gained life-years ranging from 
168 (49 + biennial 50-74) to 242 (annual 40-49 + biennial 50-74), compared to no 
screening. Offering annual screening from age 40 to 49, in addition to the current 
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strategy, would lead to three additional deaths averted, 85 additional LYG and 
105 additional false-positive findings (Table 2), by performing 7,842 additional 
mammograms, per 1000 women, aged 40 years, with life-long follow-up.
Biennial screening from age 50 to 76 gained 161 undiscounted life-years and averted 
12 breast cancer deaths (data not shown).
Incremental cost-effectiveness
Additional screening at age 49 and additional annual screening from age 45 to 
49 were dominated by biennial strategies that were more effective and required 
lower costs to generate an additional LYG. Biennial screening from age 50 to 
76 was dominated by biennial screening from age 48 to 74, which gained more 
additional life-years for similar costs (data not shown). All other strategies were 
on the efficiency frontier (Figure 2).
Total costs due to breast cancer diagnosis, treatment and death in the absence 
of screening were estimated at €1,161,008 per 1,000 women, followed over their 
lifetimes (3.5% discounted; Table 2). The estimated costs of the current screening 
program were €3,376 per LYG (3.5% discounted) (Table 3). One additional 
screening round at age 48 was predicted to gain 5 additional life-years, per 1,000 
women, and to cost €5,329 per additional LYG. Biennial screening from age 45 
instead of 48 would gain 6 more life-years that cost €7,628 per LYG. Lowering the 
starting age of biennial screening from age 45 to age 40 would gain 9 additional 
life-years that would cost €10,826 each. Screening annually instead of biennially 
from age 40 would result in a gain of 9 more life-years that cost €18,759 per LYG. 
All ICERs were below the cost-effectiveness threshold.
Sensitivity analyses
Estimated costs per (additional) LYG were only slightly influenced by varying the 
PPV for women under the age of 50 or by assuming that only 50% of women recalled 
for further assessment would undergo an additional mammogram (Supplementary 
material 5). Assuming a constant breast cancer incidence or lower test sensitivity 
of digital mammography for women aged 40 to 49 led to more unfavourable ratios 
of costs and effects (maximum €21,459) whereas a constant annual increase in 
incidence or higher test sensitivity led to more favourable ratios. Adjustment for 
quality of life resulted in a slightly higher reduction in life-years in the absence 
of screening than in the presence of screening, which led to a higher number of 
QALYs gained than the number of life-years gained for the different screening 
scenarios (Table 2). ICERs calculated by dividing the change in costs by the change 
in QALYs gained are therefore slightly more favourable than the ICERs based on 
the change in life-years gained (Supplementary material 6).
The ranking of strategies was not affected by any of the sensitivity analyses 
performed and ICERs were below the cost-effectiveness threshold (£20,000, 
€24,000) in all scenarios.
Figure 2. Efficiency frontier of screening strategies
Both costs and LYG are relative to a situation without screening and are presented per 
1,000 women (3.5% discounted).The current screening strategy (B 50-74) is displayed by 
a square, all other points reflect ICERs of additional screening strategies. Points on the 
frontier represent efficient strategies (i.e. no alternative strategy exists that gains more 
life years for fewer costs per additional LYG). Dominated strategies are represented by 
grey dots. Strategies consist of annual (A), biennial (B) or combined (A + B) screening.
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B 50-74 (current) 137,057 41 3,376
49 + B 50-74 1 158,680 44 dominated
B 48-74 1 163,704 46 5,329
B 45-74 2.5 210,234 52 7,628
A 45-49 + B 50-74 5 281,643 56 dominated
B 40-74 5 306,590 61 10,826
A 40-49 + B 50-74 10 475,420 70 18,759
aBoth costs and life-years gained are 3.5% discounted and are presented per 1,000 
women, aged 40 years, followed over their lifetimes and are relative to a situation without 
screening.
bcalculated as the difference in costs divided by the difference in life-years gained between 
a strategy and the previous, less effective, non-dominated strategy in the ranking (no 
screening for the current strategy).
Abbreviations: life-year gained (LYG); incremental cost-effectiveness ratio (ICER); biennial 
screening (B); annual screening (A).
DISCUSSION
This study shows that digital mammography screening between age 40 and 49 in 
the Netherlands, in addition to the current screening strategy, is cost-effective. 
Our results indicate that, from a cost-effectiveness perspective, biennial screening 
from age 40 to 49 is more efficient in addition to current screening than annual 
screening from age 45 to 49. Furthermore, our analysis suggests that one additional 
screening round is more efficient at age 48 than at age 49 and that extending the 
lower age-limit of screening by one additional screening round is more effective 
and will result in lower costs per additional LYG than extending the upper age-
limit by one screening round.
Our model predicted that both the number of LYG and breast cancer mortality 
reduction due to screening would increase with decreasing starting age. However, 
aside from benefits, additional screening before age 50 years is also associated 
with additional harms. We estimated that the number of false positive findings 
would increase by 74 per 1,000 women (60%), if biennial screening starts at age 
40 instead of age 50. A higher false positive rate may result in more unnecessary 
biopsies. However, false positive rates of current screening in the Netherlands 
are considerably lower than rates in other countries43 and will therefore 
probably remain relatively low if women are screened from age 40, despite the 
substantial increase in absolute number of false positive findings. False positive 
mammograms were recently shown to increase short-term anxiety 44. However, 
long-term anxiety and health utility scores did not differ between women with 
false positive mammograms and women with negative mammograms. The number 
of overdiagnosed cancers was estimated to increase by 0.33 per 1,000 women (11%) 
if biennial screening starts at age 40 instead of age 50 (cannot be read from Table 
2 because numbers are rounded). Overdiagnosis is defined as screen-detection of 
a cancer that would never have presented clinically in the absence of screening, 
during a woman’s lifetime. As overdiagnosed cancers would not have led to 
symptoms in the absence of screening, treatment of these cancers is considered 
to be harmful.
This study shows that the current screening programme in the Netherlands 
is highly cost-effective (€3,376 per LYG), which corresponds with findings of 
an earlier conducted Dutch study 21. Our model predicted a 26% breast cancer 
mortality reduction due to screening from age 50 to 74, which is in line with the 
outcomes of randomized controlled trials 4. Our results show that lowering the 
starting age of biennial screening to age 40 would reduce breast cancer mortality 
additionally by 5%. This finding is comparable to results of a previous modelling 
study in which the additional mortality reduction due to biennial screening from 
age 40 was determined using 6 different models (range, 1 to 6%) 45. This previous 
study also showed that most strategies on the efficiency frontier are biennial 
strategies. Correspondingly, in our analysis 4 of the 5 efficient strategies have 
a biennial screening interval. The only annual strategy on the frontier, annual 
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screening from age 40 (+ biennial 50-74), is efficient because it is the most intensive 
strategy that we simulated and it therefore yields the largest effect (i.e. could not be 
dominated by an alternative strategy). However, the ICER increases considerably 
shifting from biennial to annual screening between ages 40 and 49 (from €10,826 
per LYG to €18,759 per LYG), which has been reported before46.
A micro simulation study based on data from the US showed that biennial 
mammography screening from age 40 to 79 is cost-effective only for women 
with either BIRADS breast density categories 3 or 4 or a previous breast biopsy 
as well as a family history of breast cancer and that annual mammography from 
age 40 to 49 is not cost-effective for any high-risk group (using a threshold of 
$100,000 per QALY gained) 47. In contrast, we found that both annual and 
biennial mammography screening from age 40 are cost-effective, regardless of 
risk factors. However, Schousboe et al. 47 focused on film mammography, which 
has been shown to be less cost-effective than digital mammography for younger 
women 48. Furthermore, sensitivity analyses showed that results were sensitive 
to the proportion of false positive findings assumed and false positive rates in 
the Netherlands are significantly lower than in the US 43. This probably (partly) 
accounts for the more favourable ratio of costs and effects in our analysis. A more 
recent US modelling study showed that extending biennial digital mammography 
screening to all women aged 40 to 49, regardless of breast density, is cost-effective 
49, which is in line with our findings. However, results were sensitive to decreases 
in quality of life associated with screening and false positives.
Although our results are primarily based on Dutch screening data, outcomes 
regarding the efficiency of screening strategies are likely to be translatable to 
other countries.
To our knowledge, our study is the first cost-effectiveness analysis, using Dutch 
population data and including digital mammography screening from age 40 to 49. 
One of the strengths of our study is that we used digital mammography screening 
data for the calibration of our model. An advantage of using a model to determine 
the effectiveness of screening is that long-term effects are predicted, as women 
are followed over their lifetime.
This study also had a few limitations. First, our model outcomes depend on 
assumptions and input values. We assumed a constant PPV for women aged 40 
to 49 and a higher constant PPV for women aged 50 and older. In reality there 
may be a gradual increase in PPV with increasing age and changes in PPV over 
time. However, sensitivity analyses showed that differences in PPV were of 
little influence on our outcomes. Differences in test sensitivity did affect model 
outcomes. We estimated test sensitivity for women aged 40 to 49 to be up to 25% 
lower, using studies that were based on the use of film mammography, 31 because 
digital data on age-specific test sensitivity is scarce. The ratio in sensitivity of 
digital mammography between younger and older women may be different due 
to improved sensitivity associated with digital mammography for younger but 
not for older women 17. The estimated difference in sensitivity may therefore be 
overestimated and the number of additional LYG by screening before age 50 could 
be a conservative estimate. Model outcomes were also sensitive to the assumed 
trend in background breast cancer incidence. Extrapolating the earlier trend in 
incidence to the time period of our analysis would lead to an extremely high and 
unlikely incidence. We therefore assumed that the earlier annual rise in incidence 
would decrease over time. Although differences in test sensitivity and background 
breast cancer incidence were of influence on costs per additional LYG, the 
ranking of strategies and whether a strategy was efficient or dominated remained 
unchanged. Furthermore, in the worst-case scenarios (low test sensitivity or 
constant background breast cancer incidence) ICERs did not exceed the cost-
effectiveness threshold (£20,000, €24,000).
Another limitation is that we compare costs per LYG to a threshold expressed as 
costs per QALY gained, in our base case analysis. However, our sensitivity analysis 
showed that adjusting for quality of life has little impact on cost-effectiveness 
estimates, which is in line with earlier findings41, 50. In addition, when we adjust 
for quality of life, the incremental cost-effectiveness ratios are slightly more 
favourable and therefore remain below the threshold of £20,000 per QALY gained 
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(approximately €24,000 per QALY gained). When we compare the ICERs to the 
willingness-to-pay threshold of €20,000 per QALY gained, often cited in Dutch 
cost-effectiveness analyses51-53, all screening scenarios remain cost-effective.
Apart from age, we did not consider risk factors for breast cancer (e.g. breast 
density). The cost-effectiveness of risk-based screening strategies that start before 
age 50 is therefore an important area for further research.
Finally, the effect of adjuvant treatment was modelled using the most recent data of 
the EBCTCG trial28. Future improvements in therapy may reduce the effectiveness 
and therefore the cost-effectiveness of screening.
In conclusion, our results indicate that additional screening between age 40 and 
49 in the Netherlands is cost-effective. However, the decision about whether or 
not to implement screening before age 50 years will also depend on the balance 
of benefits and harms. If it is decided to extend the screening programme, our 
findings provide information that could be useful for selecting an appropriate 
screening strategy, by taking into account the cost-effectiveness of different 
starting ages between age 40 and 49 and suggesting that biennial strategies have 
more favourable ratios of costs and effects.
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SUPPLEMENTARY MATERIAL
1. Model parameters on natural history of breast cancer, and sur-
vival after adjuvant treatment and screening















stage by age and 
stage1, 2 b
Stage
Age DCIS T1AN– T1AN+ T1BN– T1BN+ T1CN– T1CN+ T2+N– T2+N+
40 2.1 0.1 0.1 0.3 0.3 0.6 0.6 0.7 0.7
50 2.1 0.1 0.1 0.4 0.4 0.8 0.8 0.9 0.9
60 2.1 0.1 0.1 0.5 0.5 1.2 1.2 1.3 1.3




age and preclinical 
stage1-3 b
Stage
Age DCIS T1AN– T1AN+ T1BN– T1BN+ T1CN– T1CN+ T2+N– T2+N+
<50 100% 70% 70% 83% 83% 80% 80% 93% 93%
≥55 100% 94% 94% 100% 100% 100% 100% 100% 100%
Long-term relative 
survival by clinical 




Age DCIS T1AN– T1AN+ T1BN– T1BN+ T1CN– T1CN+ T2+N– T2+N+
≤30 1.000 0.761 0.510 0.696 0.408 0.557 0.236 0.310 0.0555
40 1.000 0.798 0.575 0.741 0.481 0.618 0.310 0.386 0.102
50 1.000 0.815 0.605 0.762 0.512 0.646 0.341 0.418 0.118
60 1.000 0.796 0.568 0.738 0.472 0.612 0.298 0.375 0.0885
70 1.000 0.737 0.476 0.667 0.376 0.524 0.213 0.282 0.0524
≥80 1.000 0.678 0.383 0.597 0.279 0.435 0.128 0.189 0.0163
Long-term relative 
survival by clinical 
stage and age, with 
hormonal  
treatment2, 10, 11 b,c
Stage
Age DCIS T1AN– T1AN+ T1BN– T1BN+ T1CN– T1CN+ T2+N– T2+N+
≤30 1.000 0.854 0.701 0.814 0.639 0.730 0.534 0.579 0.424
40 1.000 0.865 0.714 0.826 0.650 0.743 0.533 0.585 0.388
50 1.000 0.860 0.699 0.819 0.629 0.731 0.499 0.558 0.330
60 1.000 0.856 0.696 0.815 0.628 0.727 0.505 0.559 0.357
70 1.000 0.832 0.666 0.788 0.601 0.696 0.497 0.541 0.394
≥80 1.000 0.797 0.612 0.746 0.546 0.644 0.451 0.489 0.380
Long-term relative 
survival by clinical 
stage and age, with 
chemotherapy2, 10, 11 b,c
Stage
Age DCIS T1AN– T1AN+ T1BN– T1BN+ T1CN– T1CN+ T2+N– T2+N+
≤30 1.000 0.831 0.652 0.784 0.580 0.686 0.458 0.510 0.329
40 1.000 0.858 0.700 0.817 0.634 0.731 0.513 0.567 0.366
50 1.000 0.855 0.691 0.814 0.619 0.723 0.486 0.546 0.314
60 1.000 0.820 0.620 0.769 0.535 0.659 0.382 0.450 0.198
70 1.000 0.767 0.535 0.705 0.446 0.578 0.301 0.363 0.157
≥80 1.000 0.720 0.464 0.649 0.373 0.509 0.241 0.294 0.144
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Long-term relative 
survival by clinical 
stage and age, with 
hormonal and 
chemotherapy2, 10, 11 b,c
Stage
Age DCIS T1AN– T1AN+ T1BN– T1BN+ T1CN– T1CN+ T2+N– T2+N+
≤30 1.000 0.905 0.806 0.879 0.765 0.824 0.697 0.726 0.626
40 1.000 0.912 0.814 0.887 0.772 0.833 0.697 0.730 0.602
50 1.000 0.890 0.765 0.859 0.711 0.790 0.611 0.655 0.481
60 1.000 0.872 0.729 0.835 0.669 0.757 0.559 0.608 0.428
70 1.000 0.851 0.702 0.811 0.645 0.730 0.552 0.592 0.461
≥80 1.000 0.820 0.654 0.774 0.596 0.683 0.511 0.545 0.448
Reduction in risk of 
dying of breast cancer 




Age DCIS T1AN– T1AN+ T1BN– T1BN+ T1CN– T1CN+ T2+N– T2+N+
≤30 100% 85% 67% 81% 59% 71% 43% 50% 18%
40 100% 88% 72% 84% 65% 75% 50% 57% 25%
50 100% 89% 74% 85% 67% 77% 53% 60% 28%
60 100% 87% 72% 84% 64% 75% 49% 56% 24%
70 100% 88% 72% 84% 65% 75% 50% 57% 25%




In situ or localised 0.9 for 2 years
Regional or distant 0.75 for 2 years
Breast cancer death 0.6 until death
Adapted from de Gelder et al., 201416. Abbreviations: ductal carcinoma in situ (DCIS); 
lymph node negative breast cancer with diameter of 5 mm or smaller (T1AN-); lymph 
node negative breast cancer with diameter of 6-10 mm (T1BN-); lymph node negative 
breast cancer with diameter of 11-20 mm (T1CN-); lymph node negative breast cancer with 
diameter of more than 20 mm (T2+N-); lymph node positive breast cancer with diameter 
of 5 mm or smaller (T1AN+); lymph node positive breast cancer with diameter of 6-10 mm 
(T1BN+); lymph node positive breast cancer with diameter of 11-20 mm (T1CN+); lymph 
node positive breast cancer with diameter of more than 20 mm (T2+N+).
a based on assumptions, b data used for model fit (calibration), c data used directly as 
input
2. Costs, effects and incremental cost-effectiveness ratios, dis-
counted in accordance with Dutch standards (effects 1.5% dis-
counted, costs 4% discounted)
Screening 
strategy
Costsa (€) Life-years gainedb ICERc (€/LYG)
No screening 1,049,093
B 50-74 (current) 131,158 87 1,509
49 + B 50-74 151,956 93 dominated
B 48-74 157,237 96 2,774
B 45-74 203,062 107 4,128
A 45-49 + B 50-74 272,069 116 dominated
B 40-74 299,430 123 6,258
A 40-49 + B 50-74 464,913 139 10,029
aThe costs of screening strategies reflect the additional costs relative to a situation without 
screening.
bLife-years gained relative to a situation without screening.
cICERs are calculated as the difference in costs divided by the difference in life-years gained 
between a strategy and the previous, less effective, strategy in the ranking (no screening 
for the current strategy).
Abbreviations: life-year gained (LYG); biennial screening (B); annual screening (A).
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3. Observed and modelled breast cancer incidence between 1989 
and 2011 in five-year age groups, per 100,000 women
4. Observed and modelled breast cancer mortality between 1989 
and 2011 in five-year age groups, per 100,000 women
4
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ICERs (€/LYG) additional screeningb
Scenario






A 40-49 + 
B50-74
Baseline 3,376 5,329 7,628 10,826 18,759
50% of women undergo 
additional mammogramc 
after recall for further 
assessment
3,269 5,129 7,443 10,653 18,595
PPV for women aged <50 
is 30% of PPV for women 
aged ≥50
3,376 5,584 7,833 11,020 18,938
PPV for women aged <50 
is 50% of PPV for women 
aged ≥50
3,376 5,177 7,505 10,710 18,651
Breast cancer incidence is 
constant over the years
4,139 6,404 8,509 11,666 21,459
Breast cancer incidence 
increases annually with 1%
2,737 5,298 7,326 9,800 18,691
Test sensitivity of DM 
for women aged <50 is 
50% of test sensitivity for 
women aged ≥55
3,655 8,076 11,075 15,299 21,170
Test sensitivity of DM for 
women aged <50 is equal 
to test sensitivity for 
women aged ≥55
3,263 4,457 6,596 9,204 18,020
aThe cost-effectiveness ratio of current screening is calculated as the difference in costs 
between current screening and no screening divided by the life-years gained by current 
screening.
bICERs of additional screening are calculated as the difference in costs divided by the 
difference in life-years gained between a strategy and the previous, less effective, strategy 
in the ranking.
c 50% of women who were screened and recalled for further assessment undergo a second 
mammogram in the hospital, in addition to the screening mammogram
Abbreviations: cost-effectiveness ratio (CER); incremental cost-effectiveness ratio (ICER); 
life-year gained (LYG); biennial screening (B); annual screening (A); positive predictive 
value (PPV); below age 50 (<50); age 50 and older (≥50); age 55 and older (≥55).



















49 + B 
50-74
1 158,680 58 dominated
B 48-74 1 163,704 61 4,060
B 45-74 2.5 210,234 69 5,802
A 45-49 + B 
50-74
5 281,643 75 dominated
B 40-74 5 306,590 80 8,259
A 40-49 + B 
50-74
10 475,420 92 14,300
aBoth costs and QALYs gained are 3.5% discounted and are presented per 1,000 women, 
followed over their lifetime from age 40. The costs of screening strategies reflect the 
additional costs relative to a situation without screening.
bQALYs gained relative to a situation without screening.
cICERs are calculated as the difference in costs divided by the difference in QALYs gained 
between a strategy and the previous, less effective, strategy in the ranking (no screening 
for the current strategy).
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7. Pathway of screening and treatment
Women with a positive screening mammogram will be referred by their GP to a 
hospital. In order to discriminate between true positive and false positive results, 
these women will undergo a consultation, an additional mammogram and a 
proportion of these women will undergo ultrasound-guided biopsy. Women with 
a false positive or true negative result will be invited to the subsequent screening 
round. Women with a false negative result are invited to subsequent screening if 
the tumour is not clinically detected during the interval between screening rounds. 
Women with a true positive result may receive (adjuvant) treatment. In our model, 
treatment starts immediately once a tumour is screen- or clinically detected.
References
1. National Evaluation Team for Breast cancer screening (NETB). National evaluation 
of breast cancer screening in the Netherlands 1990-2007. Twelfth evaluation report. 
Erasmus MC University Medical Center Rotterdam, Radboud University Nijmegen 
Medical Centre, 2009.
2. Nederlandse Kankerregistratie. http://www.cijfersoverkanker.nl/. (Accessed: December, 
2014)
3. van Luijt PA, Fracheboud J, Heijnsdijk EA, den Heeten GJ, de Koning HJ, National 
Evaluation Team for Breast Cancer Screening in Netherlands Study G. Nation-wide data 
on screening performance during the transition to digital mammography: observations 
in 6 million screens. Eur J Cancer 2013;49:3517-25.
4. Adami HO, Malker B, Holmberg L, Persson I, Stone B. The relation between survival 
and age at diagnosis in breast cancer. N Engl J Med 1986;315:559-63.
5. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival 
in 24,740 breast cancer cases. Cancer 1989;63:181-7.
6. Tabar L, Vitak B, Chen HH, Duffy SW, Yen MF, Chiang CF, Krusemo UB, Tot T, Smith 
RA. The Swedish Two-County Trial twenty years later. Updated mortality results and 
new insights from long-term follow-up. Radiol Clin North Am 2000;38:625-51.
7. Michaelson JS, Silverstein M, Wyatt J, Weber G, Moore R, Halpern E, Kopans DB, 
Hughes K. Predicting the survival of patients with breast carcinoma using tumor size. 
Cancer 2002;95:713-23.
8. Michaelson JS, Silverstein M, Sgroi D, Cheongsiatmoy JA, Taghian A, Powell S, Hughes 
K, Comegno A, Tanabe KK, Smith B. The effect of tumor size and lymph node status 
on breast carcinoma lethality. Cancer 2003;98:2133-43.
9. Sant M, Allemani C, Capocaccia R, Hakulinen T, Aareleid T, Coebergh JW, Coleman 
MP, Grosclaude P, Martinez C, Bell J, Youngson J, Berrino F, et al. Stage at diagnosis is 
a key explanation of differences in breast cancer survival across Europe. Int J Cancer 
2003;106:416-22.
10. Sukel MP, van de Poll-Franse LV, Nieuwenhuijzen GA, Vreugdenhil G, Herings RM, 
Coebergh JW, Voogd AC. Substantial increase in the use of adjuvant systemic treatment 
for early stage breast cancer reflects changes in guidelines in the period 1990-2006 in 
the southeastern Netherlands. Eur J Cancer 2008;44:1846-54.
11. Early Breast Cancer Trialists’ Collaborative G. Effects of chemotherapy and hormonal 
therapy for early breast cancer on recurrence and 15-year survival: an overview of the 
randomised trials. Lancet 2005;365:1687-717.
12. de Koning HJ, Boer R, Warmerdam PG, Beemsterboer PM, van der Maas PJ. Quantitative 
interpretation of age-specific mortality reductions from the Swedish breast cancer-
screening trials. J Natl Cancer Inst 1995;87:1217-23.
13. Nystrom L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist LE. Long-
term effects of mammography screening: updated overview of the Swedish randomised 
trials. Lancet 2002;359:909-19.
14. Bjurstam N, Bjorneld L, Warwick J, Sala E, Duffy SW, Nystrom L, Walker N, Cahlin 
E, Eriksson O, Hafstrom LO, Lingaas H, Mattsson J, et al. The Gothenburg Breast 
Screening Trial. Cancer 2003;97:2387-96.
15. Stout NK, Rosenberg MA, Trentham-Dietz A, Smith MA, Robinson SM, Fryback DG. 
Retrospective cost-effectiveness analysis of screening mammography. J Natl Cancer 
Inst 2006;98:774-82.
16. de Gelder R, Heijnsdijk EA, Fracheboud J, Draisma G, de Koning HJ. The effects of 
population-based mammography screening starting between age 40 and 50 in the 
presence of adjuvant systemic therapy. Int J Cancer 2014.
4
Chapter 5
Risk stratification in breast cancer 
screening: cost-effectiveness and 
harm-benefit ratios for low-risk 
and high-risk women
Valérie D.V. Sankatsing, Nicolien T. van Ravesteyn, Eveline A.M. Heijnsdijk, 
Mireille J.M. Broeders, Harry J. de Koning
International Journal of Cancer 2020;147(11):3059-3067.
134 135
Risk stratification in breast cancer screeningChapter 5
ABSTRACT
Background: In mammography screening programmes, women are screened 
according to a one-size-fits-all principle. Tailored screening, based on risk levels, 
may lead to a better balance of benefits and harms.
Methods: With microsimulation modelling, we determined optimal mammography 
screening strategies for women at lower (relative risk (RR)0.75) and higher (RR1.8) 
than average risk of breast cancer, eligible for screening, using the incremental 
cost-effectiveness ratio (ICER) of current uniform screening in the Netherlands 
(biennial (B) 50-74) as a threshold ICER. Strategies varied by interval (annual (A), 
biennial (B), triennial (T)) and age range. The number of life-years gained (LYG), 
breast cancer deaths averted, overdiagnosed cases, false-positive mammograms, 
ICERs and harm-benefit ratios were calculated.
Results: Optimal risk-based screening scenarios, below the threshold ICER of 
€8,883/LYG, were T50-71 (€7,840/LYG) for low-risk and B40-74 (€6,062/LYG) for 
high-risk women. T50-71 screening in low-risk women resulted in a 33% reduction 
in false-positive findings, a similar reduction in costs and improved harm-benefit 
ratios compared to the current screening schedule. B40-74 in high-risk women led 
to an increase in screening benefit, compared to current B50-74 screening, but a 
relatively higher increase in false-positive findings.
Conclusions: In conclusion, optimal screening consisted of a longer interval and 
lower stopping age than current uniform screening for low-risk women, and a lower 
starting age for high-risk women. Extending the interval for women at lower risk 
from biennial to triennial screening reduced harms and costs while maintaining 
most of the screening benefit.
INTRODUCTION
Most European countries offer uniform mammography screening between age 
50 and 69 or 74 to all eligible women, regardless of their individual risk of breast 
cancer1. This is in agreement with the European guidelines for quality assurance 
in breast cancer screening and diagnosis2. However, besides sex and age, there are 
other known risk factors for breast cancer that may affect the benefits and harms 
of screening, including breast density, family history of breast cancer, having had 
a previous breast biopsy and lifestyle-related factors3, 4. A risk-based screening 
approach may positively affect the balance between benefits and harms. In such an 
approach, the target age range and the screening interval are adjusted to different 
risk levels. There are several ongoing studies with respect to risk-based breast 
cancer screening in Europe, which collect information on risk factors for breast 
cancer for risk stratification5-7.
The potential of risk-based screening has also been explored by modelling studies. 
Studies from the United States showed that biennial screening from age 40 onward 
in women at increased risk of breast cancer is cost-effective8 and results in a 
similar ratio of false-positive (FP) findings and life-years gained (LYG) as biennial 
screening in average-risk women between age 50 and 749. There are only a few 
European modelling studies that addressed risk-based mammography screening 
strategies. These studies also found that risk-based screening is cost-effective 
compared with uniform screening and that it reduces overall harms10, 11. Only one 
of these studies searched for optimal risk-based strategies for specific risk groups10. 
However, the authors had limited access to national data on screening performance 
and did not include ductal carcinoma in situ (DCIS) in their model10.
In this study, we aimed to determine the optimal (i.e. most effective in terms of 
life-years gained) screening strategy for low-risk and high-risk women eligible 
for digital mammography screening in the Netherlands (no BRCA1/2 mutation 
carriers), under the condition that the cost-effectiveness did not exceed that 
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METHODS
Model parameters and assumptions
We used the MIcrosimulation SCreening ANalysis (MISCAN) model, which 
simulates individual life histories 12. Subsequently, the natural history of breast 
cancer (without screening) is simulated resulting in the onset of breast cancer in 
some women, which may be diagnosed and may eventually lead to breast cancer 
death. In MISCAN, breast cancer starts with the development of preclinical ductal 
carcinoma in situ (DCIS), which may progress through the invasive successive 
stages T1a, T1b, T1c and T2+ (semi-Markov process). A very small fraction of DCIS 
is assumed to regress13.
Model outcomes are first estimated for a situation without screening, in which 
breast cancers can be detected when in the reach the clinical detectable phase or 
progress to the next preclinical stage. Hereafter, mammography screening and 
improvements in survival after screen-detection are modelled. In the presence 
of screening, tumours can also become screen-detected during the preclinical 
phase. Screening can therefore lead to earlier detection and treatment of breast 
cancer and possibly to aversion of breast cancer death. In the model, clinically and 
screen-detected cancers are treated with primary therapy and may also be treated 
with adjuvant therapy, which improves survival.
Recently, we recalibrated several parameters of the model, including stage- and 
age-specific sensitivity of screen-film and digital mammography, breast cancer 
background incidence, stage- and age-specific mean duration of preclinical screen-
detectable breast cancer and progression and regression rate of DCIS. These 
parameters were calibrated to recent data from the Dutch screening programme 
on interval cancers (2004-2011), screen-detected cancers (2004-2013) and stage 
distribution at detection of cancers14, 15. Simultaneously, parameters were calibrated 
to data from the Netherlands Comprehensive Cancer Organisation14 on breast 
cancer incidence between 1975-2013 by five-year age groups.
In addition, probabilities of being treated with adjuvant treatment (endocrine-, 
chemo-, a combination or a combination with targeted therapy) by age, stage 
and calendar year were updated using data from the Netherlands Comprehensive 
Cancer Organisation over the years 2004-201114. Values of important model 
parameters are listed in Table 1.
We simulated a cohort of women born in 1974. The time horizon for estimating 
effects was from age 40 until death. In order to fairly compare strategies consisting 
of different screening intervals, we simulated 100% attendance to screening. We 
also simulated 100% adherence to primary treatment.
Risk groups
We simulated different risk groups: low, average (total population) and high, based 
on common risk factors (other than breast density) and their relative risk (RR) 
estimate (Supplementary material 1). Combining these factors led to a combined 
low RR of 0.75 and a combined high RR of 1.8. Risk was defined based on RR rather 
than absolute risk to make results more comparable to countries with different 
average absolute breast cancer risk. BRCA1 and BRCA2 mutation carriers were not 
included in the high-risk group.
Our standard model represented the total Dutch female population with an overall 
average risk for breast cancer (RR=1). The underlying breast cancer incidence in 
the absence of screening (by age and calendar year) was modified for the low- 
and high-risk group by multiplying the onset hazards of average risk by the RR of 
low- and high-risk (Supplementary material 2). A woman’s RR was assumed to be 
constant from birth until death.
Besides current screening (biennial 50-74), low and high-risk women were 
simulated to be screened with a range of strategies, which varied by interval, 
starting and stopping age. Intervals were annual (A), biennial (B) or triennial 
(T). Digital mammography was the screening test in all scenarios. Outcomes of all 
strategies were compared to no screening and outcomes of optimal screening also 
to current B50-74 screening in the respective risk-group. Strategies for women at 
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Stage-specific sensitivity of digital mammography DCIS 0.87
Stage-specific sensitivity of digital mammography T1a 0.55
Stage-specific sensitivity of digital mammography T1b 0.48
Stage-specific sensitivity of digital mammography T1c 0.86
Stage-specific sensitivity of digital mammography T2+ 1
Relative sensitivity‡ of younger ages digital mammography 0.75
Breast cancer onset 0.291
Onset hazard age 30 years 7.049E-05
Onset hazard age 50 years 0.010
Onset hazard age 70 years 0.019
Onset hazard age 100 years 0.024
Stage-specific duration† (years) screen-detectable preclinical 
stage DCIS
3.5
Stage-specific duration† (years) screen-detectable preclinical 
stage T1a
0.1
Stage-specific duration† (years) screen-detectable preclinical 
stage T1b
0.5
Stage-specific duration† (years) screen-detectable preclinical 
stage T1c
1.5
Stage-specific duration† (years) screen-detectable preclinical 
stage T2+
0.9
Probability of DCIS progressing into next stage (T1A) immediately 0.842
Probability of DCIS progressing into next stage (T1A) slowly 0.038
Stage-specific reduction in risk of dying from breast cancer after 
screen-detection* DCIS
100%
Stage-specific reduction in risk of dying from breast cancer after 
screen-detection* T1a, N-
88%
Stage-specific reduction in risk of dying from breast cancer after 
screen-detection* T1b, N-
84%
Stage-specific reduction in risk of dying from breast cancer after 
screen-detection* T1c, N-
75%








Stage-specific reduction in risk of dying from breast cancer after 
screen-detection* T1a, N+
72%
Stage-specific reduction in risk of dying from breast cancer after 
screen-detection* T1b, N+
64%
Stage-specific reduction in risk of dying from breast cancer after 
screen-detection* T1c, N+
49%
Stage-specific reduction in risk of dying from breast cancer after 
screen-detection* T2+, N+
24%
Costs late stage breast cancer €18000
Stage-specific treatment costs DCIS €4569
Stage-specific treatment costs T1a, N- €4333
Stage-specific treatment costs T1b, N- €5057
Stage-specific treatment costs T1c, N- €11146
Stage-specific treatment costs T2+, N- €10815
Stage-specific treatment costs T1a, N+ €16103
Stage-specific treatment costs T1b, N+ €6744
Stage-specific treatment costs T1c, N+ €20822
Stage-specific treatment costs T2+, N+ €15063
Positive predictive value of recall with digital mammography 
screening
28%
Positive predictive value of biopsy 67%
Positive predictive value of recall by a general practitioner 58%
†Given values for the stage-specific durations represent values for women aged 50 years. 
In the model, different durations are used for different age groups ‡The relative sensitivity 
is 1 for age 55 and older, 0.75 for <50 and interpolated between 0.75 and 1 for 50-55 *Given 
values for the stage-specific reduction in risk of dying from breast cancer after screen-
detection represent average values across all ages. In the model, different values are used 
for different age groups N.B. Onset hazards were adjusted for risk based screening; the 
positive predictive value of recall with digital mammography screening was adjusted for 
annual and triennial screening
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Low risk (RR=0.75; 101 strategies):
- Starting age: between 50-60 years
- Stopping age: between 64-74 years
- Interval: B or T
High risk (RR=1.8; 182 strategies):
- Starting age: between 40-50 years
- Stopping age: between 74-84 years
- Interval: A or B
Predicted lifetime outcomes included LYG, breast cancer deaths averted, FP 
findings, overdiagnosis and costs.
Cost-effectiveness
Total costs (represented in Euros) were based on costs associated with screening, 
additional diagnostics and stage-specific treatment, using data from the MRISC 
study16 and represent the additional costs compared with no screening. Costs and 
LYG were discounted at 3.5% per year. in agreement with the recommendations of 
the National Institute for health and Care Excellence (NICE).17
Strategies were ranked according to their effectiveness (in terms of LYG). 
Incremental cost-effectiveness ratios (ICERs) were calculated as the difference 
in costs divided by the difference in LYG between two consecutive strategies (i.e. 
costs required to yield one additional LYG, compared to previous strategy).
B50-74 (current) in the total population was very close to but not on the frontier 
and an ICER for this strategy could therefore not be calculated. We used the ICER 
of B48-72 (same number of screening rounds (13) and similar cost-effectiveness 
ratio; €8,883 per LYG; Table 2) as a proxy for that of current screening and as the 
threshold to compare risk-based strategies to. The most effective strategy under 
this ICER was considered optimal. Selected risk-based strategies were therefore 
optimal in terms of the ratio of costs to effects, the cost-effectiveness. Optimal 
strategies were thus not selected based on the highest possible benefit.
Harm-benefit ratios
We compared harm-benefit ratios between optimal screening in risk groups and 
current uniform screening. FP findings were calculated using screen-detected 
cancers (model output) and the positive predictive value (PPV1) of recall (PPV=TP/
(TP+FP)).
The PPV of biennial screening in the Dutch screening programme was recently 
reported to be 28%18. Based on the literature, we estimated that the PPV for women 
aged 40-49 years is 12%19, 20. The ratios of the PPV of annual and triennial screening 
to that of biennial screening were calculated based on findings in the U.S., Norway 
and Spain published by Domingo et al.21 Subsequently, these ratios were used to 
estimate the PPV for annual and triennial screening in the Netherlands, which 
resulted in a PPV of 24% (≥50 years) and 10% (40-49 years) for annual screening 
and a PPV of 31% (≥50 years) for triennial screening21.
Overdiagnosis was calculated by comparing the number of breast cancers detected 
in women in the presence and in the absence of screening, using lifelong follow-
up and accounting for an increase in the background incidence of breast cancer 
over the years.
Scenario analyses
To assess the influence of realistic attendance on our outcomes, we performed a 
scenario analysis using observed attendance in the Netherlands (80%), instead 
of full attendance.
In a second scenario analysis, the RR of low and high-risk women was modelled to 
vary by age as opposed to a constant RR. We modelled a substantial attenuation of 
the RR with increasing age for both risk groups – i.e. both the RR of 1.8 of high risk 
women and the RR of 0.75 of low risk women attenuate gradually with increasing 
age and approach RR 1 at higher age.
5
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RESULTS
Offering all eligible women uniform current B50-74 screening gained 206 life-years 
(non-discounted) and averted 16 breast cancer deaths at the expense of 187 FP 
findings and 5 overdiagnosed cases per 1000 women followed from age 40 until 
death, compared to no screening (Table 3).
Low-risk
Considering the threshold ICER of €8,883 per LYG, optimal screening for low-risk 
women was T50-71 (ICER:€7,840 per LYG), with 5 fewer screening rounds than 
current B50-74 (Table 2, 3). T50-71 led to 134 LYG and 10 breast cancer deaths 
averted per 1000 women (non-discounted), compared to no screening, at the 
expense of 102 FP findings and 3 overdiagnosed cases. Harm-benefit ratios of 
T50-71 screening for low-risk women were better than that of uniform B50-74 
screening for all women (RR=1) and B50-74 screening for low-risk women (Table 
2, 3). T50-71 led to 50 fewer FP findings than B50-74 in low-risk women (-33%) 
and 31 fewer LYG (-19%; Table 1), thus also resulting in a better balance between 
benefits and harms. Optimal screening reduced cost by 37% (Table 2). Triennial 
strategies yielded higher (or similar) benefit for lower costs compared to biennial 
alternatives (Figure 1).
High-risk
Optimal screening for high-risk women was B40-74 (ICER:€6,062 per LYG), 
which consists of 5 additional rounds before the starting age of current uniform 
screening. B40-74 resulted in increased benefits but also in an increase in harms 
(Table 3). Harm-benefit ratios for B40-74 in high-risk women were slightly more 
favourable than for current uniform B50-74 screening in the total population 
when overdiagnosis was considered and considerably less favourable with FP 
findings (Table 3). B40-74 led to 77 additional LYG (+25%) compared to B50-74 
in high-risk women and 113 additional FP findings (+44%; Table 2). Harm-benefit 
ratios (FP findings/LYG) were less favourable for annual than biennial scenarios. 
Under a threshold of net costs of approximately €500,000, annual strategies were 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































False positives 187 102 371






















*Screening outcomes are presented per 1000 women, aged 40 years followed over their 
lifetime invited for screening. N.B. Due to rounding of numbers used in the analysis, it may 
seem that outcomes represented in the Table do not add up to the total number.T: triennial 
(3-year interval); B: biennial (2-year interval)
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Scenario analyses
When modelling observed attendance (80%), costs and effects decreased 
(Supplementary material 3). Modelling realistic attendance did not change the 
optimal strategy for women at lower than average risk of breast cancer. For women 
at higher risk there was a slight change in the optimal strategy, which shifted from 
B40-74 to B42-74 with realistic attendance, as the ICER of B40-74 just exceeded 
the cost-effectiveness threshold of current screening in this case (Supplementary 
material 3). When assuming an attenuating RR with increasing age, both benefits 
and harms including deaths averted, LYG, false-positive findings and overdiagnosis 
decreased with similar percentages for high risk women and increased with similar 
percentages for low risk women. For high risk women, lifetime costs increased 
considerably compared to high risk women with a constant RR, which – in 
combination with the decreased screening effects - negatively affected the cost-
effectiveness of screening strategies (data not shown).
DISCUSSION
We provided estimates of optimal risk-based mammography screening strategies, 
with ICERs similar to that of uniform screening, for women with a relatively low 
and high risk of breast cancer, compared to the average population. Offering 
triennial screening to women at lower risk of breast cancer, would limit the harms 
associated with biennial screening in this group, by resulting in less overdiagnosis 
and fewer false-positive findings and additional diagnostic tests, while maintaining 
most of the benefit of biennial screening. Additional screening before age 50 for 
high-risk women would lead to greater benefit but also to a relatively high increase 
in FP findings.
In this study, optimal screening scenarios for both low and high risk were assessed 
by quantifying screening outcomes for a large number of strategies. We used a 
validated model, which was recently updated with the newest available screening 
data and improvements in adjuvant therapy. Our results are likely to be relevant 
to other (European) countries, in particular those with comparable breast cancer 
incidence, screening indicators and programme characteristics. However, before 
implementing risk-based screening, there are still many practical and ethical issues 
that need to be considered.
This study had several limitations. First, we did not take into account that a woman’s 
relative risk can change over time in our base case analysis. Mammographic 
breast density, for example, generally decreases with increasing age altering 
test sensitivity22. Our scenario analysis showed that modelling a decreasing RR 
with increasing age in high-risk women, leads to considerably higher costs than 
modelling a constant ‘high’ RR. A decreasing RR with increasing age will therefore 
result in a less intensive strategy being considered as optimal. Risk prediction 
models usually generate absolute risk levels23. We used RR levels however, to make 
our results generalisable to other countries. Second, we assumed that breast cancer 
risk only affects the incidence of breast cancer and no other important parameters 
including tumour growth rate, sojourn time and stage distribution. Assuming a 
higher growth rate for high-risk women, for example, could cause the optimal 
interval to shift from biennial to annual screening. Further, we could not calculate 
the ICER of current uniform screening as B50-74 was close to but not on the 
frontier and thus we used B48-72 as the cost-effectiveness threshold.
Finally, we had no data on the distribution of risk groups among the Dutch 
female population or the distribution of breast density among risk groups. We 
could therefore not assess the impact of a risk-based screening programme for 
the population as a whole. Considering the effects of risk-based screening for 
low, average and high-risk women all together, with tailored scenarios for each 
risk group, is an important next step for future research. Our study is however 
an important first step as it shows that both the screening programme itself and 
women at lower and higher than average risk of breast cancer could benefit from 
tailored screening, while the cost-effectiveness is not affected. Preliminary data of 
the Dutch PRISMA study (approximately 5000 women) show that the risk factors 
‘age at first child 20-24 years’ and ‘first degree family member with breast cancer’ 
with RRs corresponding to our low- and high-risk group (0.7 and 1.8 respectively) 
are both present in approximately 19% of the study population6. However, it is still 
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unknown how large the low-risk and high-risk groups are when taking into account 
more single risk factors and combinations of risk factors.
We found that low-risk women could benefit, in terms of reduced harms, from less 
frequent, triennial screening, which is consistent with other work8, 10. However, 
one of these studies, in which optimal strategies for risk groups were determined 
by selecting the least expensive strategy with benefit similar to that of current 
uniform screening10, found that annual screening is optimal for high-risk women, 
which contradicts our results. This can be (partially) explained by the fact that 
in our study there was a greater restriction in terms of costs with the selection of 
optimal strategies, since we only allowed for strategies with a lower ICER than 
current screening to be optimal. In general, studies show that risk-based screening 
leads to improved harm-benefit ratios and is more efficient than uniform screening, 
which is in agreement with our results10, 24.
We used full attendance to screening and full adherence to treatment (100%) 
as the goal of our study was to select optimal strategies for women who fully 
adhere to screening and treatment recommendations. In reality, not all women 
attend to every screening round. When modelling realistic attendance, screening 
strategies with shorter intervals could turn out to be more cost-effective than 
with full attendance. Shorter screening intervals compensate for lower than full 
attendance by ensuring that women, on average, are still screened the optimal 
number of screening rounds.25 For women who do show up for every screening 
round this could thus result in too intensive screening being recommended as 
optimal. Our scenario analysis showed that using observed attendance did not 
influence the conclusion with respect to women at lower than average risk of breast 
cancer. The optimal strategy for women at higher risk reduced with one screening 
round – i.e. a two year higher starting age. The conclusion that women at higher 
risk are optimally screened before the age of 50, in their early 40s, however still 
holds.
Weighing harms and benefits is subject to personal preferences and it is therefore 
important to consider different ratios of benefits and harms and perspectives. 
Women attending screening may have a higher tolerance for accepting increasing 
harms with increasing benefits than policymakers. Research on attitudes to FP 
mammography results among 479 women without a history of breast cancer 
showed that 63% of women would accept up to 500 FP findings per life saved26. Our 
findings suggest that optimal B40-74 screening in high-risk women would result 
in approximately 15 FP findings per death averted, which is much lower. Harm-
benefit ratios worsen when switching to annual screening for high-risk women. 
In addition, the net costs of screening double when switching from biennial to 
annual screening.
Stratified screening will lead to differences in screening approaches between 
women. This may be difficult to accept, particularly for women with the lowest 
risk, for whom risk-based screening will probably result in less frequent screening. 
Less screening is beneficial for women at lower risk as it results in a reduction in 
screening harms. However, although the ratio of costs to effects with the optimal 
strategy for low risk women identified in our study is similar to current uniform 
screening, the absolute screening benefit decreases for these women, compared to 
uniform screening. If women will not agree with these differences, the attendance 
rate of the screening programme could drop. It is therefore important to inform 
women and screening professionals on breast cancer risk and the harms and 
benefits associated with screening, related to different risk levels. Women at lower 
risk of breast cancer could then make an informed decision on whether a reduction 
in screening harms outweigh a slightly reduced number of LYG.
Conclusion
Our findings show that risk-based screening has the potential to respectively 
reduce absolute harms and increase absolute benefits in low- and high-risk women, 
while maintaining current cost-effectiveness. The optimal low-risk scenario T50-71 
improves the ratio of false-positive findings to LYG for low-risk women, thus 
resulting in a greater reduction in harms than in benefit, compared to current 
screening. With the optimal high-risk scenario B40-74 however, the increase in 
screening benefit is smaller than the increase in false-positive findings. Future 
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research is needed to link the RRs to risk factors and their prevalence in order to 
estimate the impact of risk-based screening at the population level.
REFERENCES
1. Giordano L, von Karsa L, Tomatis M, Majek O, de Wolf C, Lancucki L, Hofvind S, 
Nystrom L, Segnan N, Ponti A, Eunice Working G, Van Hal G, et al. Mammographic 
screening programmes in Europe: organization, coverage and participation. J Med 
Screen 2012;19 Suppl 1: 72-82.
2. Perry N, Broeders M, de Wolf C, Tornberg S, Holland R, von Karsa L. European 
guidelines for quality assurance in breast cancer screening and diagnosis. Fourth 
edition--summary document. Ann Oncol 2008;19: 614-22.
3. Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, O’Meara ES, Buist DS, Kerlikowske K, 
van Ravesteyn NT, Trentham-Dietz A, Mandelblatt JS, Miglioretti DL. Risk factors for 
breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. 
Ann Intern Med 2012;156: 635-48.
4. Tice JA, Miglioretti DL, Li CS, Vachon CM, Gard CC, Kerlikowske K. Breast Density 
and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast 
Cancer. J Clin Oncol 2015;33: 3137-43.
5. Gabrielson M, Eriksson M, Hammarstrom M, Borgquist S, Leifland K, Czene K, Hall 
P. Cohort Profile: The Karolinska Mammography Project for Risk Prediction of Breast 
Cancer (KARMA). Int J Epidemiol 2017;46: 1740-1g.
6. https://www.prisma-studie.nl. Accessed: March 2020.
7. Giordano L, Gallo F, Petracci E, Chiorino G, Segnan N, Andromeda working g. The 
ANDROMEDA prospective cohort study: predictive value of combined criteria to 
tailor breast cancer screening and new opportunities from circulating markers: study 
protocol. BMC Cancer 2017;17: 785.
8. Schousboe JT, Kerlikowske K, Loh A, Cummings SR. Personalizing mammography by 
breast density and other risk factors for breast cancer: analysis of health benefits and 
cost-effectiveness. Ann Intern Med 2011;155: 10-20.
9. van Ravesteyn NT, Miglioretti DL, Stout NK, Lee SJ, Schechter CB, Buist DS, Huang 
H, Heijnsdijk EA, Trentham-Dietz A, Alagoz O, Near AM, Kerlikowske K, et al. Tipping 
the balance of benefits and harms to favor screening mammography starting at age 40 
years: a comparative modeling study of risk. Ann Intern Med 2012;156: 609-17.
10. Vilaprinyo E, Forne C, Carles M, Sala M, Pla R, Castells X, Domingo L, Rue M, Interval 
Cancer Study G. Cost-effectiveness and harm-benefit analyses of risk-based screening 
strategies for breast cancer. PLoS One 2014;9: e86858.
11. Gray E, Donten A, Karssemeijer N, van Gils C, Evans DG, Astley S, Payne K. Evaluation 
of a Stratified National Breast Screening Program in the United Kingdom: An Early 
Model-Based Cost-Effectiveness Analysis. Value Health 2017;20: 1100-9.
5
154 155
Risk stratification in breast cancer screeningChapter 5
12. Sankatsing VD, Heijnsdijk EA, van Luijt PA, van Ravesteyn NT, Fracheboud J, de Koning 
HJ. Cost-effectiveness of digital mammography screening before the age of 50 in The 
Netherlands. Int J Cancer 2015;137: 1990-9.
13. Segnan N, Minozzi S, Armaroli P, Cinquini M, Bellisario C, Gonzalez-Lorenzo 
M, Gianola S, Ponti A. Epidemiologic evidence of slow growing, nonprogressive or 
regressive breast cancer: A systematic review. Int J Cancer 2016;139: 554-73.
14. https://www.iknl.nl. Accessed: May 2019.
15. National Evaluation Team for Breast cancer screening (NETB). National evaluation 
of breast cancer screening in the Netherlands 1990-2011/2012. Thirteenth evaluation 
report. Erasmus MC University Medical Center Rotterdam.
16. Saadatmand S, Tilanus-Linthorst MM, Rutgers EJ, Hoogerbrugge N, Oosterwijk JC, 
Tollenaar RA, Hooning M, Loo CE, Obdeijn IM, Heijnsdijk EA, de Koning HJ. Cost-
effectiveness of screening women with familial risk for breast cancer with magnetic 
resonance imaging. J Natl Cancer Inst 2013;105: 1314-21.
17. http://www.nice.org.uk/. Accessed: March 2020.
18. van Luijt PA, Fracheboud J, Heijnsdijk EA, den Heeten GJ, de Koning HJ, National 
Evaluation Team for Breast Cancer Screening in Netherlands Study G. Nation-wide data 
on screening performance during the transition to digital mammography: observations 
in 6 million screens. Eur J Cancer 2013;49: 3517-25.
19. Skaane P, Hofvind S, Skjennald A. Randomized trial of screen-film versus full-field 
digital mammography with soft-copy reading in population-based screening program: 
follow-up and final results of Oslo II study. Radiology 2007;244: 708-17.
20. Perry NM, Patani N, Milner SE, Pinker K, Mokbel K, Allgood PC, Duffy SW. The impact 
of digital mammography on screening a young cohort of women for breast cancer in 
an urban specialist breast unit. Eur Radiol 2011;21: 676-82.
21. Domingo L, Hofvind S, Hubbard RA, Roman M, Benkeser D, Sala M, Castells X. Cross-
national comparison of screening mammography accuracy measures in U.S., Norway, 
and Spain. Eur Radiol 2016;26: 2520-8.
22. Sprague BL, Gangnon RE, Burt V, Trentham-Dietz A, Hampton JM, Wellman RD, 
Kerlikowske K, Miglioretti DL. Prevalence of mammographically dense breasts in the 
United States. J Natl Cancer Inst 2014;106.
23. Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, Barlow WE, Kerlikowske K. 
Using clinical factors and mammographic breast density to estimate breast cancer 
risk: development and validation of a new predictive model. Ann Intern Med 2008;148: 
337-47.
24. Pashayan N, Morris S, Gilbert FJ, Pharoah PDP. Cost-effectiveness and Benefit-to-Harm 
Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model. JAMA Oncol 
2018;4: 1504-10.
25. Wilschut JA, Hol L, Dekker E, Jansen JB, Van Leerdam ME, Lansdorp-Vogelaar 
I, Kuipers EJ, Habbema JD, Van Ballegooijen M. Cost-effectiveness analysis of a 
quantitative immunochemical test for colorectal cancer screening. Gastroenterology 
2011;141: 1648-55 e1.
26. Schwartz LM, Woloshin S, Sox HC, Fischhoff B, Welch HG. US women’s attitudes to 
false positive mammography results and detection of ductal carcinoma in situ: cross 
sectional survey. BMJ 2000;320: 1635-40.
5
156 157
Risk stratification in breast cancer screeningChapter 5
SUPPLEMENTARY MATERIAL






Combination 1st child and 
no. children
25-29 vs. <20 
y >5 vs. 1-2
0.5 [1]
Physical activity (5h/w)
per hour per 
week
0.7 [2]
Ever breastfeed vs. never 0.78 [3]
Age at menopause 45-49 y vs. 50-54 y 0.86 [4]



















1st degree family member 
with breast cancer
1 vs. 0 1.8 [2, 8]







member with breast cancer 
and smoking






Combined high risk 
estimate
1.8
2. Simulated cumulative probability† of onset of breast cancer in 
women at low, average or high-risk
†The maximum value for the y-axis is 25%
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3. Cost-effectiveness outcomes† with observed attendance (80%) 
for efficient strategies
Net costs (€) ‡ LYG ‡ ICER
Low risk (RR=0.75)
T 58-64 50,614 11 4,686
T 55-64 72,230 15 4,804
T 52-64 98,240 20 5,911
T 51-66 117,304 23 6,355
T_50_6 136,560 25 7,406
T 50-71 148,889 27 8,807
T 50-74 160,396 28 12,785
B 50-72 228,106 32 15,389
B 50-74 239,395 33 16,127
High risk (RR=1.8)
B 50-74 170,827 61 2,819
B 48-74 200,631 68 3,922
B 46-74 234,199 75 4,937
B 44-74 271,600 81 5,937
B 42-74 313,068 88 6,582
B 40-74 360,280 93 9,635
A 41-74 709,858 120 12,620
A 40-74 758,332 124 14,689
A 40-75 767,543 124 18,423
A 40-77 784,556 125 28,354
A 40-80 806,899 125 37,239
A 40-81 813,276 125 63,768
A 40-84 829,316 126 80,204
†Per 1000 women aged 40 years followed over their lifetime, compared to no screening ‡ 
Discounted at 3.5% per year. N.B. the optimal strategy is marked in grey. RR: relative risk; 
LYG: life years gained; ICER: incremental cost-effectiveness ratio; T: triennial (3-year interval); 
B: biennial (2-year interval); A: annual (1-year interval)
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ABSTRACT
Background: Digital breast tomosynthesis (DBT) is a promising screening 
test, but its outcomes and cost-effectiveness remain uncertain. To determine if 
biennial DBT is cost-effective in a screening setting when compared with digital 
mammography (DM) in the Netherlands and to quantify the uncertainty.
Methods: In this study, performed from March 2018-February 2019, the 
MIcrosimulation SCreening ANalysis (MISCAN) model was used to conduct a 
probabilistic sensitivity analysis (PSA), consisting of 10,000 model runs with 
1,000,000 women simulated per run. The Bayesian Cost-Effectiveness Analysis 
(BCEA) package and the Sheffield Accelerated Value of Information (SAVI) 
tool were used to process PSA outcomes. Two simulated cohorts born in 1970 
were invited to biennial screening between age50-74; one to DM and one to 
DBT. DM input parameters were based on data from the Dutch breast cancer 
screening program. DBT parameters were based on literature and expert opinion. 
Willingness-to-pay-thresholds of €20,000 ($22,000) and €35,000 ($38,500) per 
life-year gained (LYG) were considered. Effects and costs were discounted at 3.5% 
per year.
Results: DBT gained 13 additional life-years per 1000 women invited to screening 
(7% increase;13/193), followed over lifetime, compared with DM and led to 2% 
(4/159) fewer false-positives . DBT screening led to incremental discounted 
lifetime effects of 5.09 LYG (95% confidence interval:-0.80-9.70) and an 
increase in lifetime costs of €137,555 ($151,311) per 1000 women (95% confidence 
interval:€31,093($34,202)-€263,537($289,891)) compared with DM, resulting in a 
mean incremental cost-effectiveness ratio (ICER) of €27,023 ($29,725) per LYG. 
The probability of DBT being more cost-effective was 0.36 at €20,000 and 0.66 
at €35,000 per LYG.
Conclusion: Switching to biennial digital breast tomosynthesis (DBT) from digital 
mammography (DM) is not cost-effective at a willingness-to-pay-threshold of 
€20,000 per life years gained (LYG), but DBT has a higher probability of being 
more cost-effective than DM at €35,000 per LYG.
INTRODUCTION
Several European trials and observational studies have demonstrated that DBT 
screening, as a stand-alone modality, combined with DM or with synthetic 2D 
images reconstructed from the 3D DBT acquisitions, improves the breast cancer 
detection rate compared with DM alone1-6. Although many studies show improved 
breast cancer detection rate with DBT, only a few report interval cancers, which 
are required to calculate the sensitivity of DBT1, 7. Also, the few reported sensitivity 
estimates were based on interval breast cancers of the first screening round only as 
there are no long term trial results available. Estimates for the positive predictive 
value (PPV) for DBT in a screening setting vary from similar to that of DM to a 
twofold higher PPV1, 3, 5, 6.
When considering a new screening modality, it is important to assess how its 
implementation will affect screening outcomes and cost-effectiveness. A model 
study from the United States (US) showed that adding annual DBT screening to 
DM is cost-effective compared with DM screening only, whereas a more recent 
study concluded that DBT screening is not cost-effective at current reimbursement 
rates in the United States8, 9. These conflicting results may occur due to the 
unavailability of long term DBT screening data, leading to uncertainty in model 
input parameters. Microsimulation models can be used to predict long-term 
screening outcomes and account for all uncertainty in input parameters through 
probabilistic sensitivity analysis (PSA). These models recalculate the output 
multiple times by incorporating probability distributions for input parameters 
and sampling from those distributions using a large number of runs. From 
PSA outcomes, the generated cost-effectiveness acceptability curves show the 
probability of a strategy being cost-effective, given a particular willingness-to-
pay-threshold (WTP)10.
Currently, to our knowledge, no studies have conducted a PSA to assess the 
uncertainty associated with the cost-effectiveness of biennial DBT screening in a 
population-based breast cancer screening program. We used the MIcrosimulation 
SCreening ANalysis (MISCAN) model to predict long-term benefit, harm and 
costs with DBT versus DM in the Netherlands. Performing a PSA, we estimated 
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the mean incremental cost-effectiveness of DBT versus DM and the probability of 
DBT being the more cost-effective option, for different WTPs.
METHODS
Model overview
We used the MISCAN model, described previously11. MISCAN simulates individual 
life histories and the natural history of breast cancer as progression through 
preclinical screen-detectable (either preceded by ductal carcinoma in situ (DCIS) 
or not) T1A, T1B, T1C and T2+ tumors. When screening is modeled, tumors can 
be detected in the preclinical phase. MISCAN models actual DM screening 
participation and therapy use11. An overview of the model parameters is shown in 
the Supplementary material (Supplementary material 1). MISCAN is exempt from 
institutional review board approval.
This study was performed from March 2018 to February 2019. Given the scarcity 
of DBT data at this time, we used expert elicitation to obtain estimates for three 
input parameters and their distributions: test sensitivity, the PPV and screening 
costs with DBT, following guidelines12, 13. Experts were asked to give estimates for 
a situation with stand-alone DBT. Expert elicitation is valid to use early in the 
development of new techniques, when input parameters are not available from 
literature, scarce or when published values are inconsistent12, 14. Invited experts 
were researchers with extensive experience in breast cancer screening, 23 years on 
average, who were involved in DBT trials or affiliated with the Dutch Expert Centre 
for Screening. One expert, a Professor of radiology with 20 years of experience in 
the field, is an author of this study. Elicitation sessions were conducted using the 
EXPLICIT tool14. Nine of the thirteen experts invited responded.
During the expert elicitation, two studies published sensitivity with DBT, using 
interval cancers from the first screening round: the Oslo Tomosynthesis Screening 
Trial (OTST) and the Screening with Tomosynthesis Or standard Mammography 
(STORM) trial1, 7. Estimates for the increase in sensitivity with DBT were 6% and 
11%, respectively, although the difference between DBT and DM was not significant 
for either study. We decided not to dismiss the expert estimates but to pool them 
with the trial results. We did not only use trial results because: 1. The lack of long 
term data (only one screening round); 2. One trial7 had a very low number of 
interval cancers with DBT, making the estimate less reliable; 3. The use of combined 
DM and DBT was compared to DM alone. Combined DM and DBT considerably 
increases the radiation dose, acquisition- and reading time and it may thus not be 
ideal to implement this combination in a screening program15-19. Reconstructing a 
two-dimensional image from DBT data seems a good alternative4-6, 20.
The PPV of recall and screening costs with DBT were based on expert opinion only 
as synthesis of the literature was difficult. Published PPV estimates vary widely, 
making it difficult to yield an estimate1, 3, 5, 6. Screening costs with DBT are also 
uncertain. Increased reading time (reading the stack of images and synthetic 2D) 
will probably increase costs the most, compared with DM, but studies on plausible 
DBT reading strategies are scarce.
Assumptions
We assumed no difference in treatment rates between DM and DBT. For DM, we 
assumed that all women undergo diagnostic mammography after recall. As this is 
less likely after DBT, only 30% of the women would undergo mammography after 
recall from DBT21. Some studies show that the biopsy rate over multiple screening 
rounds is similar for DM and DBT22, so we used the same frequencies and costs 
for other diagnostic tests. Finally, we assumed that switching from DM to DBT 
increases sensitivity.
Costs
Costs are reported in Euros and United States Dollars (USD) in parentheses 
(1 Euro=1.10 USD; May 19, 2020). Screening costs are based on data from the 
Dutch Screening Organizations23 (DM) or expert opinion (DBT). Costs of breast 
cancer diagnosis after recall and treatment are from a published Dutch study 
(Supplementary material 2)24. Total costs with screening are presented as net costs, 
compared with a situation without screening. All costs and effects are discounted 
at 3.5% per year.
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Analysis
Two cohorts, each consisting of 500,000 women born in 1970, were simulated and 
followed over their lifetime, starting at 50 years. Cohort 1 was invited to biennial 
DM screening between 50-74 years (current practice). Cohort 2 was invited to 
biennial DBT between 50-74 years, assuming DBT would fully replace DM. For both 
scenarios, we assumed an attendance rate of 80%, reflecting actual participation 
over 2013-2018 in the Netherlands23.
Benefits and harms
Undiscounted benefits and harms were based on a single run and included LYG, 
breast cancer deaths averted, and false-positives - i.e. screening examinations 
resulting in further diagnostics but not leading to breast cancer diagnosis, 
calculated using the PPV of recall. The PPV was defined as the percentage of 
breast cancers detected, among all recalls.
Probabilistic sensitivity analysis (PSA)
Input parameters were varied simultaneously in 10,000 runs, sampling from 
fixed probability distributions, generating 10,000 incremental cost-effect pairs 
for DBT versus DM (Table 1a-b). In each run, one million women were simulated. 
In MISCAN, model parameters are calibrated with the Nelder-Mead algorithm25, 
which does not provide distributions around calibrated values. But we could not 
obtain uncertainty measures from the literature for most calibrated parameters. To 
account for uncertainty, we used a previously described approach (Supplementary 
material 3)26, 27.
For parameters not calibrated, distributions were chosen based on: 1) unobservable 
parameters have a uniform distribution and vary 5% around the mode (fixed 
value); 2) parameters representing costs or PPVs have a beta-PERT (Program 
Evaluation and Review Technique) distribution and vary10% ; and 3) bounds 
for DBT parameters, based on expert opinion, have a beta-PERT distribution14. 
The beta-PERT distribution is a version of the beta distribution (interval [0, 1]) 
defined by the minimum, most likely and maximum value of a parameter and was 
used because expert estimates were defined by the lowest, most likely and highest 
parameter value. Individual expert estimates were combined through unweighted 
linear pooling by averaging the lowest, highest and most likely values, generating 
an average most likely value and distribution13. We assumed that sensitivity of DBT 
is higher than that of DM1, 7. Therefore, we induced correlation between sensitivity 
of DBT and DM, after sampling, using the method of Goldhaber-Fiebert and Jalal28. 
We adopted a tolerance threshold of 5%, to allow for some ordering violation to 
occur.
PSA outcomes were mean incremental costs and effects of DBT versus DM, the 
mean incremental cost-effectiveness ratio (ICER) and mean incremental net 
benefit (INB). The ICER was calculated by dividing the difference in costs between 
DBT and DM by the difference in LYG. A screening scenario was considered cost-
effective if the ICER was below the willingness-to-pay (WTP) threshold. The 
common Dutch WTP is €20,000 ($22,000) per (quality adjusted) LYG29, generally 
used with 4% annual discounting of costs and 1.5% of effects. But we used 3.5% 
discounting of both costs and effects because this is recommended by the National 
Institute of health and Care Excellence30, which uses a higher threshold range of 
£20,000-£30,000 per LYG; thus a maximum of around €35,000 ($38,500) per LYG. 
We also used this threshold to account for a more internationally representative 
WTP and because the WTP of €20,000 per LYG has been argued to be low.
The mean INB of DBT vs. DM was calculated as the difference between the 
expected net benefit (ENB) of DBT and DM, with:
ENB:WTP*LYG – Cost
INB:ENBDBT – ENBDM
Cost-effectiveness acceptability curves were calculated selecting the screening 
modality with the highest ENB in each of the 10,000 runs. Subsequently, we 
determined the proportion of runs for which the modality has the highest net 
benefit. The curves for DBT and DM show the probability of each being cost 
effective, given a particular WTP10.
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Table 1b. Input parameter values, distributions types and boundaries for probabilistic 
sensitivity analysis (PSA) for parameters based on expert opinion
Input parameters 






















beta-PERT 1 0.91 1
Positive predictive 
value of recall with 
tomosynthesis 
screening










§T2+ was not varied in the probabilistic sensitivity analysis as the lower limit of the 
distribution was already 1 (100%)
Abbreviations: DCIS (ductal carcinoma in situ); PERT (program evaluation and review 
technique)
Scenario Analyses
To account for different DBT scenarios we performed one-way scenario analyses, 
based on a single run:
-The percentage diagnostic mammography after recall from DBT (30% in base 
case) was varied between 0%-100%
-Biopsy after recall is 38% higher with DBT than with DM21, 31.
-Attendance with DBT varies between 70%-90% but was kept constant with DM 
as this was based on observed rates
6
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-PPV of recall with DBT is 50% higher than with DM32.
-DBT parameters were varied using the boundaries from the distribution obtained 
by expert opinion.
Statistical analysis
MISCAN was used for the cost-effectiveness analysis with 10,000 iterations. The 
Sheffield Accelerated Value of Information (SAVI) tool33 and the Bayesian cost-
effectiveness analysis (BCEA) package34 were used to post-process the results of 
the 10,000 runs, to obtain mean incremental costs and effects with confidence 
intervals and the ICER and to assess uncertainty constructing cost-effectiveness 
planes and acceptability curves. We used R version 3.4.1 (2017) for the BCEA 
package and SAVI 2.1.2 (R Shiny Server application)33, 34.
RESULTS
Expert opinion
Based on the pooled results from the expert elicitation and the trials, test 
sensitivity was estimated to increase by 18% when switching from DM to DBT 
screening (distribution range: 6%-31%) (Table 2)1, 7. The pooled expert estimates 
were a PPV with DBT of 30% (23% - 37%) and DBT screening costs of €91 ($100) 
(€72 ($79) - €125 (138)), respectively.
Undiscounted benefits and harms
Biennial DBT screening between 50-74 years, compared with biennial DM, was 
expected to result in 13 additional LYG (7% increase; 13/193) and 0.9 additional 
breast cancer deaths averted (6% increase; 0.9/14.5) per 1000 women invited to 
screening followed over their lifetime (Table 3). There were 4 fewer false-positive 
findings predicted per 1000 women invited to screening with DBT (2.3% decrease; 
4/159) compared with DM.

















Expert 1 50 5 80 30 23 45 95 70 130
Expert 2 10 5 25 32 22 38 95 75 105
Expert 3 15 5 25 30 25 35 130 70 200
Expert 4 15 5 30 35 30 45 90 80 150
Expert 5 8 4 15 30 26 35 80 70 90
Expert 6 13 4 23 24 15 28 85 75 150
Expert 7 30 10 40 28 20 35 75 67 90
Expert 8 20 0 50 30 25 35 75 70 85
Expert 9 22 15 25 30 25 35 - - -
OTST 5 1 11  -  -  -  -  -  -
STORM 11 7 12 - - -  -  -  -
Pooled 
value







Pooled values reflect the mean of all estimates; Empty cells indicate that an estimate was 
not given or, in case of the trials, that these data were not used.
N.B. Values for ‘percentage increase sensitivity’ are based on estimates of nine experts and 
the estimates of the Oslo Tomosynthesis Screening Trial (OTST)15 ref and Screening with 
Tomosynthesis OR standard Mammography STORM16 trial
Abbreviations: PPV (positive predictive value); DBT (digital breast tomosynthesis)
Probabilistic sensitivity analysis (PSA)
Based on 10,000 model runs, the mean lifetime incremental costs of DBT versus DM 
were €137,555 ($151,311) per 1000 women invited (95% confidence interval:€31,093 
($34,202)-€263,537 ($289,891)) and the mean incremental discounted lifetime 
effects 5.09 LYG per 1000 women invited (95% confidence interval:-0.80-9.70). 
The mean ICER of DBT versus DM was estimated at €27,023 ($29,725) per LYG 
(Table 3). The uncertainty around the ICER estimate is represented by the cost-
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effectiveness plane (Figure 1a and b). The majority of the incremental cost-effect 
pairs of DBT, relative to DM, fell within the northeast quadrant of the cost-
effectiveness plane. But a small part occurred within the northwest quadrant. 
This indicates that DBT is more costly than DM and for a high proportion of the 
iterations more effective (94.7%).
Table 3. Long-term screening outcomes and results probabilistic sensitivity analysis per 




Life-years gained† 179.9 192.5 12.6
Breast cancer deaths 
averted†
13.6 14.5 0.9
False-positive findings 158.8 155.2 -3.6









Mean effect (life-years 
gained)†
67 73 5
Mean ICER (DBT vs DM) - -
€27,023 
($29,725)
ENB (WTP = €20,000) 1,043,980 1,008,231 -35,749
ENB (WTP = €35,000) 2,056,337 2,096,943 40,606
†Relative to no screening; ‡DBT relative to DM;
N.B. Women were invited to biennial screening between 50-74 years and followed over 
their lifetimes
Abbreviations: PSA (probabilistic sensitivity analysis); DM (digital mammography); DBT 
(digital breast tomosynthesis); ICER (incremental cost-effectiveness ratio); ENB (expected 
net benefit); WTP (willingness-to-pay-threshold); INB (incremental net benefit)
Figure 2 shows the cost-effectiveness acceptability curves for DBT and DM (Figure 
2). At a WTP of €20,000 ($22,000) per LYG, DBT had a low probability of being 
(most) cost effective (0.36) and a negative INB of -35,749 compared with DM 
(Table 3). At €35,000 ($38,500) per LYG, the INB was positive (40,606) and the 
probability of cost-effectives 0.66, which means that DBT had the highest ENB in 
66% of the 10,000 iterations (Table 4; Figure 2).
One-way scenario analyses
The ICER only ranged between €27,281 and €30,710 per LYG ($30,009-$33,782) 
when varying the percentage of diagnostic mammography after recall from DBT, 
the biopsy rate with DBT or the PPV of DBT (Supplementary material 4). Ranging 
attendance with DBT, resulted in considerable changes in the ICER (€51,898 
($57,088) per LYG with 70% attendance;€19,722 ($21,694) with 90% attendance). 
Substantial ranges in the ICER of €1,276-€76,685 ($1,404-$84,353) and €22,841-
€96,745 ($25,125-$106,419) were found when varying screening costs between €72 
and €125 ($79-$138) and the increase in sensitivity with DBT between 31% and 6%, 
respectively (S4).
DISCUSSION
As only short term outcomes of DBT screening have been published, we predicted 
long term costs and effects of DBT in a population-based screening setting, 
performing a PSA to account for the uncertainty in model parameters. Using 
current data, biennial DBT screening between 50-74 years is expected not to be 
cost effective, considering the Dutch WTP of €20,000 ($22,000) per LYG and 
3.5% annual discounting. But Dutch discounting recommendations (1.5% annually 
for effects;4% for costs) would likely change this conclusion12. Internationally, 
a threshold of €20.000 per LYG is rather low, also putting the conclusion in a 
different perspective. Switching to biennial DBT in the Netherlands is likely to 
be cost-effective when using a higher threshold of €35,000 ($38,500) per LYG, as 
DBT was most cost effective in 66% of the iterations with this threshold. When 
converting our findings to U.S. dollars and using a WTP of $100,000, biennial 
screening with DBT between age 50 and 74 would be cost effective.
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Figure 1a and b. Cost-effectiveness plane of tomosynthesis vs. mammography at a will-
ingness-to-pay-threshold of €20,000 (a; $22,000) and €35,000 (b; $38,500) per LYG (costs 
and effects per 1000 women invited to screening)
The grey dots show the simulated values for the joint distribution of the effectiveness and 
cost differentials; The red dot indicates the average of the distribution of the outcomes 
(ICER); The grey area reflects the part of the plane for which the simulated values are below 
the willingness-to-pay-threshold; k: willingness-to-pay-threshold
Abbreviations: LYG (life years gained); ICER (incremental cost-effectiveness ratio)
Figure 2. Cost-effectiveness acceptability curves for DBT and DM
Dashed vertical lines represent the WTPs of €20,000 ($22,000) and €35,000 ($38,500) 
per life year gained
Abbreviations: DBT (digital breast tomosynthesis); DM (digital mammography)
In agreement with a study of Lowry et al., we found that ICERs were most sensitive 
to costs of DBT9. Our results suggest that, at a WTP of €35,000 per LYG, biennial 
DBT between 50-74 years is more cost-effective than DM in the majority of runs. 
Using a higher WTP, of 100,000 USD, Kalra et al. showed that in the US annual 
DBT starting at age 40 years is also more cost-effective than DM in the majority 
of runs8.
Some DBT trials and observational studies show lower false-positive rates with 
use of DBT, compared with DM, whereas others suggest higher rates4, 15, 35, 36. In 
contrast to a study from the United States, which demonstrated a 24-28% reduction 
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in false-positives, we only found a slight decrease as we assumed a minor increase 
in the PPV with DBT, relative to DM9. Recall- and false-positive rates with DM in 
the Netherlands are relatively low compared with other countries, thus a reduction 
when switching to DBT may be less likely than in other settings. Correspondingly, 
a meta-analysis evaluating recall rates with DBT compared with DM showed that 
reductions in recall rates with DBT were predominantly found in studies from the 
United States that reported high baseline recall37. The decrease in recall rates and 
false-positives with DBT thus depends on the initial rate with DM.
Prospective studies show that DBT increases breast cancer detection, compared 
with DM1-3, 5, which could contribute to overdiagnosis of breast cancer. Recent 
literature shows that DBT detects a higher proportion of invasive cancers than 
DM but it may be too soon to assess the effect on interval cancer rates38, 39.
Our findings show the impact of DBT, compared to DM, in a European screening 
setting, supplementing earlier published outcomes for the screening setting in 
the United States8, 9.
Our study had some limitations. First, as trial estimates of DBT sensitivity were 
based on interval cancers of the first screening round only1, 7, and the performance 
of combined DBT and DM was compared to DM alone1, 2, the actual effect of DBT 
alone could be smaller than reported. We did not account for increased radiation 
dose with DBT compared with DM. We also did not specify our results for different 
breast density levels as there was not sufficient evidence from the trials that DBT 
performs better for dense breasts than for non-dense breasts compared with DM2. 
Furthermore, we assumed no differences in frequency and costs of diagnostics 
after recall between DBT and DM. But our scenario analyses showed that the 
diagnostic mammography and biopsy rate hardly influenced the ICER. Finally, 
we relied on expert opinion for some DBT inputs, which may have induced bias. 
Still, our inputs fairly represent the latest literature. The OTST recently reported 
a 28% increase in sensitivity with combined DBT and synthetic 2D, compared with 
DM32. In addition, an Italian screening pilot published an increase of 11%31. When 
averaging these new estimates with the earlier published 11% increase from the 
STORM trial7, the average increase in sensitivity with DBT, compared with DM, is 
17%. This is similar to the 18% increase we used for the PSA, based on the expert 
estimates and trial results at the time of our study. Our estimate for the PPV 
also falls within the range of published estimates1, 5, 6, 35. Furthermore, although 
DBT costs in the Dutch screening setting are unclear, costs of diagnostic DBT in 
university medical centers in the Netherlands (€94.58 ($104))40 are similar to the 
€91 (($100) used in our analysis.
In conclusion, when analyzing currently available preliminary data, based on one 
screening round with DBT, switching from biennial DM to DBT screening in the 
Netherlands is not cost-effective using a WTP of €20,000 ($22,000) per LYG. 
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SUPPLEMENTARY MATERIAL
1. Model parameters on natural history of breast cancer, perfor-
mance and survival after adjuvant treatment and screening















stage by age and 
stage1, 2 b
Stage
Age DCIS T1AN– T1AN+ T1BN– T1BN+ T1CN– T1CN+ T2+N– T2+N+
40 3.5 0.1 0.1 0.4 0.4 1.1 1.1 0.7 0.7
50 3.5 0.1 0.1 0.5 0.5 1.5 1.5 0.9 0.9
60 3.5 0.1 0.1 0.8 0.8 2.2 2.2 1.3 1.3




age and preclinical 
stage1-3 b
Stage
Age DCIS T1AN– T1AN+ T1BN– T1BN+ T1CN– T1CN+ T2+N– T2+N+
<50 65% 41% 41% 36% 36% 64% 64% 90% 90%
≥55 87% 55% 55% 48% 48% 86% 86% 100% 100%
Test sensitivity 
of digital breast 
tomosynthesis by 
age and preclinical 
stage15-16 a,c
Stage
Age DCIS T1AN– T1AN+ T1BN– T1BN+ T1CN– T1CN+ T2+N– T2+N+
<50 85% 55% 55% 48% 48% 85% 85% 85% 85%
≥55 100 65% 65% 57% 57% 100% 100% 100% 100%
Long-term relative 
survival by clinical 




Age DCIS T1AN– T1AN+ T1BN– T1BN+ T1CN– T1CN+ T2+N– T2+N+
≤30 1.000 0.761 0.510 0.696 0.408 0.557 0.236 0.310 0.0555
40 1.000 0.798 0.575 0.741 0.481 0.618 0.310 0.386 0.102
50 1.000 0.815 0.605 0.762 0.512 0.646 0.341 0.418 0.118
60 1.000 0.796 0.568 0.738 0.472 0.612 0.298 0.375 0.0885
70 1.000 0.737 0.476 0.667 0.376 0.524 0.213 0.282 0.0524
≥80 1.000 0.678 0.383 0.597 0.279 0.435 0.128 0.189 0.0163
Long-term relative 
survival by clinical 




Age DCIS T1AN– T1AN+ T1BN– T1BN+ T1CN– T1CN+ T2+N– T2+N+
≤30 1.000 0.854 0.701 0.814 0.639 0.730 0.534 0.579 0.424
40 1.000 0.865 0.714 0.826 0.650 0.743 0.533 0.585 0.388
50 1.000 0.860 0.699 0.819 0.629 0.731 0.499 0.558 0.330
60 1.000 0.856 0.696 0.815 0.628 0.727 0.505 0.559 0.357
70 1.000 0.832 0.666 0.788 0.601 0.696 0.497 0.541 0.394
≥80 1.000 0.797 0.612 0.746 0.546 0.644 0.451 0.489 0.380
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Long-term relative 
survival by clinical 
stage and age, with 
chemotherapy2, 10, 11 b,c
Stage
Age DCIS T1AN– T1AN+ T1BN– T1BN+ T1CN– T1CN+ T2+N– T2+N+
≤30 1.000 0.831 0.652 0.784 0.580 0.686 0.458 0.510 0.329
40 1.000 0.858 0.700 0.817 0.634 0.731 0.513 0.567 0.366
50 1.000 0.855 0.691 0.814 0.619 0.723 0.486 0.546 0.314
60 1.000 0.820 0.620 0.769 0.535 0.659 0.382 0.450 0.198
70 1.000 0.767 0.535 0.705 0.446 0.578 0.301 0.363 0.157
≥80 1.000 0.720 0.464 0.649 0.373 0.509 0.241 0.294 0.144
Long-term relative 
survival by clinical 
stage and age, with 
hormonal and 
chemotherapy2, 10, 11 b,c
Stage
Age DCIS T1AN– T1AN+ T1BN– T1BN+ T1CN– T1CN+ T2+N– T2+N+
≤30 1.000 0.905 0.806 0.879 0.765 0.824 0.697 0.726 0.626
40 1.000 0.912 0.814 0.887 0.772 0.833 0.697 0.730 0.602
50 1.000 0.890 0.765 0.859 0.711 0.790 0.611 0.655 0.481
60 1.000 0.872 0.729 0.835 0.669 0.757 0.559 0.608 0.428
70 1.000 0.851 0.702 0.811 0.645 0.730 0.552 0.592 0.461
≥80 1.000 0.820 0.654 0.774 0.596 0.683 0.511 0.545 0.448
Reduction in risk of 
dying of breast cancer 




Age DCIS T1AN– T1AN+ T1BN– T1BN+ T1CN– T1CN+ T2+N– T2+N+
≤30 100% 85% 67% 81% 59% 71% 43% 50% 18%
40 100% 88% 72% 84% 65% 75% 50% 57% 25%
50 100% 89% 74% 85% 67% 77% 53% 60% 28%
60 100% 87% 72% 84% 64% 75% 49% 56% 24%
70 100% 88% 72% 84% 65% 75% 50% 57% 25%
≥80 100% 88% 73% 84% 65% 76% 50% 57% 25%
Abbreviations: ductal carcinoma in situ (DCIS); lymph node negative breast cancer with 
diameter of 5 mm or smaller (T1AN-); lymph node negative breast cancer with diameter of 
6-10 mm (T1BN-); lymph node negative breast cancer with diameter of 11-20 mm (T1CN-
); lymph node negative breast cancer with diameter of more than 20 mm (T2+N-); lymph 
node positive breast cancer with diameter of 5 mm or smaller (T1AN+); lymph node positive 
breast cancer with diameter of 6-10 mm (T1BN+); lymph node positive breast cancer with 
diameter of 11-20 mm (T1CN+); lymph node positive breast cancer with diameter of more 
than 20 mm (T2+N+).
a based on assumptions, b data used for model fit (calibration), c data used directly as 
input
2. Costs of diagnostics and treatment and positive predictive values 










additional DM/DBT in hospital €103.23
Costs of diagnostics and treatment were obtained from Saadatmand et al.17
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3. Methods to obtain parameter bounds and distributions
In MISCAN, model parameters are calibrated with the Nelder-Mead algorithm18,19 
to minimize the likelihood-based deviance between modeled and observed values. 
As this algorithm does not provide measures of uncertainty around calibrated 
values, the sampling distributions needed to be determined empirically. For 
most model parameters, however, we could not obtain measures of uncertainty 
from the literature. In order to still be able to account for the uncertainty 
around input parameters, we used an approach similar to previously described 
methods.20-22 With this approach, blocks of parameters were varied within given 
bounds (percentages), yielding new deviances, while the remaining parameters 
were kept constant at their calibrated values. The deviance increases as the 
parameters become more distant from their maximum likelihood estimates. As 
the deviance points form a U-shape, the approximation of the parameter bounds 
are obtained by fitting a second degree polynomial. Parameter values that yielded 
a 5% higher deviance than the calibrated value were chosen as lower and upper 
bounds. By varying parameters in a block simultaneously, the maximum allowed 
percentage change was the same for all parameters in a particular block. The 
parameter bounds were used to create appropriate probability distributions, which 
were chosen according to a previously described method by Briggs et al.23 Beta 
distributions were assumed for parameters expressing probabilities and lognormal 
distributions for non-negative parameters. Distribution parameters were fitted by 
method of moments, using the calibrated parameter value as the mean and the 
standard deviation of the estimated uncertainty level.
4. Tornado plot of one-way scenario analyses
N.B. The outcomes for the different scenarios were based on a single run, because it would 
be too time consuming to run the scenarios for all 10,000 iterations. The ICER of 28,310 
per LYG was the outcome of this single run; the mean ICER reported in the results section 
of the main text was based on the 10,000 runs.
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Part One: Evaluation of current breast cancer screening in the 
Netherlands
Screening is a form of prevention and is therefore offered to a ‘healthy’ population. 
Screening for breast cancer in asymptomatic women can lead to early diagnosis 
of tumours and, therefore, to earlier treatment of breast cancer than in a clinical 
setting. Early detection and treatment can result in improved survival and may 
avert cancer deaths, but screening can also yield adverse effects and cause harm. 
The majority of women attending screening will not benefit from it, whereas they 
are exposed to screening harms. It is therefore important to frequently evaluate 
the impact of screening programmes.
The Dutch breast cancer screening programme was initiated in 1990. We estimated 
important performance indicators for cancer screening over the period in which 
the transition from screen-film to digital mammography took place and we 
evaluated the effect of 20 years of mammography screening on breast cancer 
mortality in the Netherlands.
Performance indicators during the transition from screen-film to digital mammog-
raphy screening
Analysing screening data from the years 2004 to 2011, we found that the breast 
cancer detection rate in the Netherlands significantly increased by more than 20%, 
for both in situ (DCIS) and invasive cancers. The interval cancer rate remained 
stable during this period. In line with the increased detection, the programme 
sensitivity, recall rate and false-positive rate also increased significantly. From 
2008, digital mammography gradually replaced screen-film mammography in the 
Netherlands. Although the detection rate was significantly higher with digital 
mammography screening - a 15% increase compared to screen-film mammography 
- there was only a small non-significant reduction in interval cancer rates in a 
subgroup of younger women. As a result, the programme sensitivity was the 
highest for this subgroup.
We also found that the false-positive rate was higher with digital than with screen-
film mammography, which is in line with results from other observational studies.1 
Although we found that breast cancer detection rates were higher with digital 
mammography than with screen-film mammography, there was no reduction in 
the interval cancer rate in the first years after digital mammography use. This may 
suggest that digital mammography adds to overdiagnosis of breast cancer. Other 
studies also showed similar interval cancer rates with digital mammography1, 2, 
although fewer interval cancers with digital mammography were found to have 
microcalcifications, relative to screen-film mammography.3 However, at the time 
of our study, we had limited follow-up data after the full transition to digital 
mammography, which made it difficult to assess the long-term effect of digital 
mammography on interval cancer rates.
A relatively new screening technique which may replace digital mammography 
in the future is digital breast tomosynthesis, which yields a pseudo 3D image by 
acquiring multiple images of the breast from different angles. At this stage, no 
statistically significant decreases in interval cancer rates have been reported for 
tomosynthesis compared to digital mammography.4-6 These results were, however, 
based on 2-year follow-up after only the first screening round with tomosynthesis 
and the number of interval cancers in some of the studies were rather small.
Breast cancer mortality reduction in the Netherlands
Mammography screening was implemented gradually throughout the Netherlands 
between 1989 and 1997. Taking the time of implementation in municipalities as 
starting point, we analysed breast cancer mortality trends between 1980 and 2010. 
We found that, after the introduction of screening in the Netherlands, breast 
cancer mortality decreased by 30%. A similar reduction had been shown previously 
in other European studies.7-10 Although near the end of the implementation period 
and for certain age groups adjuvant treatment was better and more available, we 
found that a statistically significant decline in breast cancer mortality was present 




It is difficult to disentangle the separate contributions of screening and (adjuvant) 
treatment in reducing breast cancer mortality. While multiple trend studies suggest 
a significant role for screening in reducing breast cancer mortality11, some argue 
that the effect of screening is negligible.12 In contrast, a recent study analysing 
Dutch data showed that a single invitation to participate in mammography 
screening, in addition to current biennial screening, already leads to a reduction 
in breast cancer mortality.13
Models are able to predict the separate effects of screening and treatment on breast 
cancer mortality. A study that estimated the proportions of breast cancer mortality 
reduction attributable to screening and treatment in 2008 in the Netherlands 
using the MISCAN microsimulation model, showed that 47% of the reduction was 
associated with screening and 53% with treatment.14 Another study found that for 
the United States in 2012, these contributions were 37% and 63% for screening and 
treatment respectively.15 Inevitably, the improvement of adjuvant treatment affects 
the effectiveness of screening. If late stage treatment will improve sufficiently in 
terms of effectiveness and treatment burden, early detection of breast cancer by 
screening may become less essential.
Part Two: Quantifying the cost-effectiveness, harms and benefits 
of different screening strategies and screening modalities in the 
Netherlands using microsimulation modelling
There is wide consistency between breast cancer screening programmes in Europe 
with regard to the screening interval, the age group invited to screening and the 
screening test.16 Most countries offer biennial mammography screening to women 
between age 50 and 69 or age 50 and 74 years. The evidence for the benefit of 
these screening strategies is most clear as the majority of trials targeted these 
age groups.17
In the Netherlands, biennial screening is offered to women aged 50 to 74 years. We 
explored the cost-effectiveness and the benefits and harms of extending screening 
to younger women, risk-based screening strategies and screening with a different 
modality (digital breast tomosynthesis).
Extending screening to women aged 40 to 49 years
Whether or not women should be screened for breast cancer before age 50 years 
has been a topic of debate for a long time. At the same time, the incidence of 
breast cancer in women younger than 50 years increases.18 The impact of screening 
on breast cancer mortality may be different for women in their forties because 
of several factors associated with younger age, including a lower breast cancer 
incidence than in older women and a lower sensitivity of mammography due to 
denser breasts and a higher tumour growth rate.19-21 Incorporating these differences 
in our model, we found that extending screening to include women aged 40-49 
years is cost-effective, considering a cost-effectiveness threshold of €20,000 per 
QALY gained. This has been confirmed by later work.22 We simulated biennial 
strategies and hybrid strategies, which consisted of annual screening before age 
50 years and biennial screening between age 50 and 74 years. In particular biennial 
strategies were efficient and thus had greater gains in life years per unit of cost 
than annual alternatives. In general, the literature shows that annual screening, 
for women at average risk of breast cancer, is not cost effective and considerably 
more harmful than biennial screening.23-25 The European Commission Initiative 
on Breast Cancer (ECIBC) recommends against annual screening for women aged 
50-74 years as they consider the evidence for annual screening to be of very low 
certainty.26
Overall, we found that screening before age 50 years increased the number life 
years gained but only moderately lowered breast cancer mortality. When screening 
biennially from age 40 instead of age 50 years, the breast cancer mortality reduction 
was 7% higher. Extending screening will inevitably lead to a higher absolute 
number of harms. We found that the number of false-positive findings increases 
considerably with increasing the number of screens before age 50 years. When 
starting biennial screening at age 40 instead of age 50 years, false-positive findings 
were predicted to increase by 60%. Screening in younger women leads to relatively 
more false-positive findings than in older women as the positive predictive value 
of recall is lower.27, 28 Overdiagnosis – i.e. screen-detection of tumours that would 




only slightly increased. Overdiagnosis is higher among older women than younger 
women, due to more competing causes of death at older age.
Our results indicate that starting screening earlier, between age 40 and 49 years, 
is cost-effective and leads to a modest increase in benefits at the expense of a 
substantial increase in false-positive findings. Different people may have different 
viewpoints on whether the modest increase in benefits outweigh the increase in 
harms, that come with additional screening before age 50 years.
Today, only a few European screening programmes offer screening to women 
who are younger than 50 years. The evidence for the effectiveness of screening 
in women between age 40 and 49 years is still debated. Trials that aimed to 
determine the effectiveness of mammography screening in younger women were 
methodologically limited because it is not ethically justified to withhold these 
women from being screened after age 50 years.29-31 The International Agency for 
Research on Cancer therefore concluded that the evidence that mammography 
screening in women aged 40-49 years reduces breast cancer mortality is limited.17 
Although the benefit of mammography screening for women aged 40-49 is less 
conclusive than for older women, a small non-significant effect for this age group 
is supported by several studies.30 In addition, an observational study, performed 
in a period in which adjuvant therapy was available (1986-2005), compared 
a screened cohort to women who were not screened and demonstrated a 26% 
statistically significant breast cancer mortality reduction for women aged 40-49.32 
We, therefore, think it was reasonable to assume some benefit of screening for 
women age 40-49 years in our analyses, even in the presence of adjuvant therapy. 
The European Commission Initiative on Breast Cancer (ECIBC) now recommends 
triennial or biennial screening for women aged 45-49 years.26
Tailoring breast cancer screening to a woman’s individual risk
A woman’s individual risk for breast cancer may influence the balance between 
benefits and harms of mammography screening. Well-known risk factors for breast 
cancer are a family history of breast cancer, a previous biopsy, high breast density 
and genetic risk factors including Single Nucleotide Polymorphisms (SNPs).33-36 
With risk-stratified screening, women are offered a tailored strategy based on 
their level of breast cancer risk. At this moment, there are no European screening 
programmes that offer risk stratified screening. There are however multiple 
initiatives with regard to risk-based projects.37-40
A small part of the female population has a relatively high risk of breast cancer, 
whereas a larger group has a relatively low risk.41 Using a model with three different 
risk groups (low relative risk; relative risk of 1; high relative risk), we identified 
optimal screening strategies for women with a low (relative risk of 0.75) and 
high (relative risk of 1.8) breast cancer risk. Optimal strategies were defined as 
strategies with the highest possible benefit, given that the ICER was similar to 
and did not exceed the ICER of current screening. Optimal strategies were thus 
not the ones with the highest absolute benefit. We found that optimal screening 
for women with a low relative risk consisted of triennial screening between age 50 
and 71 years, which would lead to a 30% reduction in false-positive findings and 
costs and would improve the ratio of benefits and harms.
Biennial screening starting at age 40 instead of age 50 years and ceasing at age 74 
was identified as the optimal screening strategy for women with a high relative 
risk. This strategy would lead to an increase in screening benefit, but at the same 
time to a relatively higher increase in false-positive findings, leading to a worsened 
harm-benefit ratio. In this study, risk-based strategies with an ICER higher than 
that of current screening were not a candidate for optimal screening. Considering 
a cost-effectiveness threshold of €20,000 per (quality adjusted) life year gained, 
as recommended by Dutch guidelines42, would allow for more intensive strategies 
to be identified for risk-based screening. 
To determine the overall impact of a risk-based screening programme - using 
the identified optimal strategies for women eligible for screening with a low and 
high relative risk and the current strategy for women at average risk – data on the 




A woman’s risk of breast cancer can be (partially) identified using a questionnaire 
to collect data on risk factors, including a family history of breast cancer, previous 
biopsy and age at first childbirth, age at menarche or menopause. A study using 
questionnaires to assess women’s preferences with regard to knowing their breast 
cancer risk showed that among women attending the breast cancer screening 
programme in the United Kingdom, the desire of women to know their risk of 
breast cancer is high, around 95%.43 However, stratified screening will result 
in less intensive screening being offered to women at the lowest risk, which 
women may find difficult to understand and accept. Woman at the highest risk 
should be alerted to their high risk and informed about the fact that, even with 
more intense screening, there is still a risk of developing an interval cancer. 
Particularly for these women, it is important not to miss a screening round. 
The attendance rate of screening could decrease if there is low acceptance of 
risk-based screening, due to low compliance with the recommended strategy. It 
is therefore important that women are well informed on the harms and benefits 
associated with screening, related to different risk levels, before risk stratified 
screening is implemented.
Screening with digital breast tomosynthesis
Digital breast tomosynthesis is a fairly new imaging technique which generates 
multiple images of the breast at different angles, as opposed to a single image with 
digital mammography, creating a pseudo 3D image. There are several European 
studies that show an increased breast cancer detection rate with tomosynthesis 
screening, compared to digital mammography screening.6 Tomosynthesis is 
therefore considered as a replacement for digital mammography in breast cancer 
screening programmes. In order to evaluate the impact of the use of tomosynthesis 
in the Dutch screening setting on the cost-effectiveness, harms and benefits of 
breast cancer screening, we performed a cost-effectiveness analysis including a 
probabilistic sensitivity analysis (PSA). The MISCAN model has a large number 
of parameters, which are informed based on the long running Dutch breast cancer 
screening programme and published studies, including randomised trials. Since 
tomosynthesis is not yet used as a screening tool in the Netherlands, there were no 
direct data from the Dutch screening setting to inform the model. Information from 
the literature to inform model input parameters was also scarce. Although there 
are various (ongoing) tomosynthesis screening trials, only a few have reported the 
effect of tomosynthesis on interval cancer rates, which are required to calculate 
estimates for the test sensitivity of tomosynthesis. In addition, several studies 
published estimates for the PPV with tomosynthesis, but these vary widely.4, 6, 44-47 
Furthermore, all tomosynthesis trials are international and findings from other 
countries might not be directly applicable to the Dutch screening setting. As it 
was therefore difficult to obtain estimates for tomosynthesis parameters from 
the literature, we made use of expert opinion. The aim of the expert elicitation 
was not to get consensus on values for input parameters but rather to capture 
the full distribution, including the uncertainty, around the estimate. Using this 
for the PSA, we found that biennial screening with tomosynthesis between age 
50 and 74 years leads to an incremental cost-effectiveness ratio of €27,023 per 
life year gained, compared to digital mammography screening. The probability 
of tomosynthesis being more cost effective than digital mammography in the 
Netherlands was 0.36 at a threshold of €20,000 and 0.66 at €35,000 per life year 
gained. For this analysis, we assumed an increased sensitivity for tomosynthesis 
compared to digital mammography, based on the estimates obtained from the 
expert elicitation. A significant increase in sensitivity has recently been confirmed 
by the latest publication of the Oslo Tomosynthesis Screening Trial48 and other 
new studies.49
With respect to screening benefits and harms, tomosynthesis screening would 
lead to a 7% lifetime increase in the number of life years gained, compared to 
screening with digital mammography, a 6% increase in the number of breast 
cancer deaths averted and a 2% decrease in false-positive findings. Although 
expectations were raised that screening with tomosynthesis may decrease false-
positive rates considerably compared to digital mammography, this was thus not 
what we found. This can probably be explained by the fact that the baseline false 
positive rate with digital mammography in the Netherlands is already relatively 
low in Europe and considerably lower than recall rates in the United States. A 
substantial decrease in false positive findings, when switching to tomosynthesis 




cancer detection and recall with tomosynthesis showed that tomosynthesis recall 
rates are lower than recall rates with digital mammography in pooled US studies 
but not in European studies.50 This suggests that initial recall rate with digital 
mammography is an important determinant for the extent of the reduction in 
recall rates with tomosynthesis.
Another expectation of tomosynthesis was that it would particularly perform 
better in women with dense breasts than digital mammography. This has, however, 
not (yet) been confirmed sufficiently by the outcomes of the prospective trials.4, 5, 
51 We did therefore not specify our input for different levels of breast density.
An important remaining question is how tomosynthesis use will add to 
overdiagnosis due to breast cancer screening. A recent publication on a 
tomosynthesis screening pilot in Italy showed that interval cancer rates did not 
significantly decline following the increase in cancer detection rate.6 This may 
indicate that at least part of the additionally detected cancers by tomosynthesis 
reflect overdiagnosed cases. The authors noted however that the size of the pilot 
may not have been adequate to assess an effect on interval cancer rates.6
LIMITATIONS / METHODOLOGICAL CONSIDERATIONS
The findings in this thesis are based on either the analysis of trends or the 
predictions of a microsimulation model. Although these are often used methods, 
both have their limitations.
Analyses of trends in population breast cancer mortality can provide an insight 
into possible changes in these trends after the implementation of breast cancer 
screening, which may be an important step in the evaluation of population based 
screening. Quantification of the screening effect using trend studies, however, 
comes with serious limitations.11 On the one hand, the effect of screening may 
be diluted when analysing trends due to the inclusion of deaths occurring before 
invitation to screening, the time lag between first screening and the visibility of the 
screening effect and the inclusion of the period directly after the implementation 
of screening.11 On the other hand, trends in breast cancer mortality are not solely 
a reflection of the effect of screening over time but also of (improvements in) 
other diagnostic measures and (adjuvant) therapy. In the same period of time that 
screening was implemented in the Netherlands, the quality and administration 
of adjuvant therapy improved considerably.52, 53 Opportunistic screening - i.e. 
screening outside the population based programme - may also contribute to the 
breast cancer mortality reduction.54 The annual percentage change in breast cancer 
mortality is therefore not a quantification of the screening effect alone, but of the 
overall effect of (early) breast cancer detection and treatment. These drawbacks are 
important to take into account when interpreting the findings of trend studies.
Microsimulation models can be a proper tool to obtain insight in the effect of 
screening regimens when prospective studies are not feasible. In the present, 
performing screening trials is not always ethically justified as women in the age 
range eligible for screening cannot be withheld from current screening to function 
as a control group. In addition, to accurately evaluate the effect of screening 
on breast cancer mortality, large sample sizes and long follow-up are essential. 
Although models reflect a simplification of reality, they are able to extrapolate 
findings of RCTs and easily allow for the evaluation of multiple strategies, different 
attendance rates, different sub groups of women and lifelong follow-up. For our 
studies, we used the MISCAN model which is based on tumour progression 
through successive tumour stages, in terms of the tumour diameter. Probabilities 
of screen-detection and the prognosis after early detection by screening and 
treatment are different for these different tumour stages.55, 56 MISCAN simulates 
the natural history of breast cancer at the individual level and, subsequently, the 
effect of screening for individual women. In this way, outcomes for a situation 
with and without screening can be compared at the individual level, as in a trial 
with perfect randomisation. There are, however, also several limitations to using 
microsimulation models for the evaluation of screening. An important limitation 
of breast cancer screening models in general is that there is a lack of proper 
external validation to demonstrate the generalizability of model outcomes to 





Another drawback is that the quality of the model output is directly determined by 
the quality of the data used as model input. To incorporate the effect of screening 
on breast cancer mortality and the age- and stage-specific survival in MISCAN, 
data from the Swedish randomised trials on mammography screening were used.55, 
59, 60 The Independent UK Panel on Breast Cancer Screening concluded in 2013 that 
best evidence for the effectiveness of breast cancer screening in reducing breast 
cancer mortality reduction still comes from the randomised controlled trials of 
mammography screening.61 However, these trials were conducted decades ago 
and several factors may have changed including for example the sensitivity of 
mammography – digital mammography screening is used now instead of screen-
film mammography. In addition, even randomised controlled trials have their flaws 
and trials outcomes may thus be biased to a certain extent.61 Furthermore, not 
all data needed to inform model input parameters are available from randomised 
trials (or observational studies). A significant part of the parameters associated 
with tumour progression in the natural history of disease part of the MISCAN 
model cannot be directly obtained from available data as they are unobservable, 
for example the duration of the preclinical screen-detectable stages. Parameters 
that are unobservable from data are estimated through model calibration and 
often depend on various assumptions. For certain other parameters, the literature 
may be scarce. Direct data on the natural history - the progression and possible 
regression - of DCIS, for example, are limited, as women diagnosed with DCIS are 
almost always treated directly. Recently trials in which DCIS is monitored instead 
of treated directly have started, including the LORD62, LORIS63 and COMET64 
trials. Data from these studies will provide more insight into the natural history 
of DCIS in the future.
Since the development of MISCAN, the model has been frequently recalibrated 
by updating parameters associated with breast cancer incidence, rates of screen-
detected and interval cancers and adjuvant treatment probabilities, using 
the most recent data from the Dutch Screening Organisations and the Dutch 
National Cancer Registry.65, 66 Although this concerns national data from reliable 
institutions, in some cases the sample sizes can still be rather small. For example 
the probabilities of adjuvant treatment regimens for less common breast cancer 
stages as T1aN+ were based on small numbers of women with breast cancer.
As described above, a drawback of using models to predict the cost-effectiveness 
and benefits and harms of screening is that model parameters can be uncertain. 
Parameters with the most uncertainty in the MISCAN model are without doubt 
the unobservable parameters in the natural history of disease part of the model. 
Parameters estimated using empirical data can, however, also be uncertain. 
Inevitably, estimated quantities are uncertain to some extent. In addition, as 
mentioned before, the quality of the data from which parameters are estimated 
also contributes to parameter uncertainty. These data may come from screening 
trials that itself are limited in terms of validity, there may be trials that report 
conflicting results, or trial results may not be translatable to a population based 
screening programme.67 Important to note is, however, that varying MISCAN 
parameters does usually not lead to altered conclusions, indicating that parameter 
uncertainty only affects model output to a certain extent. Studies that compare 
the outcomes of the MISCAN model for the United States to other models, with 
different model structure and assumptions, show consistency in conclusions based 
on model output.23, 68 Furthermore, despite the uncertainty in model parameters 
MISCAN reproduces breast cancer incidence and mortality in the Netherlands 
quite accurately.56
To determine the impact of single parameters on model outcomes, one-way 
sensitivity analyses, in which single parameters are varied to a certain extent, 
can be conducted. However, the uncertainty around the single parameters is not 
taken into account in these analyses, which can lead to biased findings. It could 
be that uncertain parameters to which model outcomes are only slightly sensitive, 
actually have more impact on model outcomes because of their uncertainty than 
parameters to which model outcomes are very sensitive but that are estimated 
with little uncertainty.67 In a PSA, the uncertainty around model parameters is 
taken into account by repeatedly sampling from a probability distribution around 




conducted for MISCAN studies as these are extremely time consuming and 
methodologically complex.
A limitation specifically for Chapter 4 and Chapter 5 is that the effectiveness of 
mammography, which is incorporated in MISCAN through an improved survival 
after screen-detection of breast cancer, compared to clinical detection, is not 
specified by age. The modelled effect of screening is thus the same for the age 
group 40 to 49 years and for 50 years and older. This is not in line with findings 
from randomised trials that included women aged 40 to 49 years, which showed 
a lower reduction in breast cancer mortality for this age group.29, 30 However, 
MISCAN does predict a lower reduction in breast cancer mortality as a result of 
screening because of several aspects: the duration of the preclinical tumour stages 
is shorter for women aged 40 to 49 years than for older women, which results 
in lower screening benefit; the sensitivity of digital mammography is lower for 
younger women; the survival after clinical detection of a tumour is higher for 
younger than for older women, which means that the improvement from detection 
by screening is relatively smaller than for older women.55, 56
FUTURE DIRECTIONS
Some of the topics addressed in this thesis will develop further in the future, when 
more advanced study outcomes will be available. For all future developments in 
breast cancer screening, it will be important to assess how they will affect the cost-
effectiveness and the balance between the benefits and harms of screening.
Tomosynthesis
Digital breast tomosynthesis is already used regularly in clinical settings and will 
most likely gradually replace digital mammography in breast cancer screening 
programmes. To estimate the effectiveness and costs with tomosynthesis more 
accurately, additional information on subsequent screening rounds, optimal 
reading strategies and associated screening costs is required.
Risk stratification
As the knowledge on risk factors for breast cancer has improved substantially over 
the years, breast cancer screening stratified for different risk levels has become 
an interesting alternative to uniform screening. Important factors with regard 
to risk-based approaches are: assessing individual risk, identifying strategies for 
different risk levels and the acceptance among women eligible for screening. There 
are multiple ongoing studies that evaluate risk-based screening approaches, of 
which many are European initiatives. The MyPeBS (My Personal Breast Screening) 
initiative is a European project in which personalised screening based on a 
woman’s risk of breast cancer for women aged 40-70 years is compared to current 
screening practice for five European countries.37 In the Italian TBST (Tailored 
Breast Screening Trial) study, women aged 45-49 years with dense breasts in the 
intervention group are screened annually instead of biennially.69 From age 50 
years, all women are screened according to current screening practice. In the 
Dutch PRISMA study, risk factors for breast cancer are identified and data on 
the distributions of these risk factors among the Dutch female population are 
collected.38 The findings of this study will be used to evaluate the effect of tailored 
screening strategies for women at relatively high and low risks of breast cancer 
in the Netherlands. A publication associated with the PRISMA study showed that 
women are receptive to individual risk assessment but that there are differences 
in preferences and needs of women between countries.70
Screening for women with dense breasts
A form of risk-based screening that receives a lot of attention lately is tailored 
screening of women with dense breasts. High breast density is a risk factor for 
breast cancer and is associated with lower sensitivity of mammography.19, 71, 72 The 
value of MRI in addition to standard digital mammography screening practice 
was evaluated in the Dutch randomised controlled DENSE trial.73 Women aged 
50-75 years, eligible for breast cancer screening, with extremely dense breasts 
(American College of Radiology category 4 breast density) and a negative screening 
mammogram were either assigned to the control arm (standard practice) or to 
the intervention arm, in which they received an invitation for additional MRI. A 




that was invited to additional MRI was significantly lower than in the control 
group, emphasizing the additional value of MRI for women with extremely dense 
breasts.74 Currently, the MISCAN model is used to estimate the impact of these 
outcomes, in terms of cost-effectiveness and the balance between benefits and 
harms, on the population level.
Recommendations for future research
· Estimating the impact, in terms of cost-effectiveness and the balance 
between benefits and harms, of a risk-based screening strategy addressing 
the different risk groups, for the population as a whole
· Assessing the feasibility and the acceptance among women of a risk-based 
screening approach in the Netherlands
· Determining how to best inform women, in particular women with a low 
relative risk, on the advantages and disadvantages of risk based screening
· Quantifying the possible additional overdiagnosis with digital breast 
tomosynthesis use, compared to screening with digital mammography
· Determining the optimal reading strategy with digital breast tomosynthesis 
in the Netherlands and estimating the corresponding costs of screening
· Determining what research would be most valuable to make a decision on 
implementing digital breast tomosynthesis
· Incorporating the four different categories of breast density in MISCAN 
model
· Using individual level risk factors linked to individual tumour progression 
in MISCAN model
FINAL CONCLUSIONS
· The programme sensitivity with digital mammography screening is higher 
than with screen-film mammography due to increased breast cancer 
detection with digital mammography.
· Despite the increase in referral rates with the transition to digital 
mammography screening, programme specificity in the Netherlands is still 
quite high compared to other European countries.
· Breast cancer mortality rates in the Netherlands declined significantly over 
the last decades as a result of the implementation of breast cancer screening 
and (improved) adjuvant treatment.
· Starting screening before age 50 years is a cost-effective approach to increase 
the screening benefit but comes at the expense of higher false-positive 
rates
· If generally accepted, screening stratified by risk has the potential to improve 
screening benefit for women with a high relative risk of breast cancer and 
to limit harms for women with a low relative risk, while not substantially 
affecting the cost-effectiveness of the screening programme.
· Analysing currently available data, screening with digital breast 
tomosynthesis is not expected to be a cost effective alternative in the 
Netherlands to digital mammography screening, but this conclusion 
may change in favour of tomosynthesis when using a somewhat higher, 
internationally accepted cost-effectiveness threshold or Dutch rates for 
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Breast cancer incidence in the Netherlands is among the highest in Europe. 
Almost all women with breast cancer are treated, regardless of the breast cancer 
stage. Mammography screening can result in early detection of breast cancer and, 
possibly, earlier treatment and better prognosis. In the Netherlands, women aged 
50 to 74 are invited biennially to digital mammography screening. The benefits 
of screening are (quality adjusted) life years gained and prevented breast cancer 
deaths. However, screening also leads to harms including false-positive screens, 
overdiagnosis and overtreatment and false reassurance.
Screening programmes are assessed using several performance indicators 
including the detection rate, the interval cancer rate, programme sensitivity, the 
referral rate, the false-positive rate and programme specificity.
Several factors that may increase the risk of breast cancer have been identified. 
Common risk factors are age, a family history of breast cancer, high breast density 
and a previous biopsy. Reproductive and life style factors have also been associated 
with higher breast cancer risk. Currently, there are multiple studies that explore 
risk-based breast cancer screening.
There is no consensus about the optimal screening strategy, in terms of for 
example the age range. In addition, new developments could improve current 
strategies. Using simulation models, the long-term effects of different screening 
strategies can be predicted. The aim of this thesis was to quantify the effects of 
the current screening programme in the Netherlands and to determine the effects 
and cost-effectiveness of alternative screening strategies including strategies 
starting before age 50 years, risk-based strategies and screening with digital breast 
tomosynthesis.
Part One: Evaluation of current breast cancer screening in the 
Netherlands
 In the study described in Chapter 2, data of the Dutch Screening Organisations 
on all screening examinations performed between 2004 and 2011 were linked to 
data of the Netherlands Cancer Registry to estimate the detection and interval 
cancer rates. Besides the trends over time, possible differences in performance 
indicators between screen-film and digital mammography were addressed. Digital 
mammography gradually replaced screen-film mammography in the Netherlands 
from 2008 to 2010. The breast cancer detection rate in the Netherlands, for both 
in ductal carcinoma in situ (DCIS) and invasive carcinomas, increased by more 
than 20% over the years 2004-2011. The programme sensitivity, referral rate and 
false-positive rate also increased. The interval cancer rate remained stable during 
the study period. Between 2004 and 2011, 7,343,327 screening examinations were 
performed, of which 64% were screen-film and 36% were digital screens. The 
detection rate was significantly higher with digital mammography (6.2 per 1000 
screens) than with film-screen mammography (5.4 per 1000 screens). The interval 
cancer rate was similar with both modalities. As a result of the higher detection 
rate with digital mammography, the programme sensitivity was significantly 
higher than with film-screen mammography. The referral rate and false-positive 
rate were also higher, resulting in a lower programme specificity with digital 
mammography. The programme specificity in the Netherlands is, however, still 
relatively high compared to other countries.
Analysing the data for 5-year age groups separately, a relatively high increase in 
programme sensitivity and a slight (non-significant) decrease in the interval cancer 
rate was observed in women younger than 60 years. These trend changes may be 
(partly) attributable to the transition to digital mammography screening. Further 
research is required to assess whether particularly younger women have benefitted 
from the change to digital mammography screening.
In the next chapter, Chapter 3, the trend in breast cancer mortality in the 
Netherlands between 1980 and 2010 is analysed. Breast cancer screening was 
gradually implemented in the Netherlands, starting with a few municipalities 
in 1989/1990 and completing implementation in 1997. Therefore, breast cancer 
mortality was analysed on a municipality-level, using the municipality specific 
year of implementation of screening as starting point of the trend analysis. Only 
overall results– on a national level – are reported. The breast cancer mortality rate 
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in the Netherlands decreased by 30%, since the introduction of screening until 
the year 2010, in women aged 55-74 years. The start of this decrease was observed 
around two years after the introduction of screening. In the age group 75-79 years, 
a significant decrease of 34% was observed. During the implementation phase of 
screening, adjuvant therapy in the Netherlands improved, in terms of usage and 
quality, which caused a decline in breast cancer mortality rates. It is difficult to 
disentangle the effect of screening, treatment and other factors on breast cancer 
mortality using trend studies. Analysing breast cancer mortality rates using 
individual data would provide more accurate and reliable estimates. However, 
a significant decrease in breast cancer mortality was also found in subgroups of 
municipalities with an early implementation year of screening, before (the use of) 
adjuvant therapy improved.
Part two: Quantifying the cost-effectiveness, harms and benefits 
of different screening strategies and screening modalities in the 
Netherlands using microsimulation modelling
In Chapter 4, the cost-effectiveness of extending digital mammography screening 
in the Netherlands below age 50 years is assessed. The current Dutch screening 
programme biennially invites women between age 50 and 74 years to digital 
mammography screening. However, the breast cancer incidence among women 
in their forties has increased over the last decades. This study quantified the cost-
effectiveness of screening women between age 40 and 50 years in addition to the 
current screening strategy and estimated the increase in benefits and harms that 
come with starting screening earlier. Using the MISCAN microsimulation model, 
different strategies with a starting age between 40 and 50 years were simulated. 
The results of this study showed that the simulated strategies were cost-effective 
using the Dutch cost-effectiveness threshold of €20,000 per life year gained. Two 
strategies were dominated: the strategy with an additional screen at age 49 years 
and the strategy with additional annual screening between age 45 and 49 years. 
These strategies were dominated by biennial strategies, which were more effective 
and less costly per additional life year gained. In terms of increased harms with 
additional screening, it was predicted that additional screening between age 40 
and 50 years only slightly increased overdiagnosis, but substantially increased the 
number of false-positive findings.
Chapter 5 addresses the cost-effectiveness of another alternative to current 
screening: screening women based on their risk of breast cancer. Using MISCAN, 
women with a relative breast cancer risk of 0.75 and 1.8 were simulated. For women 
with a low relative risk (0.75) screening strategies that were less intensive than the 
current strategy – biennial screening between age 50 and 74 years - were simulated 
and for women with a high relative risk (1.8) strategies that were more intensive. 
The optimal screening strategy was estimated for the two risk-groups by selecting 
the screening strategy with an incremental cost-efffectiveness ratio just below 
the cost-effectiveness of current screening, in order that the risk-based strategy 
does not result in a less favourable ratio of costs to effects at the population level. 
The model predicted that the optimal strategy for women at lower than average 
risk was triennial screening between age 50 and 71 years. Compared to current 
screening, this strategy resulted in a decline in the number of false-positive 
findings of 33% and an improved harm-benefit ratio, because the decrease in the 
effect of screening (life years gained) was relatively small. The optimal strategy 
for women with a high relative risk was biennial screening between age 40 and 74 
years. This strategy led to a 25% increase in the number of life years gained, but at 
the same time to a 44% increase in the number of false-positive findings, resulting 
in a more unfavourable harm-benefit ratio. The findings of this study show that 
risk-based screening for women with a lower than average risk can result in a 
decrease in screening harms while maintaining most of the screening effect. For 
women with a higher than average risk, risk-based screening can lead to a gain in 
screening effect, at the expense of a substantial increase in false-positive findings. 
Future research is required to estimate the impact of risk-based screening at the 
population level, by linking the relative risks to individual risk factors and their 
prevalence. It is also important to take breast density into account as a risk factor 
for breast cancer.
In Chapter 6, the use of an alternative screening test, digital breast tomosynthesis, 
is explored. Digital breast tomosynthesis generates multiple images of the breast 
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at different angles, creating a pseudo 3D image. Recent trials have shown that 
screening with tomosynthesis leads to an increased breast cancer detection rate, 
compared with digital mammography. In this chapter, the cost-effectiveness of 
tomosynthesis is estimated. To estimate the cost-effectiveness, 10,000 model 
runs, in which a cohort of women was biennially screened with tomosynthesis 
between age 50 and 74 years, were performed. Subsequently, the outcomes for 
tomosynthesis were compared to the outcomes of current screening – biennial 
digital mammography between 50 and 74 years. The model predicted a 7% 
increase in the number of life years gained with tomosynthesis, a 6% increase 
in the number of breast cancer deaths averted and a 2% decrease in the number 
of false-positive findings, compared to digital mammography, per 1000 women 
invited to screening with lifelong follow-up. The average incremental costs of 
tomosynthesis were estimated at €137,555 and the incremental cost-effectiveness 
ratio (ICER) at €27,023 per life year gained, using annual discounting of 3.5% for 
both costs and effects. When comparing tomosynthesis and digital mammography, 
the probability of being most cost-effective was 0.36 for tomosynthesis and 0.64 
for digital mammography, using a cost-effectiveness threshold of €20,000 per 
life year gained. At a threshold of €35,000 per life year gained, tomosynthesis 
was the strategy with the highest probability of being most cost-effective, with a 
probability of 0.66.
Using a cost-effectiveness threshold of €20.000 per life-year gained, according to 
Dutch guidelines, screening with tomosynthesis, with an ICER of €27,023, would 
not be cost-effective. However, Dutch guidelines recommend annual discounting 
with 4% for costs and 1.5 for effects, instead of equal discounting with 3.5% for 
both. Applying Dutch discounting recommendations would result in a more 
favourable ICER.
The costs and effects of tomosynthesis in a screening setting are still rather 
uncertain. Additional research taking into account the reading strategy, the 
exact screening costs with tomosynthesis and the screening effect over multiple 
screening rounds is therefore necessary.
Conclusions and recommendations
The following conclusions can be drawn from the results of the studies in this 
thesis:
· The programme sensitivity with digital mammography screening is higher 
than with screen-film mammography due to increased breast cancer 
detection with digital mammography.
· Despite the increase in referral rates with the transition to digital 
mammography screening, programme specificity in the Netherlands is still 
quite high compared to other European countries.
· Breast cancer mortality rates in the Netherlands declined significantly over 
the last decades as a result of the implementation of breast cancer screening 
and (improved) adjuvant treatment.
· Starting screening before age 50 years is a cost-effective approach to increase 
the screening benefit but comes at the expense of higher false-positive 
rates
· If generally accepted, screening stratified by risk has the potential to improve 
screening benefit for women with a high relative risk of breast cancer and 
to limit harms for women with a low relative risk, while not substantially 
affecting the cost-effectiveness of the screening programme.
· Analysing currently available data, screening with digital breast 
tomosynthesis is not expected to be a cost effective alternative in the 
Netherlands to digital mammography screening, but this conclusion 
may change in favour of tomosynthesis when using a somewhat higher, 
internationally accepted cost-effectiveness threshold or Dutch rates for 
discounting or when tomosynthesis becomes cheaper.
Based on these conclusions, the following recommendations were formulated:
· Estimating the impact, in terms of cost-effectiveness and the balance 
between benefits and harms, of a risk-based screening strategy addressing 
the different risk groups, for the population as a whole
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· Assessing the feasibility and the acceptance among women of a risk-based 
screening approach in the Netherlands
· Determining how to best inform women, in particular women with a low 
relative risk, on the advantages and disadvantages of risk based screening
· Quantifying the possible additional overdiagnosis with digital breast 
tomosynthesis use, compared to screening with digital mammography
· Determining the optimal reading strategy with digital breast tomosynthesis 
in the Netherlands and estimating the corresponding costs of screening
· Determining what research would be most valuable to make a decision on 
implementing digital breast tomosynthesis
· Incorporating the four different categories of breast density in MISCAN 
model






De borstkankerincidentie in Nederland is relatief hoog vergeleken met andere 
Europese landen. Vrijwel alle vrouwen met borstkanker, ongeacht het stadium, 
worden behandeld. Screening met mammografie kan leiden tot een vroegere 
opsporing van borstkanker en daarmee mogelijk tot een eerdere behandeling en 
betere prognose. In Nederland worden vrouwen tussen de 50 en 74 jaar eens in de 
twee jaar uitgenodigd om deel te nemen aan screening met digitale mammografie. 
De belangrijkste voordelen van screening zijn gewonnen (kwalitatief goede) 
levensjaren en voorkomen borstkankerdoden. Screening resulteert ook in 
nadelen, waaronder fout-positieve uitslagen, overdiagnose en overbehandeling en 
onterechte geruststelling. Om het functioneren van een screeningsprogramma te 
beoordelen zijn verschillende indicatoren van belang, waaronder het detectiecijfer, 
het intervalkankercijfer, de programmasensitiviteit, het verwijscijfer, het fout-
positievencijfer en de programmaspecificiteit.
Factoren waarvan bekend is dat ze het risico op borstkanker kunnen verhogen 
zijn onder anderen leeftijd, geslacht, familiegeschiedenis van borstkanker, dicht 
borstweefsel en een voorgaande biopsie. Ook factoren die samenhangen met de 
voortplanting en levensstijlfactoren kunnen bijdragen aan een verhoogde kans 
op borstkanker. Er lopen op dit moment verschillende studies naar op risico 
gebaseerde screeningsstrategieën.
Er is geen consensus over de optimale screeningsstrategie, bijvoorbeeld wat 
betreft leeftijdsgrenzen. Bovendien zijn er nieuwe ontwikkelingen op het 
gebied van screening die zouden kunnen leiden tot een verbetering van huidig 
toegepaste strategieën. Met behulp van simulatiemodellen kunnen lange-
termijn voorspellingen worden gedaan over de effecten en de kosteneffectiviteit 
van verschillende screeningsstrategieën. Het doel van dit proefschrift was 
het in kaart brengen van de voordelige en nadelige effecten van het huidige 
screeningsprogramma in Nederland en het onderzoeken van alternatieve manieren 
van screening, zoals het eerder starten met screenen, het screenen op basis van 
het risico op borstkanker en het screenen met een andere screeningstechniek 
dan digitale mammografie, namelijk tomosynthese. Hierbij is er gekeken naar de 
kosteneffectiviteit en de voor- en nadelen van alternatieve screening.
Deel 1: Evaluatie van het huidige borstkanker screeningsprogramma 
in Nederland
In hoofdstuk 2 wordt data van de Nederlandse screeningsorganisaties van alle 
screens uitgevoerd in de periode 2004 tot 2011 geanalyseerd om het detectie- en 
intervalkankercijfer te bepalen. Hiertoe zijn de screeningsdata gelinkt aan data van 
de Nederlandse Kankerregistratie. Naast de trends over de tijd is er ook gekeken 
naar eventuele verschillen in screeningsindicatoren tussen analoge en digitale 
mammografie. Deze laatste heeft analoge mammografie vanaf 2008 geleidelijk 
vervangen. Over de gehele onderzoeksperiode is het detectiecijfer van borstkanker 
in Nederland, voor ductal carcinoma in situ (DCIS) en invasieve kankers samen, 
met meer dan 20% gestegen. Ook de programmasensitiviteit, het verwijscijfer 
en het fout-positievencijfer zijn toegenomen. Het intervalkankercijfer is stabiel 
gebleven over de periode 2004 tot 2011. In de onderzoeksperiode bestond het 
totaal aantal uitgevoerde screeningsonderzoeken (7.343.327) voor 64% uit 
analoge screens en voor 36% uit digitale screens. Het detectiecijfer van digitale 
mammografie was met 6,2 per 1000 screens significant hoger dan het detectiecijfer 
met analoge mammografie (5,4 per 1000 screens). Het intervalkankercijfer was 
gelijk voor beide screeningsmodaliteiten. Als gevolg van het hogere detectiecijfer 
was de programmasensitiviteit voor digitale mammografie ook hoger dan voor 
analoge mammografie. Digitale mammografie had tevens een significant hoger 
verwijscijfer en fout-positievencijfer, waardoor de programmaspecificiteit lager 
was dan die van analoge mammografie. De programmaspecificiteit in Nederland 
is internationaal gezien echter nog steeds relatief hoog.
Wanneer de resultaten werden uitgesplitst naar 5-jaar leeftijdsgroepen viel 
op dat er in de groep vrouwen onder de 60 jaar een relatief hoge stijging in de 
programmasensitiviteit heeft plaatsgevonden en een lichte (niet significante) daling 
in het intervalkankercijfer, die bij oudere vrouwen niet geobserveerd werd. Deze 
veranderingen zijn mogelijk deels toe te schrijven aan de transitie naar digitale 
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mammografie. Toekomstige analyses moeten uitwijzen of met name jongere 
vrouwen hebben geprofiteerd van de overstap naar digitale mammografie.
Het volgende hoofdstuk, hoofdstuk 3 , behandelt de analyse van de 
trend in borstkankersterfte in Nederland over de periode 1980 tot 2010. 
Borstkankerscreening is geleidelijk ingevoerd in Nederland, beginnend met een 
aantal gemeenten in 1989/1990 tot in 1997, toen de gehele vrouwelijke bevolking 
in de in aanmerking komende leeftijdsgroep werd uitgenodigd. Om deze reden 
is de borstkankersterfte geanalyseerd op gemeenteniveau, door het jaartal van 
invoering van borstkankerscreening in de verschillende Nederlandse gemeenten 
als startpunt van de analyse te nemen. De resultaten worden alleen op nationaal 
niveau gerapporteerd. In heel Nederland is de borstkankersterfte vanaf de 
introductie van screening tot aan het jaar 2010, in vrouwen in de leeftijdscategorie 
55-74 jaar, met 30% gedaald. Het begin van de daling in de trend is zichtbaar 2 
jaar na implementatie van screening. In de leeftijdsgroep 75-79 jaar werd een 
significante daling van 34% geobserveerd. Gedurende de implementatieperiode 
van screening is de adjuvante therapie in Nederland verbeterd in kwaliteit en 
meer toegepast, wat tot een daling in borstkankersterfte heeft geleid. Het is met 
trendstudies niet mogelijk om de afzonderlijke effecten van screening, therapie en 
andere factoren op de borstkankersterfte uit elkaar te halen. Een studie gebaseerd 
op individuele data zou meer accurate en betrouwbare schattingen leveren. In 
dit onderzoek werd echter ook in subgroepen van gemeenten met een vroege 
implementatie van screening, in de periode met minder en minder goede adjuvante 
therapie, een significante daling in borstkankersterfte gevonden.
Deel 2: Het kwantificeren van de kosteneffectiviteit en de voor- en 
nadelen van verschillende screeningsstrategieën en screenings- 
modaliteiten in Nederland met behulp van micro simulatie
In hoofdstuk 4 wordt de kosteneffectiviteit van het eerder starten met digitaal 
screenen op borstkanker bij vrouwen in Nederland onderzocht. In het huidige 
screeningsprogramma worden vrouwen eens in de twee jaar uitgenodigd voor 
screening, tussen leeftijd 50 en 74 jaar. De incidentie van borstkanker onder 
vrouwen in de 40 is de afgelopen tijd echter toegenomen. In dit hoofdstuk is gekeken 
of het additioneel screenen van vrouwen tussen leeftijd 40 en 50 kosteneffectief 
zou zijn en wordt de toename in voor- en nadelen bepaald, die gepaard gaat met het 
eerder starten van screenen. Met behulp van het MISCAN model zijn verschillende 
strategieën met een startleeftijd tussen de 40 en 50 jaar gesimuleerd. De resultaten 
van dit onderzoek lieten zien dat de gesimuleerde strategieën kosteneffectief zijn, 
uitgaande van de vaak gerapporteerde drempelwaarde voor kosteneffectiviteit van 
€20.000 per gewonnen levensjaar in Nederland. Twee strategieën werden echter 
gedomineerd, namelijk: een additionele screen op leeftijd 49 als toevoeging op het 
huidige programma en jaarlijkse screening tussen leeftijd 45 en 49 als toevoeging 
op de huidige strategie. Deze strategieën werden gedomineerd door strategieën 
waarbij eens in de twee jaar wordt gescreend, die effectiever waren en minder 
kostten per additioneel gewonnen levensjaar. Wat betreft de voorspelde nadelen 
van screening viel het op dat met het toevoegen van screening tussen leeftijd 40 
en 50 aan de huidige screeningsstrategie overdiagnose nauwelijks toenam terwijl 
het aantal fout-positieve bevindingen sterk steeg met de intensiviteit van een 
screeningsstrategie.
Hoofdstuk 5 behandelt de kosteneffectiviteit van een andere variatie op het huidige 
screeningsprogramma, namelijk het verschillend screenen van vrouwen met een 
verlaagd en een verhoogd risico op borstkanker. Met MISCAN zijn vrouwen met 
een relatief risico van 0.75 en vrouwen met een relatief risico van 1.8 gesimuleerd. 
Voor vrouwen met een verlaagd relatief risico (0.75) zijn strategieën gesimuleerd 
die minder intensief zijn dan de huidige strategie (interval van 2 jaar in leeftijd 
50-74) en voor vrouwen met een verhoogd relatief risico (1.8) strategieën die 
intensiever zijn. Voor deze twee groepen is de optimale screeningsstrategie bepaald 
door van alle gesimuleerde strategieën de strategie te kiezen die een incrementele 
kosteneffectiviteitsratio heeft die net onder de kosteneffectiviteit van het huidige 
screeningsprogramma valt, zodat de kosteneffectiviteit niet minder gunstig uitvalt 
op populatieniveau dan die van de huidige screening. Met het model is geschat 
dat de optimale strategie voor vrouwen met een laag risico een interval van 3 jaar 
heeft en een start- en stopleeftijd van respectievelijk 50 en 71 jaar. Vergeleken 
met de huidige strategie resulteerde deze optimale strategie in een verlaging van 
het aantal fout-positieve bevinding van 33% en een verbeterde ratio van voor en 
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nadelen omdat het screeningseffect (gewonnen levensjaren) minder sterk afneemt. 
Voor vrouwen met een verhoogd risico is geschat dat de optimale strategie bestaat 
uit een interval van 2 jaar en een leeftijdsrange van 40-74 jaar. Deze strategie 
leidde tot een 25% toename in het screeningseffect, maar tegelijkertijd ook tot 
een 44% toename in het aantal fout-positieve bevindingen waardoor de ratio van 
voor- en nadelen ongunstiger werd. Dit onderzoek laat zien dat het screenen op 
basis van het risico op borstkanker bij vrouwen met een verlaagd risico kan leiden 
tot een verlaging van de nadelen van screening terwijl een groot deel van het 
screeningseffect behouden blijft. Voor vrouwen met een verhoogd risico geldt dat 
er een winst in screeningseffect te behalen is, maar dat dit gepaard gaat met een 
sterk verhoogde kans op een fout-positieve bevinding. Toekomstig onderzoek is 
nodig om de impact van screenen naar risico op populatieniveau te bepalen, door 
de relatieve risico’s te linken aan individuele risicofactoren en de bijbehorende 
prevalentie. Ook is het belangrijk om de borstdensiteit als risicofactor mee te 
nemen.
In hoofdstuk 6 wordt weer een andere variatie op het huidige screeningsprogramma 
onderzocht, namelijk het gebruik van digitale borst tomosynthese als screeningtest 
in plaats van de huidig gebruikte digitale mammografie. Tomosynthese genereert 
meerdere borstfoto’s, genomen uit verschillende hoeken, waardoor een pseudo 3D 
beeld wordt gecreëerd. Uit recente trials blijkt dat tomosynthese screening leidt tot 
een verhoogde borstkankerdetectie, vergeleken met digitale mammografie. In dit 
hoofdstuk wordt gekeken of screening met tomosynthese ook kosteneffectief is. 
Om dit te onderzoeken zijn 10.000 modelruns uitgevoerd voor een cohort vrouwen 
dat eens in de twee jaar wordt uitgenodigd voor screening met tomosynthese 
tussen leeftijd 50 en 74. De uitkomsten voor tomosynthese zijn vervolgens 
vergeleken met die van huidige screening (digitale mammografie tussen leeftijd 50 
en 74). Het model voorspelde dat tomosynthese screening leidt tot een verhoging 
van 7% in het aantal gewonnen levensjaren, een verhoging van 6% in het aantal 
voorkomen borstkankersterfgevallen en een verlaging in het aantal fout-positieve 
bevindingen van 2%, per 1000 vrouwen die worden uitgenodigd voor screening en 
de rest van hun leven gevolgd worden, vergeleken met digitale mammografie. De 
gemiddelde incrementele kosten van tomosynthese over de 10.000 runs werden 
geschat op €137.555 en de incrementele kosteneffectiviteitsratio van tomosynthese 
vergeleken met digitale mammografie op €27.023 per gewonnen levensjaar, 
waarbij de kosten en effecten beide met 3,5% per jaar zijn verdisconteerd. Ook 
lieten de uitkomsten zien dat de kans dat tomosynthese de meer kosteneffectieve 
optie is, vergeleken met digitale mammografie, 36% is, bij een drempelwaarde 
voor de kosteneffectiviteit van €20.000 per gewonnen levensjaar. Bij een hogere 
drempelwaarde van €35.000 per gewonnen levensjaar zou deze kans 66% zijn.
Uitgaande van de Nederlandse richtlijnen voor de drempelwaarde voor 
kosteneffectiviteit (€20.000 per gewonnen levensjaar) zou tomosynthese 
screening met een ICER van €27.023 niet als kosteneffectief worden beschouwd 
met een gelijke verdiscontering voor effecten en kosten van 3,5%. Echter, volgens 
de Nederlandse richtlijnen dienen effecten en kosten met respectievelijk 1,5% en 4% 
verdisconteerd te worden. Bij deze manier van verdisconteren zou de incrementele 
kosteneffectiviteitsratio een stuk gunstiger uitvallen.
Er bestaat nog behoorlijke onzekerheid rondom de kosten en effecten van 
borstkanker screening met tomosynthese. Aanvullend onderzoek waarbij de 
kosten van tomosynthese in een screeningssetting beter in kaart worden gebracht, 
waarin verschillende leesstrategieën worden onderzocht en waarin meerdere 
screeningsrondes worden meegenomen om de effectiviteit van tomosynthese beter 
te bepalen is daarom van belang.
Conclusies en aanbevelingen
De volgende conclusies kunnen worden getrokken op basis van de resultaten van 
de studies in dit proefschrift:
· De programmasensitiviteit met digitale mammografie is hoger dan met 
analoge mammografie als gevolg van de verhoogde borstkankerdetectie 
met digitale mammografie.
· Ondanks de verhoging van het verwijscijfer na de overgang naar digitale 
mammografie is de programmaspecificiteit in Nederland nog steeds relatief 
hoog vergeleken met andere Europese landen.
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· De borstkankersterfte in Nederland is significant gedaald over de laatste 
decennia als gevolg van de invoering van borstkankerscreening en 
(verbeterde) adjuvante therapie.
· Het starten met screenen vóór de leeftijd van 50 jaar is een kosteneffectieve 
aanpak om het effect van screening te verhogen, maar heeft een hoger fout-
positievencijfer als keerzijde.
· Indien algemeen geaccepteerd, heeft screening op basis van het risico 
van een vrouw de potentie om het effect van screening te verhogen voor 
vrouwen met een hoog relatief risico op borstkanker en om de nadelige 
effecten van screening te beperken voor vrouwen met een laag relatief 
risico, terwijl dit geen grote invloed heeft op de kosteneffectiviteit van het 
screeningsprogramma.
· Op basis van de huidig beschikbare data is niet te verwachten dat digitale 
borst tomosynthese een kosteneffectief alternatief is voor digitale 
mammografie in Nederland, maar deze conclusie kan in het voordeel van 
tomosynthese veranderen wanneer een hogere, internationaal geaccepteerde 
drempelwaarde voor de kosteneffectiviteit wordt gehanteerd, wanneer 
Nederlandse richtlijnen voor verdiscontering van kosten en effecten worden 
toegepast of wanneer tomosynthese goedkoper wordt.
Gebaseerd op bovenstaande conclusies zijn de volgende aanbevelingen 
opgesteld:
· Het schatten van de impact, wat betreft kosteneffectiviteit en de balans 
tussen voor- en nadelen, van screeningsstrategieën op basis van risico op 
borstkanker voor verschillende risicogroepen, voor de screeningspopulatie 
als geheel.
· Het vaststellen van de haalbaarheid en de acceptatie van screening op basis 
van het risico op borstkanker in Nederland.
· Bepalen hoe vrouwen het beste geïnformeerd kunnen worden over de voor- 
en nadelen van screenen op basis van het risico op borstkanker, met name 
wat betreft vrouwen met een relatief laag risico op borstkanker.
· Het kwantificeren van de mogelijke toename in overdiagnose met digitale 
borst tomosynthese, ten opzichte van digitale mammografie.
· Het vaststellen van de optimale leesstrategie met digitale borst tomosynthese 
in Nederland en het schatten van de bijbehorende kosten.
· Bepalen welk (aanvullend) onderzoek het meest van waarde zou zijn om een 
beslissing over het wel of niet invoeren van digitale borst tomosynthese te 
kunnen maken.
· Het opnemen van de vier verschillende categorieën van borst densiteit in 
het MISCAN model.
· Het gebruiken van risicofactoren op individueel niveau, gelinkt aan 
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Seminars, conferences and courses Year Workload
Planning and Evaluation of Screening (NIHES course), 
Rotterdam, the Netherlands
2013 1.4
Breast Cancer Surveillance Consortium Working Group 
Meeting, San Francisco, United States.
2013 0.7
International Workshop on Breast Cancer Risk 
Assessment, San Francisco, United States.
2013 1.0
Genetic Risk Prediction for Common Diseases, VUMC, 
Amsterdam, The Netherlands
2013 0.2
Master class: Advances in Epidemiologic Analysis 
(NIHES), Erasmus MC, Rotterdam, the Netherlands
2014 0.4
Master class: Advances in Genomics Research (NIHES), 
Erasmus MC, Rotterdam, the Netherlands
2014 0.4
CPO Course, Erasmus MC, Rotterdam, the Netherlands 2015 0.3
International Cancer Screening Network meeting, 
Rotterdam, the Netherlands
2015 0.7
Scientific Career Orientation, Erasmus MC, Rotterdam, 
the Netherlands
2015 0.1
Genetic Screening: Who, Why and When?, Amsterdam, 
the Netherlands
2015 0.3
Scientific Integrity course, Erasmus MC, Rotterdam, the 
Netherlands
2015 0.3
Werkgroep ‘Wetenschap en Innovatie’ RIVM, Utrecht, the 
Netherlands
2015 0.1
Presenting for Scientists, Erasmus MC, Rotterdam, the 
Netherlands
2016 0.2
Symposium The Impact of Breast Imaging, Utrecht, the 
Netherlands
2016 0.2
WEON Conference, Wageningen, the Netherlands 2016 1.0
Werkgroep ‘Wetenschap en Innovatie’ RIVM, Utrecht, the 
Netherlands
2017 0.1
Congres ‘Bevolkingsonderzoeken op het spoor’, Utrecht, 
the Netherlands
2017 0.3
Advanced Decision Modeling course (NIHES) 2018 1.4
Seminars, conferences and courses Year Workload
Symposium Dutch Association for Community Genetics 
and Public Health Genomics Meeting, Utrecht, the 
Netherlands
2018 0.2
International Cancer Screening Network Meeting, 
Rotterdam, the Netherlands
2019 0.7
Research Seminars, Erasmus MC, department of Public 
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Monthly seminar ‘Club Meth’, Rotterdam, the 
Netherlands. Oral presentation.
2013 1.0
European Breast Cancer Conference (EBCC-9), Glasgow, 
Scotland. Poster presentation.
2014 1.0
Research group meeting ‘Early Detection’, Rotterdam, the 
Netherlands. Oral presentation.
2014 1.0
Research group meeting ‘Early Detection’, Rotterdam, the 
Netherlands. Oral presentation.
2015 1.0
National Evaluation Team Breast cancer screening 
meeting, Utrecht, the Netherlands. Oral presentation.
2015 1.0
Research group meeting ‘Early Detection’, Rotterdam, the 
Netherlands. Oral presentation.
2016 1.0
Research group meeting ‘Journal club’, Rotterdam, the 
Netherlands. Oral presentation.
2016 1.0
WEON Conference, Wageningen, the Netherlands. Oral 
presentation.
2016 1.0
Working Group meeting RIVM ‘Wetenschap en Innovatie’, 
Utrecht, the Netherlands. Oral presentation.
2017 1.0
Meeting RIVM, ZonMW and Dutch Health Council 
‘VOI tomosynthesis’, Utrecht, the Netherlands. Oral 
presentation.
2019 1.0
International Cancer Screening Network Meeting, 





Community Project Mentor: supervising a group of third 
year Medicine students in a project on ‘Breast cancer and 
deodorants’, Erasmus MC, Rotterdam, the Netherlands.
2017 0.7
Co-supervising Econometrics master student 2018 1.5
Other
IARC Handbooks of Cancer Prevention Volume 15. Writing 
of two chapters.
2014 1.5
Contributing to Screening Evaluation part of MGZ website 2016 0.1
Writing report on regional breast cancer mortality in the 
Netherlands for the RIVM
2016 1.0
Writing report on model calibration for the RIVM 2016 1.0
Organising Scientific Career Orientation day for the Public 
Health department, Rotterdam, the Netherlands
2017 0.2
Cancer Prevention and screening: concepts, principles and 




ESMO Handbook Interpreting Oncological Study 





Fourteenth Evaluation Report National Evaluation Team 
Breast cancer screening, RIVM. Coordination of report 











Ik had nooit gedacht dat ik op mijn werkplek zoveel bijzondere mensen zou leren 
kennen. Er zijn een hoop collega’s die ik dankbaar ben. Een aantal collega’s wil ik 
hieronder in het bijzonder bedanken. 
Dit proefschrift was niet tot stand gekomen zonder de goede begeleiding van mijn 
directe collega’s.
Allereerst bedank ik graag mijn promotor, Harry. Bedankt voor het vertrouwen 
dat je in me had de afgelopen jaren, voor alle kansen die je me hebt geboden en 
de vrijheid die je me hebt gegeven om het onderzoek uit te voeren. Ik heb tijdens 
mijn ontwikkeling als onderzoeker veel geprofiteerd van jouw kennis en kritische 
blik. Daarnaast was het leuk om Japan-tips met elkaar uit te kunnen wisselen!
Nicolien, ik heb veel gehad aan onze wekelijkse meetings en je hebt dan ook een 
enorme bijdrage geleverd aan dit proefschrift. Ik heb heel veel geleerd van jouw 
kennis, inzicht en scherpe kijk op dingen, waardoor ik ook meer vertrouwen in 
mezelf heb gekregen. Ook waardeer ik het heel erg dat je, ondanks je steeds voller 
rakende agenda, altijd voor me hebt klaargestaan en betrokken bent geweest. Ik 
vond het een hele prettige samenwerking!
Eveline, ook jouw aandeel in dit proefschrift is heel groot. Je hebt me op een zeer 
efficiënte manier kennis laten maken met de wondere wereld van MISCAN. Ik heb 
veel gehad aan jouw ondersteuning, niet alleen bij modelanalyses, maar ook op het 
gebied van wandeltips! Bedankt voor de fijne begeleiding.
Arry, de screeningssectie kan onmogelijk zonder jou! Ik vond het heel fijn dat ik 
altijd bij je terecht kon met vragen over van alles en nog wat.
Ook andere collega’s met wie ik direct heb samengewerkt wil ik graag bedankten. 
Jacques, ik vond het heel fijn dat ik altijd bij je terecht kon met mijn vragen over de 
data van het IKNL, jouw zeer uitgebreide en complexe (!) Excel bestanden en met 
name ook om gewoon gezellig even bij te kletsen! Karolina, you made performing 
a PSA so much easier! I really enjoyed our night out in Rotterdam at the end of 
your internship. Verder wil ik alle leden van het LETB bedanken voor de goede 
suggesties en adviezen over meerdere manuscripten in dit proefschrift. Tenslotte 
wil ik ook alle coauteurs die mee hebben gewerkt aan mijn manuscripten graag 
bedanken voor alle goede en leerzame feedback.
Graag wil ik ook de leden van mijn promotiecommissie bedanken. De kleine 
commissie voor het beoordelen van mijn proefschrift en alle leden voor de 
bereidheid en interesse om hierover met mij van gedachten te wisselen.
Uiteraard ben ik ook al mijn kamergenootjes dankbaar, in het bijzonder die van 
mijn laatste kamer: Lea en Maryse en flex-kamergenootjes Nikki en Catherine. 
Ik vond het erg gezellig om mijn werkruimte met jullie delen. We hebben lief en 
leed gedeeld en vooral ook heel veel gelachen! Bedankt Lea en Catherine voor alle 
gezelligheid en de Warung Mini avonden (en soms ook middagen). Het Surinaamse 
eten in Rotterdam is een stuk beter dan in Utrecht! En bedankt Lea en David voor 
de vele sushi momenten. Ik ben blij dat ik jullie ‘echte’ Rotterdammers heb mogen 
leren kennen!
Ook Andrée en Suzanne wil ik bedanken voor (weer) vele sushi etentjes, de geniale 
lemon daiquiri’s bij Ayla en onze fijne gesprekken! 
Amarens, Brechtje, Carlijn, Lisanne, Lucie en Sabine, alias ‘De eetclub’, Arthur, 
Arne, Niels, Erik en Jeroen. Ik wil jullie graag bedanken voor alle leuke dingen die 
we de laatste jaren ondernomen hebben. Het waren stuk voor stuk super gezellige 
etentjes (met als hoogtepunt de High Friet in Breda (nooit meer!)), borrels en 
avondjes uit (in Rotterdam, maar natuurlijk ook carnaval!). 
Mirjam en Nadine, onze koffiemomenten waren altijd erg gezellig! Ik kon heel fijn 
met jullie praten en heb veel geleerd van hoe jullie in het leven staan.
Timor, bedankt dat je me door de vierdaagse hebt heen gesleept! Na de zoveelste 
50 km zat het soms tegen, maar we hebben het toch maar mooi gehaald samen!
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Dankwoord
Lisanne, toen we elkaar nog maar net kenden voelde het al als een jarenlange 
vriendschap. We lijken erg op elkaar wat eigenlijk best wel prettig is. Ons weekje 
weg was dan ook heel gezellig!
Amarens, ook met jou voelde het meteen heel vertrouwd. Ik ben heel blij met onze 
vriendschap en dat we zo dicht bij elkaar wonen, waardoor we regelmatig gezellig 
samen kunnen eten. Ook vind ik het heel fijn dat je mijn paranimf bent en me 
tijdens deze bijzondere (en spannende) periode steunt!
Verder wil ik ook de hele screensectie bedanken en in het bijzonder de 
borstkankerscreeningsgroep. Bedankt voor de gezelligheid tijdens onze 
borstkanker lunches en diners!
Ik heb het erg naar mijn zin gehad op de afdeling en wil tenslotte daarom alle 
overige MGZ-ers bedanken voor de praatjes in de gang of bij de koffieautomaat, 
de gezellige lunchpauzes, en de vele etentjes en borrels! 
Ook buiten mijn collega’s zijn er een hoop mensen die ik graag wil bedanken. 
Lieve vrienden uit Nijmegen, Utrecht en van mijn studie; De Lloret groep, Ca & 
Su, GEISV, de Gin-Tonic club en anderen. De meeste van jullie ken ik inmiddels al 
een hele tijd en we hebben dan ook veel samen meegemaakt. Bedankt dat jullie er 
voor me zijn geweest door samen leuke dingen te doen, goede adviezen te geven 
of gewoonweg door te vragen hoe het met me ging. 
Lieve vrienden/buurtjes, Marcel en Jacqueline, het heeft echt een meerwaarde om 
naast elkaar te wonen! Ik ben heel blij dat we in deze rare tijd vol met maatregelen 
één huishouden vormen :)
Lieve familie, bedankt voor alle ondersteuning en gezelligheid. De neevinnen, 
Amber, Iris, ik beschouw jullie meer als halfzussen dan als nichtjes. We hebben 
heel veel met elkaar meegemaakt en zijn zó op elkaar ingespeeld dat niemand onze 
gesprekken begrijpt :) Isabelle, ik vind het heel leuk dat jij nu ook met onze uitjes 
mee gaat. Ik heb zelden zo gelachen als toen we met z’n allen in het rariteiten 
museum waren.
Vandana, bedankt voor alle gezellige lunch- en koffie-uitjes. Wat toevallig dat jij 
aan de overkant van de straat werkte! De etentjes bij jullie thuis met Raaj, Karan 
en Shirani vond ik ook altijd erg leuk. Alleen wel jammer dat ik daarna nooit thuis 
kon komen zonder midden in de nacht op een of ander station te stranden!
Lieve kleine, grote Camille, mijn kleine zusje maar stiekem al een volwassen vrouw. 
Ik vind onze band heel bijzonder en ik ben erg trots op je! En natuurlijk ben ik ook 
heel blij dat jij mijn Paranimf bent! 
Lieve papa en mama, ik wil jullie graag bedanken voor jullie onvoorwaardelijke 
steun, jullie staan altijd voor me klaar. Ook geniet ik erg van het lekkere eten dat 
jullie altijd voor me meebrengen (wat jammer dat ik jullie kookkunsten niet heb 
geërfd!) en van onze vele etentjes met z’n allen in in De Plak, Merano, Hygge 
etc. 
Lieve Jeffrey, een leven zonder jou kan ik me niet voorstellen. We zijn al 12 jaar 
samen en hebben het nog steeds iedere dag gezellig met elkaar. Je geeft me 
heel vaak wijze en heldere adviezen, waar ik veel aan heb, en je helpt me altijd 
relativeren. Ik kijk erg uit naar ons verdere leven samen!

